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Summary 
 
Allergic rhinitis (AR) is an allergen-induced immunoglobulin E mediated inflammatory disease 
that affects approximately 15% of the Australian population. The AR sufferers manifest such 
nasal symptoms as sneezing, nasal congestion, runny nose and itchy nose. AR has significantly 
affected patients’ quality of life and imposed heavy financial burden to the healthcare system. 
Current conventional management takes an algorithm approach to introduce different strategies 
to patients such as education in avoidance of allergen, pharmacotherapy and allergen-specific 
immunotherapy. However, due to side effects (e.g. somnolence, fatigue, dry mouth syndrome, 
headache and epistaxis) caused by conventional treatment, more patients are seeking solutions 
from complementary and alternative medicine including Chinese herbal medicine (CHM).  
 
CHM has been used to manage AR-related signs and symptoms for thousands of years. A 
number of randomised controlled trials (RCTs) have demonstrated that CHM was effective and 
safe for managing AR. However, the effects and safety of CHM have not been adequately 
synthesised and translated to the clinical practice. This project aimed to provide a knowledge 
base on clinical effects and safety of CHM for the treatment of AR by conducting three reviews 
on modern and classic literature. 
 
Review 1: Systematic review of RCTs on CHM for the management of AR 
This systematic review was performed adhering to the Cochrane Handbook for Systematic 
Reviews of Interventions. A total of 62 RCTs involving 8,470 participants were included in this 
review. Results of the outcome measures indicated CHM was highly effective when compared 
to Western medicine (WM) (37 trials). CHM exerted positive clinical effects in improving 
global symptoms evaluated across immediate (15 trials), short-term (14 trials) and intermediate 
(four trials) durations. In the comparison of CHM plus co-intervention with same co-
intervention only (17 trials plus three comparisons from three multi-arm RCTs), stronger 
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clinical effects in improving global symptoms surfaced in CHM combined group in the meta-
analyses at immediate (nine trials), short-term (four trials), intermediate (three trials) and long-
term (four trials) follow-ups. Assessment of quality of life, use of rescue medication and IgE 
were limited owing to lack of data in the studies. There were no major side effects reported 
across all the included studies. The results of the SR surmised that CHM, used orally as alone 
or adjunct therapy could improve nasal symptoms; particularly CHM combined with co-
intervention exerted stronger and prolonged clinical effects in nasal symptom improvement. 
However, findings are limited by risk of bias within studies and associated with substantial 
heterogeneity. 
 
The most commonly used CHMs in the clinical studies were also identified through the review 
process for further investigation of their mechanism of actions. They are Huang Qi (Astragali 
Radix), Fang Feng (Saposhnikoviae Radix), Xin Yi (Magnoliae Flos), Cang Er Zi (Xanthii 
Fructus) and Xi Xin (Asari Radix et Rhizoma).  
 
Review 2: Literature review of experimental studies on mechanism of actions of 
commonly used CHMs 
Five CHMs identified from the Review 1 were further explored for their mechanism of actions 
by examining the experimental studies. Results of the review revealed these herbs possess 
characteristics of anti-inflammatory and anti-allergic, analgesic and antinociceptive, anti-
oxidative and anti-proliferative, anti-viral, anti-asthmatic, anti-bacterial, anti-gastric, anti-
vascular and cardiovascular, anxiolytic and muscle relaxant effects as well as 
immunoregulatory effects facilitating both immunopotentiating and immunostimulatory 
activities. The elucidations of the mechanism of actions mapped out its pharmacological 
actions.  
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Toxicological evidence of Cang Er Zi and Xi Xin exposed the dangers of renal failures and 
carcinomas associated with it dosage-related response. Atractyloside and carboxytractyloside 
were two main toxic constituents in Cang Er Zi, while toxicity of Xi Xin was associated with 
methyleugenol not aristolochic acid (AA-I) as postulated by many literature on the issue of 
Chinese herbs nephropathy. Chromatography fingerprinting evidence demonstrated negligible 
amount of AA-I in Xi Xin. Cases of toxicities were attributed to iatrogenesis, impart due to lack 
of education by practitioners and lack of surveillance by bodies of authorities. As these two 
toxic herbs were commonly used for AR management in classical literature, a further 
exploration of potential CHMs was conducted in ancient texts. 
 
Review 3: Data mining of classical texts on CHM for the treatment of AR-like signs and 
symptoms 
A total of 1,687 articles were included and 294 articles were analysed for of AR-like signs and 
symptoms associated with use of CHMs in the classical texts of Zhong Hua Yi Dian (ZHYD) 
and Zhong Guo Ben Cao Quan Shu (ZGBCQS). A sum of 163 herbs was identified for the 
management of AR-like signs and symptoms in retrospective diagnoses. These 163 herbs were 
analysed using principal component analysis against 11 AR-like signs and symptoms cited in 
the classical literature: sneeze, congested nose with runny nose discharge, sinusitis, nasal 
congestion, itchy nose, allergic rhinitis, postnasal drip, listlessness, headache with eye pain, 
pain the nose and red nose. Only three components namely, Component 1 (nasal congestion), 
Component 2 (congested nose with runny nose discharge) and Component 3 (sinusitis) were 
identified with eigenvalues of more than 1, which were 5.357, 1.235 and 1.029, respectively. 
The loadings for Components 1, 2 and 3 were 48%, 11% and 9%, respectively. Principal 
component analyses of the herbs demonstrated Component 1 herbs were Xi Xin, Xin Yi, Bai 
Zhi, Bai Bu, Cang Er Zi, Chuan Xiong, Fang Feng, Huang Qi, Gua Di, Bo He and Bai Zhu (in 
descending order) with Component 2 influence in Chuan Xiong, Bai Xian Pi, Gua Di and Huang 
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Qi (in descending order). Hierarchical cluster analysis also cast Xi Xin as one of the outliers 
along with Xin Yi with its distinctive pattern. Although it is clustered as an outlier, Xi Xin is 
correlated with cluster 2 herbs such as Pi Ba, Sheng Jiang, Tong Cao, Bo He, Fang Feng, Gua 
Di, Bai Zhi, Gan Cao, Cang Er Zi, Chuan Xiong, Huang Qi, Fu Zi, Jie Geng, Nan Xing, Cong 
Bai, Mu Tong, Gan Jiang, Ren Shen, Qiang Huo and Xiong Huang. All these herbs were 
grouped together, which could indicate similar characteristics in the management of AR-like 
signs and symptoms.  
 
Results of this project provide a comprehensive evaluation of clinical effects on CHM for AR 
management based on evidence from the modern clinical, experimental and classical literature. 
CHM seems effective and safe for managing AR when used alone or as an adjunct therapy. 
However, the results need to be interpreted with caution due to limited number of included 
studies in each comparison with associated high risk of bias and substantial heterogeneity. 
Seven common herbs (including Huang Qi, Fang Feng, Xin Yi, Bai Zhi, Cang Er Zi, Gan Cao 
and Xin Xi) identified from modern clinical studies and classical literature may be considered 
for AR management in future clinical practice and research. 
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Chapter 1  General introduction 
 
This chapter provides the background, the aims and objectives and rationale of the thesis 
project. The organisation of the information is also presented in this chapter. 
 
1.1. Background and rationale of the project 
Allergic rhinitis (AR) is a bothersome nasal allergy yet it cannot be underestimated as prolonged 
effects of this disease have many health implications. Currently, the worldwide affliction for 
this disease accounts for 30% of the adult population, but is rising. Climatic changes, lifestyles 
and genetic polymorphisms all have a part to play in the rising prevalence of AR. This 
prevalence has contributed to the atopic march in children as witnessed in the increasing 
allergies. Epidemiological evidence also demonstrates early onset of AR in childhood is often 
a cause of concern as development of more severe allergies are likely to set in adolescent years. 
As a result of prolonged effects of nasal allergy, AR with co-morbid asthma could potentially 
develop as a long-term condition and impact on overall quality of life. Current clinical diagnosis 
and conventional medicine for AR treatment are well developed and established but not without 
its side effects ranging from mild to severe spectrum such as headaches, dry mouth, somnolence 
and on the severe spectrum, the risk of anaphylaxis. High costs are borne by the individuals and 
national healthcare systems.  
 
There is a current shift of options in the choice of medicine; end-users of healthcare are turning 
to alternative medicine. One option is Chinese herbal medicine (CHM), a modality of Chinese 
medicine (CM), which long been used as an intervention to treat AR in China, Asia Pacific and 
is increasing in demand in the Western hemisphere. There is evidence of AR-like descriptions 
in the classical texts of CM, matching the signs and symptoms of modern medicine, therefore 
indicating that AR is not a new disease but a condition that was well-documented historically. 
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Historical medical records are important for cross reference of information for clinicians and 
researchers. It not merely allows examination of retrospective diagnosis and treatment, but also 
illuminates novel thinking and discovery as to how traditional herbs saturated with bioactive 
natural compound could treat challenging ailments of today. 
 
This research project is an all-encompassing review of the CHMs in the treatment of AR with 
CHM. There is a current knowledge gap stemming from a synthesised perspective of modern 
studies, such as randomised controlled trials (RCTs) and classical use of these herbs. The 
endeavour of this project is to deliver clinical evidence of the effects of CHMs, analyse the 
types of herbs used in controlled studies, classically and its pharmacological effects in 
experimental studies. The followings are the proponents in this project: 
 
1. Clinical studies – identify herbs used in RCTs 
2. Experimental studies – identify and elucidate the mechanisms of actions of the herbs 
commonly used on AR and in other diseases 
3. Classical literature – identify herbs used in retrospective diagnosis in ancient times 
 
Overall, the rationale of this review is to produce comprehensive clinical evidence of CHMs 
owing to the lack of evidence in current literature. It is envisioned that this review would 
translate evidence from clinical studies to bedside practice for CM clinicians. The synthesised 
clinical interventions for AR would aid clinical decision in formulation and establish confidence 
in the use of CHM for AR treatment. A clear and transparent synthesis of this SR would also 
provide easier accesses to users of CHM for clarification of herbal interventions. Last, in the 
process of this SR, the efficacious results based on the SR would assist policymakers with 
evidence-based decision making in the regulation of herbs in the Therapeutic Goods Act in 
Australia and globally. 
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1.2. Aims and objectives 
The aims of this study are to (1) review the fundamental knowledge of AR from the perspectives 
of the Western medicine and CM perspectives, (2) investigate the effectiveness and the safety 
of CHM used for the management of AR by conducting a systematic review (SR) of the RCTs, 
(3) elucidate the pharmacological effects and the mechanisms of actions of the five herbs 
commonly used in the RCTs, and (4) extract the herbs used in retrospective diagnosis of AR-
like signs and symptoms from the classical texts, conduct pattern analyses of the herbs used 
classically by employing principal component analysis (PCA) and hierarchical cluster analysis 
(HCA).  
 
1.3. Organisation of the thesis 
This thesis is a composition of three reviews, namely; a SR of RCTs on CHM used for the 
management of AR, a review on experimental studies and a review of classical literature. The 
literature reviews of Western medicine and CM are broadly discussed in Chapter 2 and 3, 
respectively. This chapter provides an overview of fundamental knowledge that pertains to AR.  
 
Chapter 4 discusses the methodologies of the three compositions in terms of search strategies, 
selection criteria as well as method of extractions and analysis of data.  
 
Outcomes on the three composites are reported in Chapter 5, 6 and 7. Results of SR for the 
comparators are highlighted in Chapter 5 along with the identification of the principal herbs 
used in the RCTs. Adverse events of the herbs in the RCTs are also a feature in this chapter. 
Chapter 6 provides an in-depth review of the effects of herbs examined in experimental studies 
and its potentiated use in other diseases. The outcomes of the data mining of classical texts and 
the statistical pattern analyses are discussed in Chapter 7.  
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Chapter 8 summarises the key findings of three reviews and assesses the overall completeness, 
applicability and quality of evidence. Detailed comparison with other studies is carried out. The 
final Chapter 9 highlights the achievements, limitations of this project, examines the 
significance as well as the implications for clinical practice and future research for AR.  
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Chapter 2  Literature review on allergic rhinitis (AR) – A 
Western medicine perspective 
 
This chapter discusses the definition, epidemiology, pathophysiology, impact, comorbidities, 
classifications, diagnosis and treatment of AR from the perspective of Western medicine. 
 
2.1. Definition of AR 
AR is an allergen-induced immunoglobulin E (IgE) mediated inflammatory disease that affects 
the nasal mucosa membranes (R. Pawankar, Canonica, Holgate, Lockey, & Blaiss, 2013). It is 
clinically characterised by sneezing, nasal congestion, sneezing, rhinorrhoea and itching of the 
nose and eyes and/or post nasal drips (J. Bousquet, van Cauwenberge, & Khaltaev, 2001). 
Exposure to allergens (antigens) which are proteins or chemicals bound proteins elicit 
immediate IgE hypersensitivity reactions (Abbas, Lichtman, & Pillai, 2012). Typical allergens 
include grass or weed pollens, pets dander, trees, pollutants and occupational agents (Greiner, 
Hellings, Rotiroti, & Scadding, 2012). Deifl and Bohle (2011) emphasises that adjuvanticity of 
these allergens are defined by its enzymatic activity, binding of lipids, interaction with toll-like-
receptors (TLR), interaction with non TLR pathogen recognition receptors, dimerization and 
oligorisation of effector cells. All of these antigenic characteristics are promoters of IgE 
production in AR. 
 
2.2. Epidemiology of AR 
2.2.1. Global prevalence of AR 
AR is often regarded as a trivial disease owing to its non-existent fatal rates, however, its 
prevalence and chronicity is a cause of major illnesses and disabilities worldwide (Ozdoganoglu 
& Songu, 2012). The Global Alliance against Chronic Respiratory Diseases (2007) reported 
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400 million persons suffered AR from 1996 to 2006, while the Allergic rhinitis and its impact 
on asthma (ARIA) guidelines 2010 revision reported AR prevalence was at 10% to 20% of the 
population, which represented 500 million AR sufferers globally (Brozek et al., 2010). The 
latest statistics reported in World Allergy Organization (WAO) White Book on Allergy for 
2013, global health prevalence for AR adult sufferers ranged from 10% to 30% and children 
with AR as high as 40% (R. Pawankar et al., 2013). Comprehensive data from Allergies in 
America, Pediatrics Allergies in America, Allergies in Latin America and Allergies in Asia 
Pacific compiled detailed prevalence of physician-diagnosed AR based on telephone survey 
and presented a clear depiction of the percentage of AR sufferers globally (Meltzer et al., 2012) 
(Table 1). In addition to the prevalence data for children with AR, the multinational studies in 
Table 1 were surveyed and assessed according to International Study of Asthma and Allergies 
in Children study methodology by independent projects. 
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Table 1. Global prevalence of AR  
Regions % of prevalence 
in adults 
% of prevalence 
in children 
(years) 
Types of 
reported AR 
References 
United States of 
America 
14 13 (4-17) 
Physician-
diagnosed AR 
Meltzer et al. (2012) 
Latin America 
7 9 (4-17) 
Physician-
diagnosed AR 
Meltzer et al. (2012) 
Asia Pacific 
9 
No data 
Physician-
diagnosed AR 
Meltzer et al. (2012) 
Thailand 
Japan 
Taiwan 
Singapore  
Vietnam 
50.6 (13-14) 
32 (13-14) 
44.4 (13-14) 
25.3 (13-14) 
34.9 (13-14) 
Self-reported AR R. Pawankar et al. 
(2009) 
China  20 
(11 major cities in 
China) 
9.8 (13-14) 
(8 cities in China) 
Self-reported AR L. Zhang et al. (2009) 
(F. Li et al., 2011) 
Europe  
 
18.7 
(5 European 
countries only) 
No data 
Self-reported AR Canonica, Bousquet, 
Mullol, Scadding, 
and Virchow (2007) 
Western   20.3 (13-14)   
Northern and    
Eastern 
 
10.6 (13-14) 
 
  
Gulf Arab - 
United Arab 
Emirates 
32 41(13-19) 
Self-reported AR Alsowaidi, Abdulle, 
Shehab, Zuberbier, 
and Bernsen (2010) 
Eastern 
Mediterranean No data available 19.5 (13-14) 
Self-reported AR Ait-Khaled et al. 
(2009) 
Oceania 
No data available 24.4 (13-14) 
Self-reported AR Ait-Khaled et al. 
(2009) 
Australia 
 
 
 
 
 
New Zealand 
15 
47.7 (13-14) 
(1 city only) 
Self-reported AR 
 
 
Australian Institute of 
Health and Welfare 
(2011) 
Ait-Khaled et al. 
(2009) 
No data available 18.8 (13-14) 
 Ait-Khaled et al. 
(2009) 
Indian sub-
continent No data available 18.5 (13-14) 
Self-reported AR Ait-Khaled et al. 
(2009) 
Africa 
Algeria 
Cameroon 
Congo 
Cote d’lvoire 
Ethiopia 
Gabon 
Kenya 
Nigeria 
Republique  
du Congo 
Reunion  
Island 
République  
de Guinée 
South Africa 
Sudan 
Togo 
Tunisia 
No data available 28.9 (13-14) 
Self-reported AR Ait-Khaled et al. 
(2009) 
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2.2.2. Prevalence of AR in Australia 
In Australia, AR is one of the most prevalent respiratory conditions affecting 15% of the 
population; one in seven people at an estimated 3.1 million people suffer AR as a long-term 
health condition from 2007 to 2008 (Australia Health Bureau Statistics, 2012; Australian 
Institute of Health and Welfare, 2011). In terms of gender differences, AR prevalence in 
females was 1.1 times higher than males; with the former 1.7 million and the latter 1.5 million, 
both sexes suffering AR as a long-term condition in Australia from 2007 to 2008 (Australia 
Health Bureau Statistics, 2012). Although it should be noted that this statistics may not be of 
significance as there may be under-reporting in AR-related cases with males population in 
remote regions and also associated-psyche of reluctance of seeking help or reporting ailments 
for fear of being labelled as being weak (Ricciardelli, Mellor, & McCabe, 2012). In addition, 
percentage of AR prevalence for children in Australia was not available for the country as a 
whole, only Melbourne city was assessed, with an astonishing high prevalence of 47.7% (Table 
1). To date, no current data on AR prevalence have been updated in Australia nor prevalence 
for children with AR are available. 
 
2.3. Risk factors of AR 
IgE allergenic reactivity in AR were linked to environmental-induced risk factors such as 
pollens, cypress, birch, animal dander, dust mites, cockroaches and moulds as well as 
occupational risks that include chemicals and toxic and non-toxic materials (Greiner et al., 
2012). Meltzer et al. (2012) noted the top three common triggers affecting AR sufferers were 
pollen, dust and grass pollens. In the United States, a survey conducted by the Allergies of 
America discovered respondents ranked the top ten triggers that cause AR which included, 
pollen (41%), dust (34%), grass (22%), weather (22%), animal dander (18%), 
damp/mould/mildew (11%), perfume (6%), tobacco smoke (6%), plants/trees/leaves (6%) and 
fumes (5%) (Figure 1). 
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Figure 1. Common triggers of nasal allergies in US (data adapted from Fig. 1. on page S117 of Meltzer et al., 
2012) 
 
In Latin America, dust was cited as the highest trigger by 55% of the respondents, while 
contrary to Asia Pacific, climate and humidity were main triggers by 55% of respondents, 
respectively (Figure 2). This could be generated by the outdoor pollutants in the changing 
modern landscape associated with city-living which Asia Pacific is undergoing rapid economic 
development and westernisation (Wong, Leung, & Ko, 2013). 
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Figure 2. Common triggers of nasal allergies in Latin America and Asia Pacific (data extracted from page S118 of 
Meltzer et al., 2012) 
 
2.3.1. Indoor pollutants 
Exposure to both indoor and outdoor pollutants is associated with new onset of rhinitis, 
rhinoconjunctivitis, asthma and asthma exacerbation and acute respiratory infections. One 
source of indoor pollutants lies in the housing characteristics of the accommodation. Housing 
characteristics of the accommodation refer to the fabric of the house, namely; its ventilation, 
renovation, decoration works and its maintenance, and presence of plants, all of which may 
influence the indoor air quality.  
 
Poorly ventilated housing with indoor damp and dust mites can result in an insidious onset of 
AR and other allergic conditions. The high humidity in the ambient air fosters proliferation of 
mould and dust mites. Poorly insulated housing, lack of indoor aeration and reduced indoor 
heating during cold winters contribute to high humidity. The most common indoor moulds are 
Cladosporium, Aspergillus and Alternaria, Pencillium (Curtis, Lieberman, Stark, Rea, & 
Vetter, 2004; Dallongeville et al., 2015). 
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These fungi or moulds are dispersed by airborne spores that thrive on moistures. Studies have 
shown that AR and comorbidities such as rhinosinusitis, wheezing and allergen-related asthma 
are associated with exposure to these airborne or dustbourne moulds concentrations (Baldacci 
et al., 2015; Norback, Lampa, & Engvall, 2014). One French study investigated the allergenic 
risk factors of moulds concentration in dwellings (Dallongeville et al., 2015). Age of building, 
ventilation, heating, ambient humidity, temperature and carbon dioxide concentration as well 
as pets, plants signs of dampness and smoking were considered as evaluation parameters. 
Results revealed that the level of fungal concentration coincided with the presence of plants in 
living rooms in cold seasons. Cladosporium and Penicillium were the most prevalent genera of 
the fungi found in homes (Dallongeville et al., 2015). Cold winters influenced the growth of 
Aspergillus and Penicillium in living rooms while Aspergillus and Alternaria were higher in 
bedrooms. Dampness and indoor smoking were associated with higher Penicillium 
concentrations. Interestingly, R. Pawankar et al. (2013) indicated that the presence of carpeting 
and flooring type had no impact whatsoever on dust mould concentration. Evidence concluded 
that presence of pets were significantly associated with allergens concentration (Baldacci et al., 
2015). Therefore, allergens within indoors can be insidiously introduced owing to the interior 
and the structure of the dwellings and contribute to AR and comorbidities.  
 
2.3.2. Outdoor pollutants 
Apart from the well-established evidence based environmental-induced causal link to grass 
pollens, mould, cypress, birch, animal dander, dust mites, and cockroaches, the environmental 
risk factors for IgE sensitization has increased. The challenge of global warming has lately been 
cited as the cause of outdoor air pollution leading to rise in ambient particulate matters as well 
as carbon dioxide and ozone pollution (R. Pawankar et al., 2013). Global warming, a 
contributory factor of outdoor pollution is an important risk factor of AR. Climatologic changes 
have prompted a change in the seasonal count of pollen production, dispersion and the transport 
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of these aeroallergens. Sensitization to pollen aeroallergens is undisputedly one of the risk 
factor of IgE-induced AR. A randomised controlled parallel group study of children (aged 6 to 
11 years) with seasonal AR (SAR) from 15 countries including US, Europe and Southern 
hemisphere revealed that pollens were the most common group of allergen ranging from 28% 
to 100% in all countries, other than Israel (Baena-Cagnani et al., 2003). The increased pollen 
counts geographically in these countries is highly attributed to extreme changes in weather 
patterns such as increasing heat waves, unpredictable floodings, thunderstorms and rainfalls 
(D’Amato et al., 2015). Based on the Working Group I report of the Intergovernmental Panel 
on Climate Change, the spike in temperature from 2003 to 2012 led to an increase of heat waves 
rising to 35ºC and greenhouse gas concentrations (D'Amato et al., 2014). Global meteorological 
analysis by the US National Oceanic and Atmospheric Administration reported the warmest 
January to October period in 2015 since 1880, creating climatic anomalies driven by El Niño 
and rising sea temperature globally (Australian Government Bureau of Meterology, 2016). The 
repercussions of global warming have an impact on the generation and dispersion of pollen and 
air pollution, all of which correlated to increasing AR, atopy and asthma. Extreme changes in 
weather have favoured an elevation of length and the severity of the pollen season. The increase 
of thunderstorms can induce severe asthma attacks in AR patients. These episodic days known 
as thunderstorm outflows, trigger a dispersion of allergenic particles from pollens and spores 
caused by the osmotic rupture, which are induced by the heightened intensity and the frequency 
of the heavy rainfall (D'Amato et al., 2014). It is posited that during these epidemic days, a 
marked increase in the patients affected by the pollen concentration was observed in cases of 
AR, allergic asthma exacerbation and chronic obstructive pulmonary disease. Incidences of the 
respiratory attacks in AR and asthma cases were recorded with the onset of thunderstorm 
outflows in London 1994, Wagga Wagga 1997 and Naples 2004 (D’Amato et al., 2015). A 
recent severe thunderstorm outflow occurred on 20 November 2016 in metropolitan Melbourne 
and outer regions in Victoria led to an unprecedented eight fatalities and one in critical care for 
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nine days (Livingston & Drape, 2016). Thousands of people suffered from ‘thunderstorm 
asthma’ because of the increased pollen dispersions in the ambient air. This was the worst 
thunderstorm recorded in history which resulted in 8,500 patients admitted to hospital and 30 
patients in critical care unit in one night (Livingston & Drape, 2016).  
 
Aside from thunderstorm outflows, heat waves are also causing more desertification and 
sandstorms as witnessed on yearly basis in Beijing and other parts of China. Sand particulates 
can cause respiratory dysfunction and AR. The Asian sand storm (ASD) is common during 
spring in North Western and Eastern regions of China. The occurrences of the ASD affect the 
Korean Peninsula and Japan annually. The chemical compounds comprise of sulphate, nitrate 
and microbes in the alkaline soil of ASD (T. Ichinose et al., 2009). These airborne sand 
particulates in ASD pose as an aggravating risk factor for AR sufferers. Combined exposure to 
ASD and Japanese cedar pollens induces and aggravates AR exhibited an exponential increase 
by 35.5 fold compared to control. Enhanced histamine levels of four-fold were also detected in 
nasal cavity lavage fluids (T. Ichinose et al., 2009). Pathological evidence unveils the impact 
of ASD on nasal mucosa with extensive proliferation of eosinophil and goblet cell infiltration 
in the nasal subepithelium, with the latter inducing mucous production and the former 
augmenting chemotactic and chemokine proteins release interleukin (IL)-5, monocyte 
chemotactic protein-3 and eotaxin in the bronchoalveolar lavage fluids (T. Ichinose et al., 
2008). The evidence suggests meteorological changes in terms of temperature, wind speed, and 
thunderstorms can influence pollen counts and exert a priming effect on AR.  
 
Ambient particulate matters (PMs) in air pollution are a contributory risk factor in the current 
modern lifestyle. PMs refer to make up of chemicals and organic particles such as carbon 
dioxide, nitrogen dioxide, sulphur dioxide and other toxic compounds found in the emissions 
of motor vehicles or biofuel mass production (Laumbach & Kipen, 2012). Diesel exhaust 
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particles produced from emissions of motor vehicles made up a large proportion of PMs. 
Studies have found that PMs with aerodynamics diameter of ≤ 2.5 μm pose a potent threat to 
respiratory diseases (Laumbach & Kipen, 2012; Leung, Ko, & Wong, 2012). With regular and 
uncontrolled exposure to these toxic air particulate, priming of eosinophilia can lead to atopy. 
 
2.3.3. The hygiene hypotheses: A changing perspectives 
The hygiene hypothesis proposes that decreased exposure to cross-infections in early life 
increases the risk of developing AR and other allergic diseases. The increase of atopic diseases 
and AR is largely attributed to reduced exposure to environmental micro-organisms such as 
multi-cellular parasites owing to changed lifestyle in developing countries (Kramer et al., 
2013).  An epidemiological study conducted by European Community Respiratory Health 
Study (ECRHS) which involved 22 countries, indicated increasing AR attributed to hygiene 
hypothesis could elevate the incidence of developing AR in adulthood (Matheson et al., 2011). 
Early life factors include gender, geographical dwellings, environmental pollution, no siblings, 
late entry to preschool or nursery, maternal smoking and lack of exposure to pets present could 
be a determinant for AR incidence in later stages of life (Matheson et al., 2011). Gender is a 
strong risk factor- it appears females tend to develop rhinitis in later childhood with more 
incidence of rhinitis in adulthood. Crude lifelong incidence of rhinitis was 7.00/1000/year for 
men and 7.95/1000/year for women (Matheson et al., 2011). Females tend to suffer from 
chronic long-term AR, insofar, there is a gap of knowledge as to why females tend to be more 
susceptible than males in later stage of childhood. Geographical dwellings, pets ownership and 
exposures to animals such as farm living also conferred a protective effect against development 
of atopic allergies and AR in adulthood. City living encumbered with exposure to ambient 
pollution produced by biofuel and diesel emission could potentially increase priming of the 
immune system (Laumbach & Kipen, 2012).  
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Recent studies have proposed corollary perspectives to the hygiene hypothesis in view of the 
changing landscape of modernisation and lifestyles. Two foremost hypotheses put forth to the 
extension of hygiene hypothesis were the “old friends” hypothesis and the “microbial 
deprivation hypothesis” (Bloomfield et al., 2016). Both involved microbiota and microbiomes 
and are inextricably intertwined. Microbial deprivation hypothesis stipulated that deprivation 
of the non-pathogenic beneficial microbes were associated to many autoimmune and allergic 
diseases, not the least AR as a chronic condition. Microbiota is regarded as the totality of all 
microorganisms in a metaorganism system while microbiomes refer to the combined genetic 
material of the microbiota (Jenmalm & Björkstén, 2016). Microbiota forms a symbiotic 
interdependency in the immune system. Early exposure to the microbiota enables the adaptive 
immune system the capacity to recognise non-pathogenic and pathogenic microbes, creating a 
complex interdependency for an immune environment to ward off atopies in later life. 
Immunologically, the proposed notion suggests that an early immune challenge to bacteria and 
viruses could essentially be priming the immune system towards a stronger T helper cell 2 (Th2) 
pro-allergic responses and an attenuated Th1 proinflammatory responses in later life. 
Microbiomes is defined as the sum of genetic information in microbiota (Jenmalm & Björkstén, 
2016). Evolutionary changes and adaptive nature of the microbiome included non-pathogenic 
commensal microbiota such as Firmicutes, Tenericutes, Proteobacteria, Bacteroidetes, 
Actionbacteria and Fusobacteria phyla (Jenmalm & Björkstén, 2016). The evolution of these 
commensal pathogens exerts complex human microbial ecosystems in the individual’s immune 
system by conferring an adaptive effect over pathogenic invasion. Reduction of the colonisation 
of these microbiota and microbiome development owing to urban living and low dietary fibre 
has led to a long-term impact of autoimmune and allergic diseases. Therefore, the increasing 
prevalence of AR as a chronic condition could in part be due to these hypotheses in our times. 
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2.3.4. Genetics and environment 
Genetics and environmental interactions have been postulated to be inextricably linked to the 
development of AR. “Atopic march” was described as increased sensitization to environmental 
stimuli such as pollens, traffic pollution or other outdoor pollutants that could give rise to other 
allergies. The proposed notion is that prolonged allergen sensitisation could alter gene 
phenotypes and lead to a Th2 dominant immune system, manifested in the development of 
chronic AR. 
 
Genetic linkage in families with IgE predominance could be susceptible to sensitisation of IgE-
specific allergens. Emerging projects have begun to employ genome-wide studies to locate the 
single nucleotide polymorphisms across the genome to identify susceptible genes which are 
likely to develop AR or other allergic diseases (Andiappan et al., 2013; Marie-Hélène Dizier et 
al., 2007; Ramasamy et al., 2011). C11orf30/LRRC32, BCAP, MRPL4 and 
TME232/SCLA25A56/TSLP are definitive susceptible genes for AR (Andiappan et al., 2011; 
Ramasamy et al., 2011). The mechanism for C11orf30 and LRRC32 related to the epithelial 
barrier function, regulatory T-cell functions and immune tolerance, while 
TME232/SLA25A/TSLP were associated to IgE levels to grass sensitisation (Portelli, Hodge, 
& Sayers, 2015). Both C11orf30 and LRRC32 potential function are related to the tetraspan 
proteins which are membrane-associated molecules that span the membrane four times and 
these teraspanins act as “molecular facilitators” for signalling complexes and transporters 
(Mahmudi-Azer, Downey, & Moqbel, 2002). BCAP, a cytosolic adaptor that connects B-cell 
receptor, is implicated in the immunoregulatory function of B cells survival while MRPL4, 
plays a significant role in adhesion inflammatory process (Portelli et al., 2015) and hypoxia-
inducible factor 1-α downstream cascade (Andiappan et al., 2011). Overlap genes in studies 
suggested a potential linkage of AR with the development of allergic diseases such as asthma 
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and atopic dermatitis although many studies have noted heterogeneity exists in the investigation 
process (Table 2).  
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Table 2. Summary of susceptibility genes and loci of AR 
Genes Loci Associations Functions Shared 
regions/ 
associations 
References 
C11orf30/LRRC32 11q13 AR 
 
 
Grass 
sensitization 
Regulates gene  
expressions, 
epithelial barrier/  
regulatory T-cell  
function 
AR 
Asthma 
Atopic 
dermatitis 
J. Li, Zhang, and 
Zhang (2015) 
Portelli et al. 
(2015) 
Ramasamy et al. 
(2011) 
TME232/ 
SCLA25A56/TSLP 
5q22 AR 
 
Grass 
sensitization 
Tetraspan 
protein/ 
transporter/ 
activates 
dendritic cells 
AR 
Atopic 
dermatitis 
J. Li et al. (2015) 
Portelli et al. 
(2015) 
Ramasamy et al. 
(2011) 
MRPL4 19p13.2 AR Inflammatory 
adhesion process 
AR Andiappan et al. 
(2011) 
BCAP 10q24 AR Activation and  
development,  
and maturation  
of B cells 
AR Andiappan et al. 
(2011) 
J. Li et al. (2015) 
FCER1A 1q23 Total IgE Alpha chain of 
the high affinity  
FϲεRI 
AR 
Asthma 
Portelli et al. 
(2015)  
J. Li et al. (2015) 
IL13/RAD50 5q31 Total IgE 
 
Cytokines in IgE  
class switch/  
DNA repair 
AR 
Asthma 
Atopic 
dermatitis 
Portelli et al. 
(2015) 
HLA DRB4 6p21 Grass 
sensitisation 
T-cell responses AR Portelli et al. 
(2015) 
HLA DRB1 6q21 Total IgE T-cell responses AR Portelli et al. 
(2015) 
HLA G 6q21 Total IgE T-cell responses AR Portelli et al. 
(2015) 
HLA-A 6q21 Total IgE T-cell responses AR Portelli et al. 
(2015) 
HLA-DQA2 6q21 Total IgE T-cell responses AR Portelli et al. 
(2015) 
STAT6 12q13 Total IgE Signal 
transduction 
linked to IgE  
synthesis 
AR Portelli et al. 
(2015) 
IL4R/IL21R 16p12 Total IgE IgE regulation 
via IL4 and IL21 
AR Portelli et al. 
(2015) 
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The atopic triad of AR, asthma and atopic dermatitis could be detected in the overlapped or 
shared associations within the loci of genes. The discovery of these susceptibility genes for 
incidence of AR in adulthood supported epidemiological findings that atopic march could be 
triggered with the hygiene hypothesis. Therefore, owing to presence of susceptibility AR genes 
and environmental factors at play, genetics-environment interaction could be a determinant 
factor of early life onset of AR and development of long-term AR or other allergic diseases at 
later life. 
 
2.4. Pathophysiology of AR 
2.4.1. Pathomechanism of AR 
Allergen interactivity induces IgE hypersensitivity. IgE hypersensitivity is caused by mast cells 
and basophils with a high affinity Fc receptor specific for ɛ heavy chains, FcɛRI (Abbas et al., 
2012). Cross-linking of FcɛRI molecules activates degranulation of mast cells and basophils to 
produce an inflammatory-mediators release, secretion and synthesis of cytokines and 
chemokines and lipid mediators (Abbas et al., 2012; R. Pawankar, Mori, Ozu, & Kimura, 2011). 
Chronic AR mainly involves Th2 and Treg, both thymus-derived and share cluster of 
differentiaton (CD)4 surface membrane markers (Osguthorpe, 2013). Atopy is closely indicated 
and linked to upregulation of Th2 that triggers cytokines and causes systemic inflammation. 
Thymic stromal lymphopoietin (TSLP) is essentially the master switch for Th2 differentiation, 
responsible for maturation of dendritic cells and recruitment of eosinophils. Both chemokine 
ligands (CCL) 17 and CCL 22 as well as thymus-activation regulated chemokine (TARC) act 
as chemoattractant facilitated by the binding to C-C chemokine receptor 4 on the cell surface 
to further promote accumulation of clonal Th2 cells response (Figure 3). 
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Figure 3. Pathomechanism of AR (extracted from Figure 2 on pg 387 of Osguthorpe, 2013)  
 
Differentiation of Th2 cells can be initiated through several pathways: cell contact with major 
histocompatibility complex (MHC) type II cell surface and cell epitope on cell surface, CD80, 
CD86, CD28 on antigen presenting cells and T-cells or interleukin (IL)25, IL33 cytokine-driven 
Th2 differentiation, IL4 stimulatory-activation and last, APCs direct stimulation of B-cells with 
IgE productions. These cytokines exhibited an interplay of different functions: IL4 is involved 
in class switching B-cells to IgE producing plasma cells and it recruits eosinophils and 
basophils; IL5 also recruits eosinophils and prolongs its lifespan; IL9 proliferates mast cells; 
IL13 stimulates goblet hyperplasia and secretes chemoattractant to dendritic cells and induces 
B-cells toward IgE production as well as granulocytes macrophage colony stimulating factor 
(Osguthorpe, 2013) (Figure 3).  
 
Immunologic studies have long postulated IgE synthesis took place at the site of bone marrow, 
splenic tissues and blood (Abbas et al., 2012; R. Pawankar, Mori, et al., 2011). In fact, IgE 
synthesis also occurred at the nasal mucosa with a marked increase of cells expressing local 
IL4 messenger ribonucleic acid (mRNA), IgE heavy chain (Cϵ) and IgE heavy chain promoter 
(Iϵ) ribonucleic acid (RNA) after pollen provocation. Iϵ-RNA is the hallmark for B cells target 
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for class switching to IgE. Genome isotype class switching and VD)J recombination caused 
deletion of Iϵ, replacing it with Cϵ, expressed at the B-cells (L. A. Cameron et al., 1998). B cells 
count, IL4 and CϵRNA and Iϵ transcripts in the biopsy of nasal mucosa obtained from 33 
subjects with seasonal and non-seasonal response to topical glucocorticosteriod treatment were 
analysed. The outcome of this study indicated that the marked increase of cells expressed IL4, 
Cϵ and Iϵ RNA within the nasal mucosa of patients with AR. Increased Cϵ and Iϵ B cells showed 
production of IgE in the nasal mucosa, however its origination is unknown. Effects of AR were 
also attenuated with the use of the gluccocorticosteriod treatments, which reflected the decrease 
of the IL4 and Iϵ RNA, indicating a halt in the transcription of Iϵ to Cϵ germline transcript. It 
strongly confirms that IgE synthesis may take place locally producing in situ inflammation in 
patients with seasonal AR (L. Cameron et al., 2000; Gevaert et al., 2013; Smurthwaite & 
Durham, 2002; Takhar et al., 2005) as well as systemic inflammation in the upper and lower 
airways (R. Pawankar, Mori, et al., 2011). 
 
2.4.2. IgE inflammatory mechanism – Early phase 
IgE interaction involves molecules MHC-II along with antigen-presenting cells such as 
macrophages and dendritic cells co-presenting IgE specific allergens to CD4+ T cells. Early 
exposure to allergens promotes cross-linked IgE molecules on cell surfaces and this in turn 
triggers an immediate reaction resulting in the degranulation of mast cells and mediators (Figure 
4). Histamines, leukotrienes, plate-activating factor, prostaglandin D2 (PDG2), are some major 
vasoactive mediators that trigger an immediate inflammatory in AR (R. Pawankar, Mori, et al., 
2011). Sensitisation takes place with recurrence of allergen exposure. This phase is known as 
the early phase reaction (R. Pawankar, Mori, et al., 2011). Concentrations of chemical 
mediators in nasal secretions after nasal allergen challenge (NAC) and during nasal allergic 
exposure were indicative of the role of mast cell in early phase inflammation (D. Wang, 
Clement, Smitz, & Derde, 1995) (Figure 4). Mast cell-driven mediators, histamine, tryptase, 
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PGD2 and leukotriene (LT) C4 and kinins significantly peaked after five minutes of NAC. 
Predominant symptoms of allergies that occurred during this phase were the onset of sneezing 
and itching. Time span for early phase reactivity after NAC was observed to almost start 
immediately after five minutes of allergen exposure and could last more than an hour (D. Wang 
et al., 1995).  
 
 
Early phase reaction 
 
Late phase reaction 
Figure 4. Early and late phases reaction of AR (extracted from Figure 1 on page 154 of Bhalla & Singh, 2008) 
 
2.4.3. Systemic inflammatory mechanism of AR – Late phase 
Late phase reactivity is a latent eosinophils-inflammatory response that results in the chronic 
AR, characterised by nasal congestion with little sneezing and rhinorrhoea (R. Pawankar, Mori, 
et al., 2011; D. Wang et al., 1995; D. Y. Wang & Clement, 2000). Late phase reaction in AR is 
characterised by severe nasal blockage within four to 10 hours of exposure. Nasal congestion 
is one of the clinical symptoms that characterises late phase reaction in AR patients. D. Wang 
and Clement (1995) discovered 17 out of total 18 atopic subjects experienced immediate 
unilateral or bilateral nasal obstruction along with sneezing and rhinorrhoea. Four types of nasal 
reactivity were detected within 10-hour fluctuation resistance such as no late phase, no major 
increase in one or both nasal cavities, one-sided nasal blockage and alternating nasal cavities. 
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Results indicated during the late phase bilateral obstruction occurred in median of 41%, 
unilateral obstruction in median of 82% while the most common alternating type is the median 
of 47%. Unilateral nasal obstruction during early phase is at 94%, and late phase is at 84%. 
Severe nasal blockage was experienced within four to 10 hours of exposure for late phase atopic 
patients.  
 
Nasal congestion is one of the clinical symptoms that characterises late phase reaction in AR 
patients while during the early phase, nasal congestion is normally accompanied with sneezing 
and rhinorrhoea (D. Y. Wang & Clement, 2000). The key driver of late inflammatory response 
lied in the production of eosinophil cationic protein (ECP). Increase of the eosinophils and ECP 
concentrations mediated by the IL5, IL4 and IL13 in Th2 differentiation were detectable in the 
nasal secretions (Figure 4). Both concentrations of eosinophils and ECP peaked at two hours 
and lasted for eight hours. Highest concentrations of ECP were reached after 24 hours with no 
clear signs of plateau. This indication strongly emphasised the role of eosinophils in late phase 
reactivity in pathophysiology of chronic AR. Clinically, nasal congestion could be used as a 
qualitative (types of nasal obstruction) and quantitative (biopsies of nasal mediators) diagnostic 
tool for AR. 
 
2.4.4. Theory of a ‘unified airspace’ inflammatory respiratory model 
The theory of the “unified airspace” has been endorsed by World Health Organization (WHO) 
collaborative health workgroups such as ARIA and WAO. Inflammation of the upper and lower 
airways shares similar pathologies as well as affliction of inflammation in the respiratory 
system. The pathophysiology of AR is characterised by the inflammation of the nasal mucosa 
with the involvement of the upper airways, while asthma involves inflammation of the 
pulmonary airways and bronchial hyperresponsiveness. A 23-year follow-up epidemiological 
research demonstrated the link between the development of AR and asthma was intertwined in 
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a cohort of 378 university students. Results demonstrated the activity of asthma occurred 
concurrently with the occurrence of AR. Improvement of AR symptoms with resolution of 
asthma and exacerbation of AR was concurrent with worsening of asthma symptoms (Greisner, 
Settipane, & Settipane, 2000). 
 
The unified airspace is essentially defined by the concept of the one airway disease. Both the 
nose and the bronchi share similar inflammatory mechanism. Specific adhesion molecule 
ICAM-1 (CD54) expressed on the epithelial and endothelial cells was essentially involved in 
the inflammation of the mucosa cells in the early phase reaction. This inflammatory infiltrate 
continued to exist causing minimal persistent inflammation even though allergen provocation 
had subsided (Compalati & Ridolo, 2010). Even so, an experimental study demonstrated 
moderate to severe persistent AR contributed to the worsening of asthma by enhancing lower 
airways inflammation irrespective of the intra-nasal corticosteroids prescribed to subjects (Oka 
et al., 2014). High levels of exhaled nitric oxide fraction were sustained indicating activity of 
atopic AR. Visual analogue scale (VAS) for nasal symptoms corresponded with the elevation 
of exhaled nitric oxide fraction levels. This study underscores the link of AR and asthma as 
well as atopic AR as a contributor to the exacerbation of asthma. 
 
2.5. Impacts of AR 
2.5.1. Quality of life 
AR comorbidities can severely impair overall physical, emotional and social aspects of life, 
causing lower vitality and poorer general health (de la Hoz Caballer et al., 2012; Leynaert, 
Neukirch, Liard, Bousquet, & Neukirch, 2000). The costs of AR extend beyond the individual 
suffrage. In fact, the costs incurred are far-reaching and burdensome to both individual and 
society. Poor physical symptoms associated with AR can encumber cognitive processes in 
terms of memory, psychomotor skills and performance (Blaiss, 2000). Mood disturbance, 
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daytime somnolence, fatigue and irritability owing to sleep disturbance are often associated 
with nasal congestion. A survey conducted by Meltzer et al. (2012) found that nearly one in 
four US adult respondents (22%) reported to experience sleep disturbance; similarly one half 
of the Latin America adults (44%) and more than 70% of the Asia Pacific reported to be 
suffering from sleep problems. Learning deficits in chronic AR are manifested in poor decision 
making, slow psychomotor and verbal learning. AR has a profound impact on the emotional 
health of sufferers. Emotionally, the respondents involved in the surveys reported 8735 US 
adults with AR felt miserable (65%), irritable (64%), depressed (36%) or embarrassed (23%) 
during the allergy season. Both adult respondents in Latin America and Asia Pacific were 
reported to suffer from depression, 17% and 16% respectively (Meltzer et al., 2012). This 
emotional impact limits the social lifestyle of AR sufferers. More than one third of the US adult 
AR sufferers (35%) interviewed noted they avoided activities because of their nasal allergies. 
Similarly, Latin America adult respondents (16%) reported limitation and restriction in their 
ability to participate in social activities and Asia Pacific respondents cited indoor (9%) and 
outdoor (7%) activities. Significant impact of AR on overall quality of life affects physical, 
mental and emotional health (Australian Institute of Health and Welfare, 2011; de la Hoz 
Caballer et al., 2012). 
 
2.5.2. Burdens of AR 
Besides impacts on quality of life, AR has significant bearing on direct and indirect costs of 
healthcare. Direct costs are expenses associated with the course of  managing the disease that 
include physician fees, any laboratory procedures, allergen testing procedures, pharmaceutical 
agents and allergen immunotherapy (Blaiss, 2010). Hidden costs refer to monies spent related 
to managing the comorbidities of AR and the exacerbation of the disease including treatment 
in X-ray screenings and emergency department visits for rhinosinusitis, surgical costs for nasal 
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polyps, and medical costs for otitis media (Gupta, Sheikh, Strachan, & Anderson, 2004; Nathan, 
2007).  
 
In United Kingdom (UK), one study indicated mean weekly visits to GP episode incidence rates 
for AR treatments in 2002 was 25 per 100,000 for AR sufferers and nasal allergy made up 4.3 
million out of 66.5 million community prescriptions dispensed (Gupta et al., 2004). Direct cost 
for UK National Health service for managing allergy was estimated over one billion UK pounds 
(equivalent to AUD $2 billion) in 2002 (Gupta et al., 2004). In the United States (US), the cost 
of treating AR is substantial. Overall AR-related direct costs had nearly doubled from US $6.1 
billion (equivalent to AUD $7.9 billion) in 2000 to US $11.2 billion (equivalent to AUD $14.6 
billion) in 2005 (Meltzer & Bukstein, 2011). More than half of the costs were accrued to 
prescription medications. Total direct medical cost was estimated at $3.4 billion (equivalent to 
AUD $4.4 billion), with a large proportion attributed to prescription medications (46%) and 
outpatient visits (51.9%) (Meltzer & Bukstein, 2011). Latest figures of 2007 and 2011 indicated 
costs of burden for AR in the US had increased by 2.3 billion within 5 year-span period in total 
estimated costs and this amount was expected to rise (Table 3). 
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Table 3. AR burden of costs in AUD (Data from Ruby Pawankar, Canonica, Holgate, and Lockey (2012) 
Countries 
Year of 
costs 
calculated 
Population  Diseases Direct costs 
Indirect 
costs 
Total costs 
estimated 
Australia 2007 23 m All allergies $1.1 b $ 8.3 b  $ 9.4 b 
2001 
 
AR $107.8 m 
  
2010 
 
AR $226.8 m 
  
Finland 2005 5.3 m All allergies $686 m $75.8 m $761.7 m 
South Korea 2005 50 m Asthma - - $2.3 b 
  
AR 
  
$344 m 
Israel   7.5 m Asthma - - $45 m 
Mexico 2007 103 m Asthma     $45 m 
USA 2007 310.2 m Asthma $19 b $6.4 b $25.5 b 
 
2011 
 
AR $14.6 b Up to   
$9.7 b 
Up to  
$27.8 b 
Notes: b: billion; m: million 
In Australia, AR-related costs data are not readily available, however wholesale costs of AR 
medications depicted the demand costs over the years. Wholesale cost to community 
pharmacies of intranasal corticosteroids and oral histamines doubled from AUD $107.8 million 
in 2001 to AUD $226.8 million in 2010, over a span of ten years (Table 3). Wholesale cost of 
over-the-counter (OTC) medications per person for oral histamines has increased from AUD 
$4.40 to AUD $7.48 and intranasal corticosteroids increased from AUD $1.15 to AUD $2.68 
(2.3 times), from 2001 to 2010 (Australian Institute of Health and Welfare, 2011).  
 
2.6. Comorbidities of AR 
AR symptoms range from mild to severe spectrum and adverse comorbidities associated with 
AR can severely impact on the quality of life. Asthma, stress (Lee, Chung, Shin, Kim, & Cho, 
2008), sleep apnoea (Benninger & Benninger, 2009), sleep disturbance (J Bousquet et al., 
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2008), fatigue, otitis media with effusion, nasal polyposis, rhinosinusitis and chronic 
rhinoconjunctivitis (R. Pawankar, Canonica, Holgate, & Lockey, 2011) are some of the health 
comorbidities of AR.  
 
2.6.1. From AR to asthma 
According to the WAO, AR is considered a risk factor for asthma (R. Pawankar, Canonica, et 
al., 2011). Studies have shown a distinct possible link of early onset of AR in childhood to the 
development of asthma with concomitant AR in later years (Ciprandi, Signori, Tosca, & Cirillo, 
2011; Compalati & Ridolo, 2010; Matheson et al., 2011; Westman et al., 2014). Ciprandi et al. 
(2011) termed this as an indicator of an “asthma march”. AR and asthma are inextricably linked, 
owing to long childhood risk factors and genetic disposition of individuals. The incidence of 
asthma is dependent on the onset of AR by seven years of age, and asthma incidence was more 
than three times in those with childhood AR compared to those who never suffered from 
childhood AR (Burgess et al., 2007). Many studies have also indicated there is a co-existence 
of AR and asthma (Burgess et al., 2007; Greiner et al., 2012; Greisner et al., 2000; Linneberg 
et al., 2002). In Australia, about 80% asthma sufferers experience AR (Asthma Australia, 2014). 
A Swiss-linked AR study in asthma confirmed 76% asthmatic patients suffered from AR 
(Taegtmeyer et al., 2009). Approximately 19-38% of patients with AR have concomitant 
asthma and 30-80% of asthmatics (Compalati & Ridolo, 2010). There is a strong body of 
evidence suggesting a strong linkage between AR and asthma. 
 
2.6.2. Sleep disturbance and fatigue 
Sleep disturbance has been cited by AR sufferers as one of the main comorbidities that affects 
their quality of life. In Asia Pacific, sleep disturbance was the main symptom that affected 
sufferers, whilst in Latin America, it was ranked the third most common symptom equivalent 
to nasal congestion (Meltzer et al., 2012). All spectrum of AR, from mild to severe, suffer from 
33 
 
sleep disturbance. AR manifests all dimensions of sleep complaints (difficulty in falling asleep, 
nocturnal awakening, early awakening, nonrestorative sleep, feeling of lack of sleep and 
snoring) and sleep disorders (insomnia, severe insomnia, sleep apnoea syndrome and 
hypersomnia) (Léger et al., 2006). The resultant impact discovered in a study was nearly half 
of the AR patients reported feeling of fatigue even though they have seemingly slept normally 
through the night. Males displayed a higher tendency for sleep apnoea, whilst asthmatic patients 
correlated with severe insomnia. Similar results were also yielded with a prospective, 
multicentre Spanish study, 52.8% of patients suffered from poor sleep quality. Nasal congestion 
and concomitant asthma were the main reasons for poor sleep (Colás et al., 2012). Patients with 
moderate to severe AR spectrum were most affected from sleep deprivation. 
 
Fatigue due to sleep deprivation contributes to a poorer quality of life for AR sufferers. Daytime 
somnolence is a marked characteristic of AR. Daytime somnolence is associated with a 
significant decline of psychomotor skills, lowered cognition and defective learning. About 40% 
of parents interviewed in a US survey for 500 children with nasal allergies reported nasal 
allergies interfered with their child’s performance at school and more than half of the group had 
difficulty with performing work or other activities or accomplishing less (Derebery, Meltzer, & 
Boyle, 2008). The ripple effect of prolonged fatigue could lead to stress and increase the risk 
of depression (Léger et al., 2006). 
 
2.6.3. Stress and anxiety 
The effects of stress and anxiety as a result of sensitisation correlate with AR comorbidities or 
vice versa. Individuals suffering from AR, displayed a higher level of emotional reactivity such 
as irritability, mood swings and anxiety when compared to non-AR (Bedolla-Barajas, Morales-
Romero, Pulido-Guillén, Robles-Figueroa, & Plascencia-Domínguez, 2016).  Experimentally-
allergen-induced in vitro models demonstrated increased activities of Th2 cytokines and 
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corticotrophin-releasing factor with a peptide hormone and a neurotransmitter generally 
released during stress responses, in the prefrontal cortex (Tonelli et al., 2009). The proposition 
was a causal link between allergen sensitisation and elevated activity of anxiety in the brain 
function. Two-fold increases in pro-Th2 cytokines IL4, IL5 and IL13 in prefrontal cortex 
indicated neural responses in allergic reactions. The authors speculated the involvement of T-
cells and corticotrophin-releasing factor could be associated with the higher stress responses in 
AR sufferers. The level of stress experienced in patients also correlated with the severity of AR. 
Patients with intermittent AR on the severity scale of moderate to severe tended to experience 
higher significant stress than mild AR sufferers (K. Lee et al., 2008). Negative parameters in 
Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), a quality of life measure 
demonstrated strong correlations with fatigue and stress (Park, Shin, Lee, Cho, & Kim, 2012). 
With amplified stress and anxiety in AR patients, the risk of depression poses a high risk factor. 
A longitudinal study in adolescents with AR showed a higher prevalence of major depression 
in later life and onset of any depressive disorder (M. H. Chen et al., 2013). However, the neural 
mechanism and allergic pro-inflammation causing depressive disorder in AR are still yet to be 
explored in its entirety.  
 
2.7. Classifications of AR 
2.7.1. Seasonal AR and perennial AR 
AR was traditionally classified as seasonal AR (SAR) and perennial AR (PAR) by ARIA and 
is still in currency. J. Bousquet et al. (2001) reiterated that the classification of AR has always 
been based on the time of exposure. SAR is associated with the exposure of outdoor allergens, 
in particular, pollens or moulds while PAR is linked to indoor allergens exposure such as dust 
mites, insects and animal danders. A comprehensive data from Allergies in America, Pediatrics 
Allergies in America, Allergies in Latin America and Allergies in Asia Pacific based on 
telephone survey noted that 56% of US adults suffered from PAR while 43% suffered from 
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SAR, one half of the US respondents experienced AR symptoms for more than four months in 
a year, with one in five patients experienced AR symptoms more than nine months in a year 
(Meltzer et al., 2012).  
 
On the contrast, both Latin America and Asia Pacific adults tend to have a higher prevalence 
of SAR sufferers (61% and 63% respectively). The remaining 1% (US), 2% (Latin America) 
and 4% (Asia Pacific) respondents cited not knowing the types of AR they suffered from 
(Figure 5). 
 
  
Figure 5. Percentage of respondents suffering from SAR and PAR globally (extracted from Figure 1C on page 
S117 of Meltzer et al, 2012) 
 
2.7.2. Intermittent AR (IAR) and Persistent AR (PER) 
ARIA proposed an additional subdivision of intermittent AR (IAR) and persistent AR (PER) to 
the existing traditional classification of seasonal AR (SAR) or perennial AR (PAR) in 2001 (J. 
Bousquet et al., 2001). The objective of this classification provide a guideline for differentiating 
the duration and severity of AR. Recognising the symptomatic disorders of AR is of a spectrum, 
this inflammatory disorder is also classified as mild or moderate-severe depending on the 
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severity of the symptoms and on the quality of life outcomes (J Bousquet et al., 2008; J. 
Bousquet et al., 2001) (Table 4). J Bousquet et al. (2008) acknowledged in ARIA 2008 update 
that IAR and PER cannot be used interchangeably with SAR and PAR. The later and the former 
classification cannot be used in the same stratum of the disease.  
 
Table 4. Nomenclatures of AR classifications according to spectrum of severity (J. Bousquet et al., 2001) 
Spectrum of AR Classifications of AR 
Intermittent  “Intermittent” means that the symptoms are present: 
Less than 4 days a week; or 
For less than 4 consecutive weeks 
Persistent  “Persistent” means that the symptoms are present: 
More than 4 days; and 
For more than 4 consecutive weeks 
Mild  “Mild” means that none of the following items are present: 
Sleep disturbance 
Impairment of daily activities, leisure and/or sport 
Symptoms present but not troublesome symptoms 
Moderate to  
Severe 
“Moderate to severe” means that one or more of the following items are present: 
Sleep disturbance 
Impairment of daily activities, leisure and/or sport 
Impairment of school or work 
Troublesome symptoms 
 
The objective of the new classification was put forth to aid practising physicians with 
administration of the pharmacologic treatments according to the spectrum of severity and 
patient’s quality of life affected by the disease. However, this new classification is encumbered 
with complexity for practising physicians and does not yield significant improvement nor 
translate to a difference in therapeutic options (J Bousquet et al., 2008). Therefore, it is common 
for physicians to still rely on the traditional AR classification in differentiating and 
administrating therapeutic options for AR patients. 
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2.8. Diagnosis of AR 
Initial physical diagnosis of AR has to be differentiated from other respiratory symptoms which 
may appear similar to AR. AR symptoms are mainly attributed to IgE specific allergens and 
physical examination are recommended to eliminate other non-allergic causes of nasal 
obstruction and rhinorrhoea that may be related to infections, tumours or other chronic 
inflammations (Seidman et al., 2015). 
 
2.8.1. AR symptoms 
AR is characterised by several symptoms mainly nasal symptoms, ocular symptoms, otic 
symptoms and systemic symptoms. Nasal symptoms involve repeated sneezing, nasal 
congestion, itchy nose, runny nose and postnasal drips. Ocular symptoms involve itchy eyes, 
crimson eyes, excessive tearing and puffy eyelids. Otic symptoms may include pain in the ear, 
itchy ears, pressure in the ear and constant blockage of the ear. While systemic symptoms can 
be widely ranged from sleep disturbance, extreme fatigue, anxiety and general poor health. 
Immunologically, in vitro results demonstrated early phase reaction of AR is marked by 
repeated sneezing and itching of the nose that may last more than one hour, while late phase 
reaction of AR manifested nasal congestion that persisted for three to 11 hours (D. Y. Wang & 
Clement, 2000).  
 
Nasal congestion was the main symptom cited by AR sufferers in the US to have the most 
impact during their worst month. However, in respondents in Asia Pacific, sleep disturbance 
was cited as the most common during their worst month (Meltzer et al, 2012) (Figure 6). In 
contrast to a recent clinical practice guideline established by the American Academy of 
Otolaryngology – Head and Neck Surgery on the types of symptoms for accurate diagnosis of 
AR (Seidman et al., 2015), it appeared that AR sufferers bore symptoms beyond nasal, otic and 
ocular ailments. 
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Figure 6. Most common AR symptoms experienced during respondents' worst month in Asia Pacific, Latin 
America and United States (data extracted from Figure 3 on page S119 of Meltzer et al, 2012) 
 
2.8.2. Ear, Nose and Throat (ENT) examination 
Physical ENT examination was highly recommended hand in hand with empirical treatment 
without first subscribing allergy testing (Seidman et al., 2015). Historical and physical findings 
of signs and symptoms as well as stimuli and exposure could potentially point to whether 
findings fit AR signs (Table 5). While empiric treatment could be subjected to the ARIA 
guidelines of diagnostic algorithm based on the severity of the symptoms (Figure 7), 
confirmatory allergy testing could be the next step for clinicians to follow up if empiric 
treatment fails. The role of patient preferences on costs, risks and benefits and the types of 
testing in shared decision with the clinician is an upmost consideration. In taking these 
recommended steps, costs of burden to healthcare system and individuals could be substantially 
reduced.  
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Table 5. Historical and physical ENT findings in AR (Seidman et al., 2015) 
Presenting Symptoms Historical Findings Physical  ENT Findings 
Nasal congestion Seasonal or perennial nature of  
symptoms 
Clear rhinorrhoea – clear or  
coloured (coloured rhinorrhoea  
may indicate comorbid disease  
with AR) 
Bluish or pale swelling of nasal  
mucosa 
Sneezing Symptoms on exposure to  
particular agent (animals,  
particular plants) 
Rhinorrhoea - clear or  
coloured (coloured  
rhinorrhoea may indicate 
comorbid disease with AR) 
Family history of atopic or  
allergic disease 
Current medications 
Itching of eyes, nose and palate Symptoms on exposure to 
irritants  
(makes allergic origin less likely) 
Ocular findings (watery  
discharge, swollen  
conjunctivae, scleral injection) 
Ocular findings (watery  
discharge, swollen  
conjunctivae, scleral injection) 
Allergic shiners 
Nasal crease 
 
Postnasal drips 
Frequent throat clearing 
Cough 
Symptoms of respiratory  
infection (makes allergy origin  
less likely) 
Frequent throat clearing  
 
Malaise (may be presented 
with complaints in children) 
Fatigue (may be presented 
with complaints in children) 
 Absence of foreign body,  
tumour, purulence suggesting  
infection 
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Figure 7. Algorithm for the diagnosis and management of AR (data adapted from page 5 of J. Bouquet.et al. 
2007) 
  
Step 1. Mild 
symptoms 
(intermittent)
• Intranasal 
•H1 blockers plus decongestants or
•Decongestants only
•Anti-leukotrienes
Step 2. 
Moderate to 
severe 
symptoms 
(intermittent)
•Similar to Mild (intermittent 
treatment) plus 
glucocorticosteroids or cromones
Step 3. Mild 
symptoms 
(Persistent)
•Review after 2 to 4 weeks for 
improvement or failure
Step 4. 
Moderate to 
severe 
symptoms
 Intranasal glucocorticosteroids   
 H1 blockers 
 Anti-leukotrienes 
 Successful – step down 
 treatment to Step 3. 
 Failure – review 
 Review  
a) Add or increase 
glucocorticosteroids 
b) If rhinorrhoea, add  
ipratropium 
c) If nasal blockage, use 
decongestant or short term 
dose of glucocorticosteroids 
d) Conjunctivitis – use oral or 
intraocular H1 blocker or 
intraocular cromones or 
saline 
 Failure – refer to specialist 
 Consider immunotherapy 
 
 
 
 
(Dazaley, 2015) 
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2.8.3. Allergen specific tests 
IgE testing is conducted in either blood or skin. The following types of IgE-specific tests are 
listed in Table 6. The most commonly used forms of IgE specific tests are skin prick test and 
intradermal dilution.  
 
Table 6. Types of allergen specific tests (Seidman et al., 2015) 
Allergen specific testings Specificity 
Skin prick-IgE 
High specificity and sensitivity, commonly used; 
Contraindicated in skin diseases 
Scratch testing-IgE 
Reduced specificity and sensitivity, with poor reproducibility, rarely 
used; 
Contraindicated in skin diseases 
Intradermal/ intradermal 
dilution 
Specific allergen identification of allergen sensitisation, commonly 
used and highly sensitive; 
Contraindicated in skin diseases 
Provocation neutralization test 
Historical interest for inhalant allergy testing; 
No clinical correlation and immunologic mechanism are established 
for this testing 
ImmunoCAP-IgE 
High specificity for anti-IgE antibodies affixed to radioactive tags; 
High sensitivity for specific allergen and costly 
Acoustic rhinometry Non-specific for IgE 
Olfactory testing Non-specific for IgE 
Microarray testing Non-specific for IgE 
Nasal nitric measurements Non-specific for IgE 
Nasal smears Lacks accuracy and sensitivity 
 
Skin testing detects sensitisation to the mast cells reactivity owing to the presence of IgE. 
Wheals and flares are formed when epithelial mast cells interacts with the antigen. Where skin 
testings are contraindicated, in vitro methods using the patient’s serum are tested for allergy 
sensitisation. For radioallergosorbent test (RAST), the term “radio’ should no longer be used, 
as the assays used currently no longer contain radioactive material (Pudupakkam, 2014). 
Currently, ImmunoCAP is a popular choice of in vitro diagnosis with high binding specificity 
for allergen testing. 
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2.9. Management of AR 
For the AR sufferers, there are three levels involved in the management of AR namely; primary, 
secondary and tertiary (J Bousquet et al., 2008).  
 
The primary level of management involves personal and community wide efforts to enforce 
good levels of physical fitness, nutrition and emotional wellbeing. Steps should be taken to 
enhance the level of self-immunity through means of immunisation to prevent infectious 
diseases. The secondary level includes early detection of AR symptoms and effective measures 
to prevent exacerbation of sensitisation when physical evidence emerges. Education in 
avoidance of allergen is highly recommended for AR sufferers. Last, the tertiary level involves 
measures to eliminate long-term impairments of AR (J Bousquet et al., 2008). When AR 
persists, despite steps taken at both primary and secondary levels, the use of pharmacotherapy 
comes into place.  
 
For the clinical physicians, poor diagnosis of AR is often met with inadequate or inaccurate 
therapies leading to poor treatment outcome. An algorithm for the management of AR was 
developed by ARIA to aid the family physician in diagnosis and prescription of medications. 
Severity spectrum of AR has to be taken into considerations whether the symptoms were mild 
or moderate to severe. First, for intermittent mild AR symptoms, oral, intranasal anti-histamines 
or combined anti-histamines with decongestant would be prescribed. Second, for intermittent 
moderate to severe AR symptoms, anti-leukotrienes antagonists may be prescribed. If the 
symptoms persisted after two to four weeks, a step up management would be considered. PER 
symptoms, ranging from moderate to severe would be reviewed after the first line of 
pharmacotherapy. At this level, glucocorticosteroids, cromones and anticholergenics would be 
prescribed. Finally, when all have failed to deliver relief of AR, immunotherapy would be in 
place as the last line of pharmacotherapy for severe PER. 
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2.9.1. Allergy avoidance and education 
The ARIA guidelines advocated allergen avoidance and education as one of the strategies for 
AR management (J. Bousquet et al., 2001). Avoidance of allergens was strongly recommended 
with the interventions in lifestyle. AR sufferers with pollen allergies might encounter pollen 
challenge on an annual basis; however, the magnitude of the exposure to allergies may be more 
extensive. Taking the extra steps to avoid immediate exposure to the risk of allergen specific 
induction could relieve the symptoms (Table 7). 
 
Table 7. Strategies for reducing allergens according to ARIA (J. Bousquet et al., 2001) 
Types of allergens Strategies of reducing allergens 
Indoor allergens   Seal mattress, pillow and duvet in mite allergen impermeable casing 
 Wash beddings in hot water (> 50°C) weekly or dry laundry in sun to terminate 
mites 
 Wash laundry in cold water to reduce dust allergen 
 Remove wall to wall carpet 
 Steam clean with liquid nitrogen or acaricides to reduce mite numbers in carpet 
if it cannot be removed 
 Wash curtains at 55°C 
 Wash in hot water (55°C), freeze or remove children’s soft toys 
 Use acaricide sprays to reduce allergens 
 Use high efficiency particulate air vacuum cleaners and double thickness bags 
 Reduce humidity levels in the home and install effective ventilation systems 
or ensure aeration for adequate ventilation 
 Repaint and treat mouldy dwellings 
 Restrict or remove pets in lodgings  
 
Outdoor allergens  Wear protective masks and eyeglasses 
 Seal the lodging by day and aerate only at night when pollen load is high 
 
 
Education of AR involves the use of the medications prescribed to AR patients, with the most 
common form being oral and intranasal. The right administration for the severity of AR and 
duration are crucial for the increase responsiveness to the right medications. Patient’s 
compliance, physician’s right diagnosis and prescription will greatly increase efficacious 
outcome on AR symptoms.  
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2.9.2. Pharmacotherapy for AR 
The mainstream pharmacotherapy for AR is well established with many options of relief for 
AR sufferers. The options of these pharmacotherapies depend on the severity and the duration 
of AR experienced by the patients and the physicians in care to accurately dispense the right 
medication for the treatment. 
 
i. Anti-histamines 
Anti-histamines are also known as H1 receptor antagonists, H1 blockers or oral H1. Anti-
histamines primarily act on selective histamine receptors and there are four subtypes of 
histamines receptors: H1, H2, H3 and H4. H1 and H2 receptors are commonly expressed in the 
human tissues, whereas H3 and H4 are limited. The former are abundant in skin, intestinal 
mucosa and respiratory tract, while the latter H3 are found throughout the nervous system with 
H4 receptors in the thymus, small intestines, spleen, colon, bone marrow and basophils. 
Histamine release is triggered by antigenic binding of IgE specific allergens. Histamine release 
causes both acute and systemic hypersensitivity reactions manifested in AR symptoms. The 
pharmacologic rationale of these anti-histamines targets inflammatory mediators associated 
with AR such as ECP, granulocyte-macrophage colony-stimulating factor (GM-CSF), 
histamine, intracellular adhesion molecule 1 (ICAM-1), interleukin (IL) 1β (ILl-β), IL6, IL8, 
kinins, myeloperoxidase, nuclear factor kappa beta (NF-κβ), nitric oxide (NO), substance P, 
TLR 3, tryptase and tumour necrosis factor-α (TNF-α) (Hernandez-Trujillo, 2009). In spite of 
their efficacy in downregulating the AR mediators, there remain many side effects of these anti-
histamines (Table 8.). 
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Table 8. Modes of administration, action onset and side effects of anti-histamines for AR (J. Bousquet et al., 
2007; Cassell & Katial, 2009) 
Generic names of anti-
histamines 
Modes of  
administration  
Action onset 
Side effects 
Cetrizine (Zyrtec) Oral 1 hour  Sedation 
 Mucosal dryness  
 Urinary retention 
Ebastine  <1 hour  Drowsiness 
 Headache 
 Dry mouth 
 Pharyngitis 
 Indigestion 
 Nausea  
 Epistaxis 
Levocetirizine (Xyzral) Oral 1 hour  Sedation 
 Mucosal dryness 
 Urinary retention 
Fexofenadine (Allegra, 
Telfast) 
Oral 1 hour  Headache 
Loratadine (Claratin, 
Alavert) 
Oral 3 hours  Sedation with  
higher dosages 
Desloratadine 
(Clarinex, Aerius)  
Oral 2.5 hours 
Olopatadine (Patanase) Intranasal 30 minutes  Bitter taste 
 Epistaxis 
 Somnolence 
 Headache 
Levocabastine 
(Livostin) 
Intranasal, intraocular <1 hour  Visual disturbance 
 Dry mouth 
 Fatigue 
 Pharyngitis 
 Eye pain 
 Dryness 
 Somnolence 
 Cough 
 Nausea  
 Rash  
 Dyspnoea 
Azelastine (Astelin,  
Astepro) 
Intranasal 15 minutes 
 
 Bitter taste 
 Epistaxis 
 Somnolence 
 Headache 
Azelastine olus  
Dymista (fluticasone) 
Intranasal 
Rupatadine Oral  Somnolence 
 Headache 
 Fatigue 
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ii. Glucocorticosteroids 
Glucocorticosteroids (Glu) is an immunosuppressant, categorised as a class of steroids 
hormones. This class of drugs is generally used as the first line therapy for moderate to severe 
PER. The anti-inflammatory mechanism of Glu is distinct. Glu targets glucocorticoid receptors 
and its ligand-binding affinity with chaperone molecules on cell membrane. Its activity is 
mainly distinct in its action on the translocation to the nucleus where it activates transcription 
of anti-inflammatory genes and destabilises the pro-inflammatory mRNA species (Barnes, 
2010; Baschant & Tuckermann, 2010). Its transcriptional inhibition extends to components 
such as activator protein-1, NF-κβ, interferon regulatory factor-3 (IRF-3), signal transducer and 
activator of transcription (STAT), cAMP response element binding (CREB) protein, nuclear 
factor of activator T-cells (NFAT), T-box transcription factor (T-bet) and trans-acting T-cell-
specific transcription factor GATA-3, all are pro-inflammatory transcription factors that 
regulate transduction of inflammation cascade of cytokines (Baschant & Tuckermann, 2010). 
Intranasal Glu are generally effective on nasal congestion. When comparing administration of 
Glu in terms of oral to immunotherapy; the latter should only entail a short duration. This is due 
to its systemic side effects that are associated with its immunosuppressive nature (Table 9).  
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Table 9. Modes of administration, action onset and side effects of glucocorticosteroids (J. Bousquet et al., 2007; 
Moghadam-Kia & Werth, 2010) 
Names of 
glucocorticosteroids 
Modes of 
administration 
Action onset Side effects 
Beclomethasone 
diproionate 
Budesonide 
Ciclesonide 
Flunisonide 
Fluticasone propionate 
Fluticasone furoate 
Mometasone furaote 
Triamcinolone 
acetonide 
Intranasal 6 to 12 hours,  
maximal effect  
after a few days 
 Suppresses wound  
healing 
Dexamethasone 
Hydrocortisone 
Methylprednisolone 
Prednisolone 
Prednisone 
Triamcinolone 
Betamethasone 
Deflazacort 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Oral/ 
Immunotherapy 
 
 
 
 
 
 
 
 
 
 
 
6 to 12 hours,  
maximal effect  
after a few days 
 
 
 Local tissue atrophy or myopathy 
 Bone loss resulting in        
osteoporosis  
 Hypercalcicuria 
 Hypertension 
 Increased osteocytes apoptosis thus 
resulting in avascular necrosis 
particularly in the femoral head 
 Elevation of serum lipids resulting 
in hyperlipidaemia 
 Decrease glucose utilisation and  
increase hepatic glucose production 
resulting in hyperglycaemia, 
development of diabetic syndrome 
 Increase in ischemic heart disease 
and heart failure 
 Mood alterations, memory deficit 
and risk of psychosis 
 Gastrointestinal (GI) complications 
such as gastritis, peptic ulcerations, 
GI haemorrhages and acute 
pancreatitis. 
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iii. Decongestants  
Decongestants are categorised as sympathomimetic drugs, which are effective in relieving nasal 
congestion. These drugs are primarily α-adrenergic agonist, targeting on α-adrenergic receptors 
on blood vessels of nasal mucosa, inducing vasoconstriction which decreases blood flow 
through the mucosa and shrinks the nasal erectile tissues (McLeod, Erickson, Mingo, & Hey, 
2001). α2-adrenergic receptors are abundant in the nasal mucosa, in vitro study on a cat with 
nasal congestion demonstrated the decongestant effect of α1-adrenergic agonist phenylephrine, 
a topical BHT-920 (a selective α1-adrenergic agonist phenylephrine)  and non-selective α-
agonist oxymetazoline, all were successful in producing a decongestant effect (McLeod et al., 
2001). This study revealed not just the positive outcome of the decongestant but it highlighted 
the potential adverse effects of the use of sympathomimetic amines. Transient hypertension was 
associated with oxymetazaoline and phenylephrine, systemic elevation of blood pressure is 
significantly related to dosage. The real concern is when this class of drugs is prescribed to 
young children, cardiovascular instability and respiratory depression and sedation could pose 
potential death (Tobias, Cartabuke, & Taghon, 2014). Abuse of this class of drugs owing to 
lack of education on the limit of use and the availability as OTC drugs could present 
cardiovascular risk and rhinitis medicamentosa due to rebound hypertrophy of nasal mucosa. 
The side effects of the sympathomimetics are summarised in Table 10. 
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Table 10. Modes of administration, action onset and side effects of decongestants (J. Bousquet et al., 2007) 
 
Names of 
decongestants 
Modes of 
administration 
Action onset Side effects 
Ephedrine Oral 15 to 30 minutes Minor effects include 
 Nausea 
 Vomiting  
 Headache  
 Dizziness 
 Dry mucosa 
 
Serious effects include  
 High blood pressure 
 Palpitations  
 Restlessness  
 Urinary retention 
 Seizures 
 Insomnia 
 Exacerbation of glaucoma  
 Thyrotoxicosis 
Rhinitis medicamentosa if used > 10 
days 
 Hypertension Stroke 
 
iv. Anti-leukotrienes 
Anti-leukotrienes are designed as mediators-specific antagonists to target cysteinyl leukotrienes 
(cysLTs). These are primarily inflammatory lipid mediators deriving from lipoxygenase 
pathway of arachidonic acid cascade (Abbas et al., 2012). LTC4, LTD4 and LTE4 are implicated 
in the pro-inflammatory responses in mast cells proliferation, monocytes and macrophages 
migration and production of reactive oxygenated species (ROS), eosinophilic migration and 
adhesion to vascular endothelium, increase in cytokines IL10 and IL8 in dendritic cells and 
neutrophils proliferation with NO production. Interaction with these cysLTs commonly 
produced responses of chronic AR or late phase reaction in AR as well as in asthma with 
manifestations of bronchial hyperresponsiveness, airway constriction, oedema, excess mucous 
secretion and increased airway resistance (Rosenwasser, 2007). Anti-leukotrienes such as 
montelukast, pranlukast and zafirlukast target neutrophils, monocytes and macrophages by 
inhibiting multi anti-inflammatory targets, namely; arachidonate 5-lipoxygenase cataclysm to 
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LTE4, production of reactive oxidative species (ROS), NF-κβ transcription, Prostaglandin E2 
(PGE2) synthase and cyclic nucleotide phosphodiesterases which subsequently increase 3′5′-
cyclic adenosine monophosphate (cAMP), a pro-inflammatory regulator in innate immunity 
(Theron et al., 2014). Table 11 summarises the modes of administration, action onset and side 
effects of anti-leukotrienes. 
 
Table 11. Modes of administration, action onset and side effects of anti-leukotrienes (J. Bousquet et al., 2007) 
Names of 
anti-leukotrienes 
Modes of 
administration 
Action onset Side Effects 
Montelukast Oral 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rapid 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Headache 
 Gastrointestinal  
 Nausea 
 Fatigue 
 Fever 
 Mild rash 
Pranlukast 
Zafirukast 
 
 
 
 
 
 
 
 
 
 
Serious side effects include 
 Exacerbation of asthma 
 Respiratory exacerbation 
 Mood changes 
 Anxiety 
 Insomnia 
 Depression 
 Severe tingling sensation in 
extremities 
 Skin rash  
 Bruising 
 Muscle weakness or  
 atrophy 
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v. Anticholinergics 
Anticholinergics are antimuscarinic agents which produce bronchodilation in the smooth 
muscle of the airways. Elevation of airway resistance attributed to the increased vagal tone of 
the cardiovascular and respiratory systems is commonly associated with moderate to severe AR 
and asthma. Anticholinergics mainly act on the muscarinic receptors namely M1 receptors 
(commonly found on cholinergic ganglia), M2 receptors (found on postganglionic fibres) and 
M3 (found on smooth muscles, mucosa and vascular endothelium) (Novelli, Malagrinò, Dente, 
& Paggiaro, 2012). The target is to restrict the release of neurotransmitter acetylcholine 
mediating through the parasympathetic pathway. The administration of this class of drug is 
mainly by use of a nebuliser and its effects are known to be short lasting; however, this drug is 
not without its side effects (Table 12).   
 
Table 12. Modes of administration, action onset and side effects of anticholinergics (J. Bousquet et al., 2007) 
Names of 
anticholinergics 
Modes of 
administration 
Action onset Side effects 
Ipratropium 
bromide 
Intranasal  Rapid Mild effects include 
 Dry mouth 
 Blurred vision 
 Constipation 
 Drowsiness 
Serious effects include 
 Memory impairment 
 Exacerbation of glaucoma 
 Prostatic hypertrophy 
 
vi. Cromones  
Cromones are also known as disodium cromoglygate, cromolyn sodium, cromoglygate, and 
cromolyns. Aside from the myriad names, this class of drugs is commonly termed as mast cell 
stabilisers. Cromones had been advocated to be administered prophylactically in order to 
achieve its maximum effect. The mechanism of cromones promoted the activation of protein 
kinase C phosphorylation and secretion of Anx-A1, an annexin peptide that possessed 
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inhibitory action on histamine-release and prostaglandin 2 (PGD2) anti-inflammatory cascade 
in mast cells (Yazid, Sinniah, Solito, Calder, & Flower, 2013). This study also discovered that 
chromones yielded variable effects only when there was an absence of the late phase reaction 
in vitro. This could explain that the timing of cromones administration is highly crucial for it to 
exert its full effects, although the mechanism is not fully known. Table 13 summarises the key 
types of cromones, their modes of administration, action onset and side effects. 
 
Table 13. Modes of administration, action onset and side effects of cromones (J. Bousquet et al., 2007) 
Names of Cromones 
 
Modes of 
administration 
Action onset Side effects 
Sodium cromoglycate Intranasal/ 
intraocular 
6 to 12 hours,  
maximal effect  
after a few days 
 Short lasting effects for intranasal  
 Administered before allergen 
exposure season for full effects 
 Excellent safety therapy 
Nedocromil sodium 
Naaga 
 
2.9.3. Allergen specific immunotherapy 
For severe PER or PAR, allergen specific immunotherapy is the last option when all Western 
pharmacotherapies have been exhausted. Allergen specific immunotherapy is a treatment 
process which involves repeated administration of specific, semi-purified allergen extracts with 
the aim of reducing symptoms on subsequent allergen exposure, improving quality of life and 
inducing long-term tolerance to a “naturalised” adaption of allergen exposure (Walker et al., 
2011). Several factors are considered before allergen specific immunotherapy is introduced to 
AR sufferers including patient’s receptiveness, adherence, medication requirements, reaction 
to avoidance measures, AR and asthma exacerbation, affordability and allergy triad 
manifestations (AR, asthma and atopic dermatitis). 
 
There are two routes of administration for allergen immunotherapy treatment namely; 
subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT). As the term 
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denotes, SCIT is a specific purified allergen injection administered under the arm on an 
incremental dose. The objective is to achieve a Th2-Th1 shift immunologically with a sustained 
maintenance dose and this regime is continued for at least over a period of two years. SLIT is 
an alternative approach where the course of immunotherapy regime is administered with a tablet 
or spray under the tongue. This mode of immunotherapy is generally dispensed for children 
with severe AR or atopic diseases.  
 
A comparative study measured the clinical efficacy of SCIT, SLIT and pharmacotherapy over 
a period of one year utilising two species of dust mites Dermatophagoides pteronyssinus and 
Dermatophagoides farina antigenic immunotherapy. Although results indicated effects of SCIT 
and SLIT decreased the specific allergen reactivity in skin and increased the threshold to induce 
nasal hyper-reactivity in VAS, however variable analysis on allergen-induced cytokine IL10 
was reflected (Eifan et al., 2010). The main role of IL10 is to inhibit further differentiation of 
Th1 cells and macrophages activation. It has an important role in turning off the T-cells 
activation as well as inhibitory effects on mast cells and basophils in adaptive response. 
Therefore IL10 is inextricably linked to down-regulation of mast cell inflammatory release in 
the nasal mucosa (Abbas et al., 2012). In this study, an observable increase in the IL10 was 
discovered with SLIT even though AR symptoms were reduced. Increase in rescue medication 
(anti-histamine, intranasal/inhaled/oral corticosteroids and β2 agonists) usage in SLIT and non-
significant titrated IgE levels also did not seem to correspond with the reduction of nasal 
symptoms reflected on VAS. Two systemic adverse events relating to SCIT emerged with 
flushing, wheezing and dyspnoea bordering on the risk of anaphylaxis required adrenaline 
treatment. 
 
Variable results of the peripheral blood mononuclear cells of AR patients in vitro were also 
rendered on IL10 in comparison with AR symptoms for SCIT, indicating greatest reduction of 
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AR symptoms corresponded with the least increase of IL10 expressions, while greatest increase 
of IL10 was detected in patients with the least reduction in AR symptoms (Savolainen, 
Laaksonen, Rantio-Lehtimaki, & Terho, 2004). The authors purported that early or transient 
increase in IL10 and IL18 mRNA expression was crucial to yield beneficial outcome in SCIT. 
However, it appears that this phenomenon is also visible in SLIT in the previous discussion. 
Clearly, the role of IL10 and correlation of symptoms attenuation require further exploration in 
immunotherapy studies. R. Pawankar, Canonica, et al. (2011) acknowledged that clinical 
studies on immunotherapies had produced heterogeneous results, of which led to weak meta-
analyses.  
 
A four-year retrospective German survey investigated on the long-term effectiveness, local 
reactions and systemic reactions of SCIT (venom or inhaled allergen immunotherapy) on a 
cohort of 1,257 patients with AR, conjunctivitis, allergic asthma and stinging insect 
hypersensitivity in a clinical study. Its results showed that overall systemic reactions prevalence 
was 13.6% (n = 195), while local reactions prevalence was at 13.9% (n=175). The major risk 
of immunotherapy was anaphylaxis (Adamic et al., 2009). Furthermore, a SR evaluating 
effectiveness of SCIT for allergic rhinoconjunctivitis and asthma indicated 35 out of 61 
included SCIT studies reported safety data. Out of 35 trials, 13 anaphylactic reactions were 
reported in four trials which involved 205 participants (Erekosima et al., 2014). Common local 
reactions associated with immunotherapy included itching and swelling of nodules, swelling of 
lips and rashes while systemic reactions were urticaria, rhinoconjunctivitis, oral allergy 
syndrome and asthma (Winther, Malling, & Mosbech, 2000). This study also indicated 
unspecific symptoms such as tiredness, headache and malaise would emerge after 
immunotherapy. Despite the side effects and heterogeneous results of meta-analyses of the 
reviews on immunotherapies, immunotherapies treatment still yielded efficacious outcomes on 
the reduction of nasal allergy symptoms.  
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2.9.4. Complementary and alternative medicine (CAM) for AR 
CAM refers to any therapeutic interventions that exist outside conventional medicine and are 
used interchangeably with traditional medicine in some countries (Kern & Bielory, 2014; 
WHO, 2013). The WHO (2013) further defined CAM as a broad set of healthcare practices that 
are not integrated into the mainstream healthcare system. In Australia, the rising demand of 
CAM was reflected in a telephone-based survey carried out in 2005. Findings revealed that 
44.1% of Australian adult respondents visited a CAM practitioner, estimated 69.2 million of 
visits during the 12-month period (C. C. L. Xue, Zhang, Lin, Da Costa, & Story, 2007). Varied 
forms of CAM for AR are available for AR such as acupuncture and CHM in CM. 
 
The foundation of CM is a unique system of medicine based on written texts that long existed 
since the second millennium (Maciocia, 2008). These written texts provide fundamental 
knowledge in CM clinical practice. Comprehensive notation of the clinical treatments and 
pharmacopoeias in genres of CM classical literature highlights effective treatments of myriad 
of diseases that still pose a challenge in healthcare today. The WHO acknowledges demands 
for CM correspond with an increasing dissatisfaction with existing healthcare services, an 
increasing awareness of options in healthcare and an interest in individualised care and disease 
prevention associated with CM (WHO, 2013). Modalities used in CM include acupuncture, ear 
acupuncture and/or ear acupressure, and CHM. 
 
2.10. Comments 
The interventions for AR are extensive and well established. Drug treatment is regarded as the 
mainstream pharmacotherapy intervention for AR in ARIA Guideline 2008 update (J Bousquet 
et al., 2008). However, there is a distinct gap in the regard of long-term efficacy and systemic 
side effects of AR pharmaceuticals drugs.  
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Mahr, Sheth, and Boyle (2008) raised the concern of a lack of efficacy of intranasal 
corticosteroids for long-term relief of symptoms reported by parents in children with AR from 
five to 17 years based on a telephone survey conducted by the Pediatrics of America. A total of 
31% reported loss of efficacy within four to seven hours of administration, 89% indicated loss 
of efficacy within 24 hours and 54% cited attenuated effects in the medication. Side effects 
attributed to the nasal sprays were post nasal drips (42%) and bad taste (38%) (Mahr et al., 
2008). Side effects such as headache, gastrointestinal symptoms, rash and Churg-Strauss 
syndrome are often associated with intranasal corticosteriods (Greiner et al., 2012).  
 
The availability of OTC drugs further indicates a high chance for abuse of medication. One 
cross-sectional study employed study of individuals self-medicating persistent rhinitis with 
intranasal decongestants. Overuse of intranasal decongestant was as high as 49%, even though 
80% of the patients were educated about the limitation of use (Mehuys et al., 2014). Frequent 
use of intranasal decongestants is associated with rebound nasal congestion on withdrawal 
resulting in hypertrophy of the nasal mucosa known as rhinitis medicamentosa. It is clinically 
characterised by nasal congestion without rhinorrhoea, postnasal drip or sneezing. Patients with 
AR comorbid nasal polyposis suffer from rebound vasodilation, oedema, and haemorrhages 
during nasal intraoperation (Mehuys et al., 2014; Robison, Pant, & Ferguson, 2010). 
Discontinuation of use of nasal decongestants is often accompanied with withdrawal syndromes 
such as headaches, restlessness and anxiety (Ramey, Bailen, & Lockey, 2006). Although 
mainstream pharmacotherapy is well established and researched, permanent resolution of AR 
symptoms is still unavailable to sufferers. The issues of the side effects of these medications 
still present a confounding challenge to AR sufferers leaving many to weigh out the risk and 
benefit ratio to adopt a suitable medication regime for the management of AR. This could 
potentially pose medication abuse, lack of education in administration, failures in the 
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medication regime as well as risks and sequelae arising from the complications of the AR 
therapies. This has prompted a rising demand to seek CAM for the management of AR (G. Hu 
& Walls, 2005).  
 
The recognition of acupuncture as a form of modality was endorsed by 103 out of 129 countries 
in the global survey conducted by WHO in 2012 (WHO, 2013). The significant progress of 
acupuncture is likely attributed to the many clinical trials such as A. R. Kim, Choi, Kim, Jung, 
and Choi (2011) and Brinkhaus et al. (2013) that were undertaken in the universities throughout 
the Eastern and Western hemispheres. Acupuncture was recommended by the American 
Academy of Otolaryngology – Head and Neck Surgery Foundation as an alternative option for 
AR sufferers seeking non pharmacologic solution for their ailments (Seidman et al., 2015). 
 
In the same vein, many experimental studies have been conducted research on CHM for the 
management of AR and the results had yielded successful outcomes. It is important to stress 
that the use of CHM is not a single-herb administration for clinical treatment, it composes of 
mixture of multiple herbs formulation based on classical understanding of the properties of the 
herbs to address ailments. Many experimental studies have generated successful outcomes on 
the effects of AR management such as Nagai et al. (2004), Xu, Liu, Dai, and Zhou (2012) and 
Kao, Lin, Hsieh, Hsieh, and Lin (2001). Similarly, many clinical trials were also carried out 
over the years. Majority of the clinical trials and experimental research on CHM were carried 
out in Eastern hemisphere such as China, Japan, Taiwan and Korea. In fact, a few research on 
CHM for the management of AR were carried out at universities in the Western hemispheres 
such as a clinical trial on Astragali Radix on AR conducted by the Children’s Hospital Srebrnjak 
in Croatia (Matkovic et al., 2010) and Zurich University of Applied Sciences in Switzerland on 
toxicities of Asari Radix et Rhizoma (C. Chen, Spriano, Lehmann, & Meier, 2009). Access to 
language as well as classical texts, knowledge of the Chinese Materia Medica, and the cultural 
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context of CM limit the extent of research in CHM. Hence, it is in the interest of this thesis 
project to present and collate synthesised reviews on the outcomes of the classical texts data-
mining and clinical trials of AR. 
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Chapter 3  Literature review on AR – A Chinese medicine 
perspective 
 
This chapter reviews the diagnostic principles of AR from the perspective of CM and the use 
of CHM as well as other modalities in CM for the management of AR. 
 
3.1. Physiological mechanisms in CM 
The terminology “allergic rhinitis” [Guo Min Xing Bi Yan, 过敏性鼻炎] does not exist in 
Chinese medical annals. Owing to the direct translation of the terminologies and the conceptual 
descriptions of the pathologies of AR from Chinese to English language, the discourse of AR 
in the concept CM can be confounding. Comprehending the medical framework from a CM 
perspective requires an understanding of the Chinese culture and its language to better 
appreciate how CM embraces the notion of Qi, blood, Yin and Yang which regulate the basic 
physiological mechanism of the human body. A disruption to Qi-blood mechanisms causes 
imbalance of Yin and Yang and weakens the body system, rendering it susceptible to invading 
pathogens. 
 
3.1.1. Qi 
Qi is the motive force of all physiological processes (Maciocia, 2008). Classified Classic of 
Viscera (Lei Jing·Zhangxianglei,《类经·脏象类》) describes Qi as the connotative visceral 
within physiological functions of the viscera, morphology of the organs and resulting in 
pathological changes that form an interrelation with the wider environment. It is the guiding 
principle and a core component of the theoretical system of CM in guiding diagnosis, 
rehabilitation of health and disease prevention. According to CM philosophy, the human body 
is made up of energetic pathways akin to the Western medicine notion of neural pathway, filled 
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with intrinsic driving force, known as Qi (pronounced chee) (Chon & Lee, 2013). Qi takes on 
many different forms and at best is transformative. The movement and the transformation of 
the Qi are crucial to the homeostasis of the body. Qi is deemed to enter and exit the organs, also 
rise and descend in dispersion or stagnate and gush in a state of disease. In one of the earliest 
text, the Plain Questions on Pulse Classics (Ling Shu · Jing Mai, 《灵枢 · 经脉》), Qi Bo 
stipulated that the construct of human is made up by the physiological aspect and the spiritual 
aspect: the former where Qi and blood is channelled by nutritive and defensive physiologically 
within the viscera and the latter emotional and mental faculties are attributed to the Heart where 
the soul is housed (Wang, 1997). Therefore, Qi is regarded as the motive force that dwells 
physiologically, regulates emotionally and interacts socially with the wider environment. 
 
3.1.2. Blood 
Blood is deemed to be produced by the Spleen in CM. The primary function of blood in CM is 
considered to nourish the body Classic of Difficult Issues, Chapter 22 (Nan Jing·Ershiernan, 
《难经·二十二难》(Wiseman & Ellis, 1996). Its role is to provide nourishment for the 
functionality of the five senses, nine orifices, organs, motor function, muscular and skeletal 
structure of the human body. Abundant blood supply in CM is detectable in ruddy facial colour, 
fleshy and sturdy muscle tone, supple skin turgor and lustrous hair while poor blood circulation 
is reflected in pallor facial colour, dry skin turgor, brittle hair, inflexible and rigid muscles tone. 
The physiological aspect of the Spleen in CM at first glance does not correlate with the Western 
physiological mechanics. However, one striking similarity stands out that is, both are related to 
production of blood. In biomedical perspectives, blood production also known as erythropoiesis 
process takes place in bone marrow whereas the stress erythropoiesis after acute anaemia takes 
place in the spleen. The spleen harbours a specialised population of non-morphogenetic protein 
4-reponsive progenitors derived from bone marrow cells, which differentiates into erythroid 
units responsible for the growth and signals of spleen erythroblasts (Millot et al., 2010). 
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Therefore, the CM ancient stance on the Spleen in its role in producing blood to nourish the 
body is aligned with the mainstream physiological function of the spleen. 
 
3.1.3. Yin and Yang 
The concept of Yin and Yang is both an anatomic and a physiologic concept in the theory of 
CM (Wiseman & Ellis, 1996). Anatomically, the human body is viewed in terms of Yin and 
Yang. The anterior aspect of the body is regarded as Yin while the posterior aspect of the body 
is Yang. Physiologically, the five viscera organs pertaining to Yin are Liver, Heart, Spleen, 
Lung and Kidney and the Yang organs are Gallbladder, Stomach, Intestines, Bladder and the 
Triple Burner (Wiseman & Ellis, 1996). Both Yin and Yang organs function differently. 
Maciocia (2008) highlighted Suwen Chapter 5 which aptly described the Yin and Yang organs 
function: Yin is in the interior and is the material foundation of Yang; Yang is on the exterior 
and is the manifestation of Yin. An example of this connotation is the Heart. The function of 
the Heart governs blood and controls the blood vessels (Yin aspect). Here, the blood vessels in 
CM refer to energetic layers with skin, muscles, sinews and bones (Maciocia, 2008). If the 
blood circulation is abundant and strong, the complexion of the face would surface as rosy and 
lustrous (Yang aspect) (Maciocia, 2008). In addition, both characteristics of Yin and Yang are 
regarded as one of mutual opposition, dependence, consummation and transformation of each 
entity (Maciocia, 2008). When both characteristics of Yin and Yang maintain an equal balance 
of physiological function, it is deemed that homeostasis of biologic in health is achieved hence, 
good health is attained. 
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3.2. Definition of AR in CM 
There is no clear definition of AR in CM as this terminology does not exist in ancient times. 
However, the understanding of AR stems from the classical medical texts written by eminent 
doctors of the early days. Descriptions in the classical texts range from elucidation of the 
pathology of the nasal cavities to diagnosis and treatments.  
 
In Huangdi’s Internal Classic (Huang Di Nei Jing, 《黄帝内经》), a key symptom of AR 
sneezing [Pen Ti, 喷嚏] was also presented in the text, similar to rhinitis-syndrome. In the 
Miraculous Pivot (Ling Shu, 《灵枢》), the chapter on oral therapy (Kou wen, 口问) further 
described the mechanism of sneezing as the exuberance of the Yang energy filling the chest 
which subsequently surface from the nose to cause sneezing reactions (Wang, 1997). The 
earliest indication of AR-like signs and symptoms in CM lies in the key word “Bi Qiu” (鼻鼽). 
In Suwen·Pulse Classics《素问·脉解篇》, Bi Qiu is described as a condition accompanied 
with sneezing, runny nose and nasal obstruction (Wang, 1997).  
 
In the Compilation of Liu He Jian’s Six Medical Books (Liu He Jian Yi Xue Liu Shu, 《刘河
间医学六书》), clearly described AR sufferers (鼽者) would be encumbered with clear runny 
nose discharge (R. Hu, 2015). Similarly, the Ming dynasty medical text, the Miraculous 
Medical Formulary (Qi Xiao Liang Fang, 《奇效良方》) authored by Dong Su during the 
Ming Dynasty (R. Hu, 2015), also described the nose as the passage of the Lung which clear 
air passes and the rhythmic rise and fall of the Yin and Yang in tandem with the body’s Qi and 
the humour, the nose is able to maintain even breathing and the physiological function of 
differentiating smell. It is apparent that descriptions of AR-like signs and symptoms in the 
classical texts do exist in retrospective diagnosis and are closely associated with modern AR. 
To date, in CM terminology, “Bi Qiu” is regarded as the closest association to AR. 
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3.3. Aetiologies 
The causes of pathological diseases are attributed to the both internal and external stimuli. 
External pathogenic factors are the result of exposure to the elements in terms of geographical 
dwellings or the occupational locality of individuals. These external pathogenic factors consist 
of wind, cold, summer-heat, damp, fire-heat and dryness. These are climatic factors that affects 
the immunity of individuals known as Zheng Qi in CM. Internal factors are derived from seven 
emotions (i.e. anger, joy, sadness, worry, pensiveness, fear and shock) associated with taxation 
in mental health, nasal injuries or trauma (Maciocia, 2008). 
 
3.4. Pathogenesis of AR 
Pathogenesis of AR is highly associated with a dysfunction of three organs namely; Lung, 
Spleen and Kidney. In the book of Miraculous Medical Formulary, Chapter 59 (Qi Xiao Liang 
Fang·Juanzhiwushiju, 《奇效良方·卷之五十九》), according to CM description, the Lung 
is responsible for penetrating arterials for Qi flow. The balance of Ying and Wei is crucial to 
maintain good health. Wei refers to the defence barrier mechanism in the interstitial spaces of 
the skin and muscles, while Ying refers to the nutritive Qi that flows in the blood (Maciocia, 
2008). Adequate nourishment of nutrients in the blood provides harmony in the Ying-Wei and 
proper protection from external pathogen would ensure the good physiological functioning of 
the nose. The nasal pathology in CM fits the description of AR, is linked to the dysfunction of 
Lung, Spleen and Kidney when either internal or external factors attack the organs and the nose 
or vice versa. The interplay of these organs is shown in the pathogenesis diagram below (Figure 
8). 
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Figure 8. Aetiology and pathogenesis for AR in CM 
 
3.5. Differentiation of syndromes of AR in CM 
The differential diagnoses of AR in CM vastly differ from WM approach of disease 
differentiation. CM diagnosis is to determine a syndrome or a pattern of a group of signs and 
symptoms and based on connotative descriptions. Differentiation in CM is an individual centred 
and microcosmic approach, which may manifest in four main patterns (D. J. Xiong & Liu, 2013) 
as below: 
 
3.5.1. Lung deficiency (cold damage) causing Wei Qi disharmony 
Wei Qi (or defensive Qi) primarily lies in the interstitial spaces of the skin and the muscles, 
also known as the Cou Li. Anatomically, Cou Li refers to the epidermis and the dermis 
(Maciocia, 2008). In CM, Wei Qi dwells in the dermis and is regarded as the first barrier of 
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defence where it wards off pathogenic factors. Wei Qi is maintained in tandem with the Lung 
Qi. Weakness in the Lung Qi to diffuse the fluids, regulate sweating and control the pores can 
cause pathogenic factors to infiltrate the slack (cold invasion) or tight pores (lack of sweating 
may amount to increase of internal heat) (Maciocia, 2008). This imbalance signifies a lack of 
Lung Qi to maintain the defensive Qi in the Cou Li, which renders it susceptible to pathogenic 
factors especially Wind and Cold pathogens. Therefore, manifestations of itchiness, sneezing 
and blockage in nose can emerge. 
 
3.5.2. Spleen Qi deficiency inhibiting clear Yang rising 
The Spleen and the Lung in CM perspective are interrelated by the formation, nourishment and 
the movement of Qi. CM regards the Spleen as part of the digestive system. The Spleen 
primarily transforms and transports food essences and ascends clear Yang Qi to the Lung. The 
Lung regulates Qi by diffusing it and descending it to other organs. With the deficiency of 
Spleen Qi, the clear Yang rising is inhibited. When Lung Qi is affected with the inhibition of 
the clear Yang rising, its diffusion function is impaired (Maciocia, 2008). Water metabolism is 
also a part of the Spleen and Lung function. The Spleen separates the usable and the unusable 
parts of fluids ingested; the clear part goes upwards to the Lung to be distributed to the Cou Li, 
and the turbid part goes downwards to the intestines where it is eliminated through the bladder 
(Maciocia, 2008). If the Spleen Qi is impaired, this will affect the Lung diffusion, which in turn 
will generate dampness. With impaired Qi diffusion, the Lung is not able to fend off external 
pathogenic factor, and the nose will be runny.  
 
3.5.3. Kidney Qi deficiency inhibiting dispersion of warm Yang Qi to orifices 
The Lung is also responsible for the descending of the Qi and fluids to the Kidney, in turn the 
Kidney Yang evaporates the fluids and sends the clear mist up to the Lung to moisten the organs 
and the nasal orifices. Insufficient Kidney Qi can produce a lack of Kidney Yang, this can 
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compromise the ascending and the descending mechanism of Qi as well as the fluids between 
the Lung and the Kidney (Maciocia, 2008). With this impairment, susceptibility to cold attack 
of the Lung, fluid retention can cause an accumulation of nasal mucus often associated with 
nasal congestion and runny nose.  
 
3.5.4. Heat attack at Lung meridian surging and assailing the nasal orifices  
Heat attack at Lung meridian is a result of accumulated heat in the meridian causing the counter 
flow of Qi to assail the orifices (D. J. Xiong & Liu, 2013). Signs and symptoms of profuse 
sneezing and nasal congestion with thick yellow or green discharge often take place on humid 
hot days instead of cold days (D. J. Xiong & Liu, 2013).  
 
3.6. Management of AR in CM 
AR has been managed by various CM modalities including CHM, acupuncture, ear acupuncture 
/ ear acupressure and Tui Na. 
 
3.6.1. Chinese herbal medicine  
CHM is an important modality in CM, utilising Chinese medicinal formulae (mixture of 
Chinese herbs according to CM theories) to treat ailments. The nomenclature “Chinese herbal 
medicine” encompasses nature-derived products from trees, leaves, roots and bark, minerals 
and animal materials. These natural products have contributed in one way or another to the 
development of drug discoveries. For treatment of AR, CHM usage is widespread and has 
existed since the advent of second millennia. Application of CHM for AR by clinicians is 
diverse in nature owing to the extent variety of herbs in CM. Unlike Western pharmacotherapy, 
standardisation of the herbal formulae used for AR treatment is an insurmountable endeavour 
owing to diversity associated with CHM usage in CM clinical practice. Based on the pattern 
differentiations of AR in CM, there are common herbs that are used to treat the different patterns 
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of AR based on CM treatment principles. The treatment principles with commonly used CHMs 
are summarised in Table 14 (D. J. Xiong & Liu, 2013).  
 
Table 14. Treatment principles with common herbs used for different patterns of AR 
Treatment principles for the different patterns 
of AR 
Common herbs used  
Tonify Lung Qi, strengthen Wei Qi and dispel 
cold 
Ren Shen (Ginseng et Rhizoma) 
Gan Cao (Glycyrrhizae et Rhizoma) 
He Zi (Chebulae Fructus) 
Xi Xin (Asari Radix et Rhizoma) 
Jing Jie (Schizonepetae Herba) 
Jie Geng (Platycondonis Radix) 
Yu Nao Shi (Asteriscus Pseudosciaenae) 
Chan Tui (Cicidae Periostracum) 
Gan Jiang (Zingiberis Rhizoma) 
Tonify Qi, strengthen Spleen and penetrate Yang Ze Xie (Alismatis Rhizoma) 
Xin Yi Hua (Magnoliae Flos) 
Bai Zhu (Atractylodis Macrocephalae Rhizoma) 
Xi Xin (Asari Radix et Rhizoma) 
Shan Yao (Dioscoreae Rhizoma) 
Gan Jiang (Zingiberis Rhizoma) 
Sha Ren (Amomi Fructus) 
Fang Feng (Saposhnikoviae Radix) 
Gui Zhi (Cinnamomi Ramulus) 
Warm Kidney Yang, strength Kidney Qi and 
regulate Qi 
Rou Gui (Cinnamomi Cortex) 
Fu Zi (Aconiti Lateralis Radix Preparata) 
Ban Xia (Pinelliae Rhizoma) 
Chen Pi (Citri Reticulatae Pericarpium) 
Yi Yi Ren  (Coicis Semen) 
Gan Jiang (Zingiberis Rhizoma) 
Ren Shen (Ginseng et Rhizoma) 
Wu Zhu Yu(Euodiae Fructus) 
Huang Qi (Astragali Radix) 
Fang Feng (Saposhnikoviae Radix) 
Cool heat in the Lung and open nasal orifices Huang Qi (Astragali Radix) 
Zhi Zi (Gardeniae Fructus 
Shi Gao (Gypsum Fibrosum) 
Zhi Mu (Anemarrhenae Rhizoma) 
Sang Bai Pi (Mori Cortex) 
Xin Yi Hua  (Magnoliae Flos) 
Pi Pa Ye (Eriobotryae Folium) 
Bai He (Lily Bulbus) 
Mai Dong (Ophiopogonis Radix) 
 
3.6.2. Acupuncture 
Acupuncture is a technique of insertion and manipulation of fine needles in specific points on 
the human body. The therapeutic effects of acupuncture rely on the practitioner’s knowledge of 
specific locations on anatomical landmarks for particular diseases to yield optimum outcome. 
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Clinical studies have shown that treatment of AR patients using acupuncture demonstrated 
significant relief of the symptoms (Brinkhaus et al., 2013; A. R. Kim et al., 2011). 
 
A recent clinical practice guideline for management of AR published by American Academy 
of Otolaryngology – Head and Neck Surgery Foundation in the US has confirmed positive 
evaluation of acupuncture as a non-pharmacologic therapeutic option for patients (Seidman et 
al., 2015). The evidence quality aggregate attributed to acupuncture was rated grade B, based 
on the assessment of RCTs and observational studies with consistent effects. It endorsed 
acupuncture as an effective alternative to medical therapies that reduced AR-related symptoms 
and improved quality of life. 
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3.6.3. Ear acupuncture and ear acupressure 
Similarly, the principle of ear acupuncture and ear acupressure lies in the basis that the human 
body microsystem is superimposed on the auricle, with specific points that correspond to 
different parts of the body. Ear acupuncture or ear acupressure is a method of stimulating the 
points by attaching dermal needle or pellets on the locations of the ear. To attach dermal needle 
or pellets on the specific locations of the ear for the treatment of ailments, a skilled practitioner 
is required. For ear acupressure, after the pellets are applied, the patients are able to self-
administer the process by simply pressing on it and controlling the intensity of the pressure. A 
SR including five RCTs concluded that ear-acupressure seemed more effective than anti-
histamines for long-term effects (C. S. Zhang et al., 2010).  
 
3.6.4. Massage therapy (Tui Na) 
Tui Na is a massage therapy in CM that is more than mere massage. Its therapeutic approach is 
targeted at invigorating the flow of Qi and blood, lubricating and relaxing the joints and 
expelling, clearing as well as dredging the pathogenic factors (Pritchard, 2010). It encompasses 
a gamut of techniques ranging from passive movements to active strike movements directed at 
the points, channels and collaterals in the body. Tui Na essentially embraces the principles of 
CM. A clinical study was conducted on 60 AR afflicted children, who were randomised into 
Tui Na group and Western medication (WM) group (Ye et al., 2016). The outcome after four 
weeks of treatment was that nasal symptoms associated with AR were significantly improved 
in both groups with Tui Na group being more remarkable in outcome. The effective rate of Tui 
Na was 90% versus 73.3% for WM (Loratadine). 
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3.7. Comments 
The modalities CHM, acupuncture, ear acupuncture and ear acupressure as well as Tui Na stem 
from a long history of use in CM from China. Its popularity and demand by the populace has 
propelled research on their efficacies in each of these modalities. Discovery on the use of 
artemisia annua L. (Qing Hao), a common herb used in CM, containing artemisinin, is currently 
used as anti-malaria monoclonal therapy drug. This has prompted the scientific community to 
look for curatives in natural products for discovery of new drugs. In this respect, more CM 
modalities are cast into research framework of chronic diseases, where it is hoped that historic 
long-honoured use of traditional CM practice can provide an answer to maladies. 
 
In recent years, RCTs and experimental studies on CHM formulae for the treatment of AR have 
researched intensively. The clinical practice guideline for AR (2015) cited limited knowledge 
of CHM products and a lack of access to Chinese literature on RCTs for AR contributed to a 
bias for its use by the panel members. Inadequate evidence, lack of access to literature and 
contradictory results of clinical studies pose a significant challenge for both clinicians as well 
as patients who are end users of CHMs.  
 
Positive outcome of an 18-herb formulation (RCM-101) for treatment of SAR in a clinical trial 
showed moderate to marked rates (60.7%) of improvement for symptomatic relief of AR 
sufferers (C.C.L. Xue, Thien, Zhang, Da Costa, & Li, 2003). Matkovic et.al (2010) also 
revealed significant treatment efficacy of Huang Qi (Astralgali Radix) in a clinical trial of 48 
adult patients with moderate to severe SAR. The outcome of this study depicted positive results 
in the symptom score, quality of life, specific IgE and IgG, nasal eosinophils, and physicians’ 
and patients’ global evaluation. Intensity of rhinorrhoea was decreased markedly. All indicators 
attested to therapeutic effects of the herb for SAR treatment. On the contrary, another RCT on 
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herbal preparation of an eight-herb formulation (RCM-102) did not find any significant 
difference between the active and placebo group for patients with SAR (Lenon et al., 2012).  
 
Experimental studies have proven that CHM are effective in pharmacological actions. RCM-
101 was discovered to inhibit proinflammatory mediators, inducible nitric oxide (Lenon, Li, 
Xue, Thien, & Story, 2008), histamine, leukotriene B4 and PGE2 in rat cultured cells (Lenon et 
al., 2007). Jung, Jung, Cheong, Kang, and Park (2012) also investigated the anti-allergic effect 
of a polyherbal formula of five herbs on ovalbumin-induced AR in mice manifesting marked 
reduction in the serum levels of histamine as well as OVA-specific IgE and TNF. Anti-
inflammatory effects have also been detected with different CHM formulae traditionally used 
to treat AR. A new mixed formula consisting of Shin-yi-san, Xiao Qing Long Tang and Xiang 
Sha Liu Jun Zi Tang was discovered to have a beneficial effect on patients suffering from PAR 
(Yang, Hong, & Yu, 2002). Stimulatory effects on polymorphonuclear neutrophils (PMN) were 
attenuated and nasal discharge (not serum) from AR group with high serum IgE was abolished 
three months after treatment. A Taiwanese study indicated the use of Bu Zhong Yi Qi Tang 
suppressed the IgE, IL4-stimulated production of PGE2 and LTC4 by PMN in PAR patients 
(Yang & Yu, 2008). Overall, nasal symptom score was improved for the active group. However, 
this study also indicated another formula Ping Wei San was not effective for the treatment of 
PAR.  
 
To date, although there exist many RCTs involving the different types of herbs and formulae 
used for the management of AR, no systematic review has been conducted on the entirety of 
RCTs on CHM for AR treatment. The existing RCTs are commonly questioned for small 
sample size and methodology. In recent years, RCTs and experimental studies on CHM 
formulae for the treatment of AR have researched intensively. The clinical practice guideline 
for AR cited limited knowledge of CHM products and a lack of access to Chinese language on 
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RCTs for AR contributed to a bias for its use by the panel members (Seidman et al. 2015). 
Inadequate evidence, lack of access to literature and contradictory results of clinical studies 
pose a significant challenge for both clinicians as well as patients who are end users of CHMs. 
The inclusion of acupuncture in the latest revision of evidence-based clinical practice guideline 
on AR in Seidman et al. (2015) has inspired research in other areas of CM. There is a need to 
conduct thorough reviews for AR in clinical and experimental studies to develop a 
comprehensive profile of CHM for AR. 
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Chapter 4  Methodologies 
 
This chapter describes the methodologies employed in the SR of RCTs, the reviews of 
experimental studies and the classical data mining in relation to AR. 
 
4.1. Methods of systematic review of RCTs 
This SR was conducted adhering to the Cochrane Handbook for Systematic Reviews of 
Interventions 5.1.0 (Higgins & Green, 2011). 
4.1.1. Search strategies 
The search strategies and the initial literature search was developed and conducted with the 
support from the Cochrane Collaboration ENT group up to 2014. A second phase search was 
updated up to April 2016, of which the similar search strategies were adopted. The series of 
literature searches were conducted to identify suitable RCTs to be included in the review. There 
were no restrictions on the language; publication year; or publication status imposed on this 
SR. There are three modus operandi in the approaches of searches: 
 
i. Electronic searches  
Twenty electronic databases were searched from their inceptions for published; unpublished; 
and ongoing trials. They include the Cochrane Ear, Nose and Throat Disorders Group Trials 
Register; the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane 
Library Issue 4, 2016); PubMed; EMBASE; China National Knowledge Infrastructure (CNKI); 
Chong Qing VIP (CQVIP); Wanfang Data; AMED; CINAHL; LILACS; KoreaMed; IndMed; 
PakMediNet; CAB Abstracts; Web of Science; BIOSIS Previews; ISCTRN; ClinicalTrials.gov; 
ICTRP; and Google. All search strategies for the databases were based on the search design for 
CENTRAL. Adaptations of the highly sensitive search strategy designed by the Cochrane 
Collaboration for identifying RCTs and controlled clinical trials (as described in The Cochrane 
74 
 
Handbook for Systematic Reviews of Interventions Version 5.1.0 (Higgins & Green, 2011) were 
combined with subject strategies, where appropriate.  
 
Keywords used for the literature search included the following: allergic rhinitis, rhinitis, 
pollionosis, Chinese herbal medicine, herbal medicine, phytomedicine, ethnobotanical, 
pharmacognosy and their synonyms. 
 
ii. Searching other resources  
In addition, the reference lists of identified publications for RCTs were scanned. Further search 
was conducted on PubMed, TRIP database, The Cochrane Library and Google to retrieve 
existing systematic reviews relevant to this systematic review, so that reference lists for 
additional trials could be scanned. Using the Cochrane Ear, Nose and Throat Disorders Group 
Trials Register, the conference abstracts were also part of the reference lists. 
 
iii. Hand search 
The following journals published in Chinese were hand searched: the Chinese Journal of 
Otorhinolaryngology of Integrated Traditional and Western Medicine (1993 onwards), the 
Chinese Journal of the Practical Chinese with Modern Medicine (1988 onwards), and the 
Chinese Journal of Integrated Traditional and Western Medicine (1981 onwards). Proceedings 
of the World Congress of Chinese Medicine held in 2003, 2006, 2008, 2009 and 2011 were 
included within the hand search. 
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4.1.2. Selection criteria 
The selection criteria for the RCTs involved four broad variables, which included types of 
studies, types of participants, types of interventions and types of outcome measures. 
 
i. Types of studies  
RCTs and quasi-randomised trials, with or without blinding, regardless of language and 
publication type were considered. If randomised cross-over trials were included, only data from 
the first phase were used for data analysis. 
 
ii. Types of participants  
Patients, male or female, of any age, with SAR or PAR were included. Allergy must be proven 
using an objective test such as a skin prick test or a specific IgE test (eg. RAST). 
 
iii. Types of interventions  
Any form (e.g. decoction, capsule, tablet, pill or powder) of single herb or Chinese medicinal 
formulae compared with the following control interventions: placebo, no intervention or 
conventional therapies, irrespective of methods of administration or dosage were considered as 
a form of intervention. CHM combined with other treatments, such as acupuncture, was also 
included. Co-interventions were allowed as long as all trial arms received the same co-
intervention. 
 
iv. Types of outcome measures  
The outcome measures encompassed both primary and secondary for systematic evaluation. 
These are the followings: 
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Primary outcomes 
 Improvement of symptoms including nasal symptoms (nasal congestion, 
rhinorrhoea, sneezing, itchy nose) and non-nasal symptoms (itchy eyes, watery eyes 
and itchy ears), using symptom scores or scales. 
Secondary outcomes 
 Quality of life (e.g. RQLQ, SF-36, defined by trial reports)  
 Medication consumption (scores)  
 Serum IgE level  
 Adverse events 
 
Independent selection of studies according to the inclusion criteria was carried out by two 
reviewers (JK and AY). Any discrepancy between the two reviewers was resolved by discussion 
or consulted with third party. Plans were arranged to contact the authors of original studies to 
clarify any unclear issues or to obtain any additional data when needed. However, after ten 
unresponsive contacts through emails, we decided to assess the studies based on published data 
only. 
 
4.1.3. Data extraction 
Data were extracted based on a self-developed data extraction form. If papers in a language 
other than English and Chinese were identified, their data were extracted with translation in 
English with the help of other researchers. The data to be extracted from each included trial 
consisted of study characteristics such as: study setting, sample size, risk of bias, inclusion 
criteria, diagnostic criteria, and characteristics of participants, interventions and outcome 
measures. If the data on the number of patients with each outcome measured were not available 
in the paper, further information was sought by contacting the chief investigator. However, 
owing to no response from initial contacts, analysis was carried out on reported data only. 
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4.1.4. Data analysis 
i. Assessment of risk of bias in included studies 
The risk of bias in the studies was assessed independently by JK and AY. Any inconsistency 
between the two authors was resolved by discussion. The following risk of bias assessment 
domains and the considerations were based on the Cochrane Handbook for Systematic Reviews 
of Interventions 5.1.0 (Higgins & Green, 2011): 
 Random sequence generation (selection bias) – Was there a randomised method 
adopted by the investigators? If so, what was the method? 
 Allocation concealment (selection bias) – Was the allocation adequately concealed? 
Could the investigators foresee means where selection bias could be introduced in 
the allocation procedures? 
 Blinding of participants, personnel and outcome assessors (performance bias) – Was 
the knowledge of the allocated interventions adequately prevented during the study 
known as blinding?  
 Blinding of outcome assessment – Were the study and outcome measurement 
blinded? 
 Incomplete outcome data (attrition bias) – Was there an imbalance of numbers or 
reasons for missing data reported in the intervention group? For reporting 
dichotomous data, was the proportion of the missing outcomes compared with 
observed event risk likely to create clinical relevant bias in an estimate? For 
reporting continuous outcome data, was the effect size among the missing data 
outcomes likely to induce clinically relevant bias in observed effect? 
 Selective outcome reporting (reporting bias) – Were the reports of the study free of 
suggestion of selective outcome reporting? Was the study protocol readily available 
with the criteria pre-specified with primary and secondary outcomes? 
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 Other bias – Was the study free from other problems associated with specific study 
design used, any extreme baseline imbalance or external funding? 
 
For heterogeneity assessment, I2 statistics was used. According to the Cochrane handbook 
(Higgins & Green, 2011), I2 between 0% and 30% was considered low. 30% to 50% as 
moderate and 50% to 100% as substantial. The overall synthesis was performed qualitatively 
or quantitatively according to categorical, continuous and risk of bias analyses of the trials. For 
outcome measures, both dichotomous data and continuous data were utilised in the SR. 
Dichotomous data refer to where the effect measures are presented as a binary form for the 
relative risk (RR) which is the ratio of risk for an event in the intervention groups (Higgins & 
Green, 2011). Meta-analysis for continuous data was applied to studies where all reported on 
the outcome measure: the same scale for mean difference (MD); different scale for standardised 
mean difference (SMD) (Higgins & Green, 2011). Dichotomous data as RR and continuous 
data as MD or SMD, both with 95% confidence intervals (CI) using inverse variance with 
random-effects methods were presented. An intention-to-treat (ITT) analysis was performed 
where possible. A "worst-case scenario" method was used as a solution to address the missing 
data. Synthesis of the data were conducted on the Cochrane software RevMan 5.3 (The 
Cochrane Collaborations, 2014). 
 
ii. Frequency of commonly used herbs  
In the process of the SR, the frequency of the most commonly used herbs in the included RCTs 
was also extracted. This was conducted after the included studies were finalised where 
characteristics of each studies were extracted and downloaded on pre–formatted Excel layout. 
The formulae of the herbs used and the number of herbs identified in the studies reported were 
collated. From the synthesis, the ranking and the frequency usage of top 10 herbs used in the 
RCTs were extracted. 
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4.2. Methods of review for CHM in experimental studies 
Based on the outcome of the SR, an evaluation was conducted on the five most frequently used 
in the RCTs. The objective was to review possible chemical compounds that elicit mechanisms 
of actions of these most commonly used herbs in their effects on AR and other diseases. 
 
4.2.1. Search strategies 
Searches were conducted on the following databases: PubMed, The Cochrane Library 
(Database of Abstracts of Reviews of Effects, DARE, issue 4 April 2015); EMBASE(Ovid); 
ProQuest; AMED; MEDLINE; CINAHL; ScienceDirect; SCOPUS; Web of Science; CNKI; 
CQVIP and Wanfang data. The search included English and Chinese terminologies such as AR 
[Guo Min Xing Bi Yan, 过敏性鼻炎], CHM [Zhong Yao, 中药], animal studies [Dong Wu 
Yan Jiu, 动物研究], Fang Feng (Saposhnikoviae Radix), Huang Qi (Astragalus Radix), Xin Yi 
(Magnoliae Flos), Cang Er Zi (Xanthii Fructus), Xi Xin (Asari Radix et Rhizoma) and their 
synonyms.  
 
4.2.2. Data extraction and analysis 
Relevant experimental studies (both animal experiments and natural products analyses) were 
extracted and downloaded onto reference management software. The studies are grouped 
accordingly under different herbs, then sorted under the clinical mechanism of actions. 
Following, these herbs were further subgrouped according to their bioactive chemical 
compounds and pharmacological actions.  
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4.3. Methods of review for CHM in classic literature 
4.3.1. Search strategies 
Two sets of classical texts were used namely, Encyclopaedia of Traditional Chinese Medicine 
(Zhong Hua Yi Dian) (ZHYD) (R. Hu, 2015) and The Complete Collection of Traditional Texts 
on Chinese Materia Medica (Zhong Guo Ben Cao Quan Shu) (ZGBCQS) (Lu, 1999). The 
classical texts are mainly made up of connotative descriptions of symptoms and prescriptions 
of herbs for myriad of maladies. Electronic search was conducted on the ZHYD which consists 
of 1,156 books while ZGBCQS containing 740 books (2,027 titles), a hand search was 
performed. 
 
Keywords used were associated with AR-like symptoms. The keyword search commenced with 
the word 鼻 (nose) in both texts. Subsequent keywords included 喷嚏 (sneeze), 鼻塞浊涕 
(congested nose with turbid nose discharge), 鼻塞流清涕 (congested nose with clear runny 
nose discharge), 鼻壅 (nasal obstruction), 鼻塞不通/鼻塞 or 鼻塞不通利 (nasal congestion), 
鼻鼽 (allergic rhinitis) and 鼻痒 (itchy nose). Descriptions of comorbid conditions are often 
accompanied with the foregoing main keywords. These comorbid descriptions 精神昏闷 
(listlessness), 精神不爽 (general unwellness), 头目疼痛 (headache, eye pain), 鼻痛 (pain in 
the nose) and鼻准赤色 (red nose) were employed in the search. 
 
4.3.2. Selection criteria 
The selection criteria for ZHYD and ZBGCQS were based on one keyword to filter the data 
and set aside words relating to nasal pathologies. Therefore, the word 鼻 (nose) was used from 
the onset. Downloaded articles were then sorted with the keyword relating to AR-like keywords. 
Words that are not related to the AR nasal descriptions such as鼻生瘜肉谓之齆 (nasal polyps), 
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and 鼻渊 /鼻渊不止 (sinusitis) were excluded. Similarly, for acupuncture treatments for AR 
and diagnosis descriptions without herbal intervention records were also excluded. Other nasal 
pathologies that were not associated with AR-like conditions were excluded automatically. 
 
4.3.3. Data extraction and analysis 
i. Data mining process 
The articles of ZHYD and ZGBCQS consist of citations of herbs used to treat AR-like signs 
and symptoms. These citations are essentially representations of clinical instances recorded by 
the author-clinicians. Data of ZHYD were accessed electronically, while for the ZGBCQS, a 
hand search was carried. For ZGBCQS, photographic profiles were developed for articles and 
pages identified with descriptions of AR-like symptoms in the literature. These profiles were 
then downloaded onto computer program for screening and sorting. Two-step processes were 
undertaken henceforward. First, the raw data were input onto Excel for both ZHYD and 
ZGBCQS. The data were sorted and combined. Then the data were transferred and transposed 
onto analytic software, Statistical Package for the Social Sciences (SPSS) version 23 for data 
analysis (IBM Corp, 2015). The combined data were evaluated for frequency of citations for 
the types of herbs used in AR-like conditions as well as the ranking of the herbs.  
 
ii. Principal component analysis and hierarchical cluster analysis 
Aside from the frequency, syndromic categorisation was conducted to identify the variety of 
herbs used to target specific AR-like signs and symptoms in the literature by means of PCA and 
HCA. SPSS is the software platform that was used to perform both multivariate statistical 
methods for pattern associations in the herbs prescribed for AR-like sign and symptoms and 
their characteristics according to the keywords searched in the search strategies. PCA was used 
to determine the variable dimension  and it emphasises on the variation and elicit strong patterns 
in a large dataset by replicating total variance among large sets of variables (Rencher & 
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Christensen, 2012). Correlations or “loadings” are calculated based on the weighted average of 
the eigenvalues. Loadings are the determinants of the variable‘s positon within the circle of 
correlation while eigenvalues are indicators of the variance of a component (Abi& Williams 
2010). Eigenvalues that are similar in magnitude indicate comparable variability in 
components’ dimensions (Raykov & Marcoulides, 2012). The importance of a component is 
determined based on the sum of squared coefficients of correlations between a variable (herb) 
and all components when eigenvalue is equal to or more than 1 (Abi & Williams 2010). When 
eigenvalue is less than the value of 1, the component is of less importance. HCA is an 
exploratory statistical method which charts the distance matrix of these herbs and groups these 
herbs into meaningful datasets by using squared Euclidean distance. The squared Euclidean 
distance was calculated by means of using average linking between groups method on the SPSS. 
Clustering creates and merges similar groupings of herbs with similar characteristics in a 
predetermined format. These visual analyses could offer a meaningful interpretation as to the 
relevance and its relational aspects to each herb or to the AR-like signs and symptoms.  
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Chapter 5  Results I – SR of RCTs for the treatment of AR 
 
This chapter reports the results of the SR that includes 62 RCTs according to the methods 
described in 4.1.  
 
5.1. Selection of studies 
A total of 4,342 records were identified and 62 RCTs were included in the reviews. The study 
selection process is illustrated in Figure 9 while the list of 62 included studies are summarised 
in Table 15. Study I.D. is assigned to each included study for the purpose of identification in 
this chapter. 
4,331 records identified 
through database search
4,331 records identified 
through database search
11 additional records 
identified through 
handsearch
11 additional records 
identified through 
handsearch
2,568 records after 
duplicates removed
2,568 records after 
duplicates re oved
2,568 records screened2,568 records screened
566 full text articles 
assessed for eligibility
566 full text articles 
assessed for eligibility
62 studies included in 
qualitative synthesis
62 studies included in 
qualitative synthesis
61 studies included in 
quantitative synthesis 
(meta-analysis)
61 studies included in 
quantitative synthesis 
( eta-analysis)
2,002 records excluded with reasons:
 Animal study (n=68)
 Non-RCT (n=490)
 Non-AR (n=460)
 Diagnosis not meeting inclusion criteria 
(n=1)
 Non-CHM (n=973)
 Control intervention not meeting 
inclusion criteria (n=10)
2,002 records excluded ith reasons:
 ni al study (n 68)
 on-  (n 490)
 on-  (n 460)
 iagnosis not eeting inclusion criteria 
(n 1)
 on-  (n 973)
 ontrol intervention not eeting 
inclusion criteria (n 10)
504 full text articles excluded with reasons:
 Animal study (n=2)
 Non-RCT (n=326)
 Diagnosis not meeting inclusion criteria 
(n=25)
 Non-CHM (n=20)
 Control intervention not meeting 
inclusion criteria (n=51)
 Non-equal number of patients randomised 
and reported (n=3)
 Different / unspecified assessment points 
(n=36)
 Duplicated studies (n=20)
 Inconsistent studies criteria with 
assessment (n=5)
 No objective diagnosis (n=14)
 Unclear outcome measures (n=1)
 Incompatible intervention (n=1)
504 full text articles excluded ith reasons:
 ni al study (n 2)
 on-  (n 326)
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(n 25)
 on-  (n 20)
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Figure 9. Study selection process for the included studies in the SR 
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Table 15. List of 62 included RCTs in SR 
No. Study I.D.  Included RCTs 
1.  Baba 1995 
Baba, S., & Takasaka, T. (1995). Double-blind clinical trial of Sho-seiryu-to 
(TJ-19) for perennial nasal allergy. Clinical Otolaryngology, 88(3), 389-405. 
2.  Bao 2013 
Bao, A. C., Zhu, J. J., & Gong, Q. (2013). Clinical observation of 
Xiaoqinglong mixture in the treatment of allergic rhinitis [Xiaoqinglongtang 
heji zhiliao bianyingxing biyan de linchuang guancha]. China Modern 
Medicine, 20(31), 109-110. 
3.  Cao 2007 
Cao, J. G., Ding, Y., & Cheng C.K. (2007). Clinical observation of Cang'erzi 
keli for the treatment of 30 cases with allergic rhinitis [Cang'erzi keli zhiliao 
bianyingxing biyan 30 li linchuang guancha]. Xinan Junyi [Journal of 
Military Surgeon in Southwest China], 9(3), 71-72. 
4.  Cao 2014b 
Cao, Z. H., & Huang, F. Q. (2014). Xiangju joint capsule combined with 
claritin syrup treatment for 30 children with allergic rhinitis [Xiangju jiaonang 
lianhe kairuitan tangjiang zhiliao xiao'er guominxing biyan 30 li]. Inner 
Mongolia Journal of Chinese Medicine [Neimenggu Zhongyiyao], 2, 19-20. 
5.  Chen 2012 
Chen, J. J. (2012). Effect of Chinese traditional medicine xingbi wenmin 
ningjiaoji in children with allergic rhinitis [Zhongyi xingbi wenmin ningjiaoji 
zhiliao xiao'er guominxing biyan de laixiao guancha]. (Masters), Fujian 
University of Traditional Chinese Medicine, Fujian, China. 
6.  Chen 2004 
Chen, K., Luo H. X., Li, D. X., & Ye, B. X. (2004). The therapeutic effects of 
a combined therapy with radiofrequency thermocoagulation to the ethmoidal 
nerve under endoscope and Yupingfeng granule orally taking on perennial 
allergic rhinitis [Bineijingxia shepin rening shaiqian shenjing jiehe 
yupingfeng keli zhiliao changnianxing bianyingxing biyan]. Chinese Journal 
of Otorhinolaryngology of Integrated Traditional and Western Medicine] 
[Zhongguo Zhongxiyi Jiehe Erbiyanhouke Zazhi], 12(4), 193-194. 
7.  Chen 2014 
Chen, L., & Chen, X. W. (2014). Analysis on therapeutic effect of Cetrizine 
combined with Yupingfengsan in treating allergic rhinitis [Xitiliqin lianhe 
Yupingfengsan zhiliao guominxing biyan liaoxiao fenxi]. World Chinese 
Medicine, 9(7), 880-882. 
8.  Chen 2011 
Chen, Y. T., & Chen, G. Q. (2011). Jiawei Yupingfengsan with budesonide 
nasal spray in the treatment of 46 allergic rhinitis cases [Jiawei 
Yupingfengsan peihe budinaide bipenwuji zhiliao bianyingxing biyan 46 li]. 
Shaanxi Journal of Traditional Chinese Medicine [Shaanxi Zhongyi], 32(7). 
9.  Gao 2009 
Gao, Y. (2009). The effect of Poria, Cinnamon Twig, Ovate Atractylodes, and 
Liarice decoction on quality of life of patients with perennial allergic rhinitis 
[Lingguizhugantang jiawei zhiliao changnianxing bianyingxing biyan de 
liaoxiao guancha ji dui huanzhe shenghuo zhiliang de yingxiang]. (Masters), 
Chengdu University of Traditional Chinese Medicine [Chengdu Zhongyiyao 
Daxue], Chengdu, China. 
10.  Guo 2010 
Guo, J. F., Zhao, Z., & Kong, Q. (2010). Clinical effects of allergic rhinitis 
with Qufeng zhiyang koufuye [Qufeng zhiyang koufuye zhiliao guominxing 
biyan liaoxiao guancha]. Hubei Journal of Traditional Chinese Medicine 
[Hubei Zhongyi Zazhi], 32(10), 24-25. 
11.  Han 2002 
Han H. Y., & Wang, D. H. (2002). Long term effects of kidney tonifying and 
warming lung capsule for the treatment of allergic rhinitis [Bushenwenfei 
jiaonang zhiliao guominxing biyan de yuanqi liaoxiao guancha]. Chinese 
Journal of Otorhinolaryngology of Integrated Traditional and Western 
Medicine [Zhongguo Zhongxiyi Jiehe Erbiyanhouke Zazhi], 10(5), 233-234. 
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No. Study I.D.  Included RCTs 
12.  Hong 2005 
Hong, W., Liu, A. H., Hong, Y., & Fang, Z. W. (2005). Clinical study of 
compounds for allergic rhinitis [Fufang biyantang zhiliao bianyingxing biyan 
de linchuang yanjiu]. Practical Clinical Journal of Integrated Traditional 
Chinese and Western Medicine [Shiyong Zhongxiyi Jiehe Linchuang], 5(5), 
41-42. 
13.  Hu 2002 
Hu, G., Walls, R. S., Bass, D., Ramon, B., Grayson, D., Jones, M., & Gebski, 
V. (2002). The Chinese herbal formulation Biminne in management of 
perennial allergic rhinitis: a randomized, double-blind, placebo-controlled, 12-
week clinical trial. Annals of Allergy, Asthma & Immunology, 88(5), 478-487. 
14.  Huang 2008a 
Huang, G. F. (2008). Impact of Wenfeizhiliu pills for perennial allergic 
rhinitis sufferers in peripheral blood IL4 and IFN-r [Wenfeizhiliudan dui 
changnianxing bianyingxing biyan huanzhe xueqing IL-4, IFN-r de 
yingxiang]. Jilin Journal of Traditional Chinese Medicine [Jilin Zhongyi 
Yao], 28(12), 884-885. 
15.  Huang 2010 
Huang, P., Yu, Y. B., & Ma, Z. X. (2010). Clinical study on "Jiemin Qufeng 
Decoction II" in treating allergic rhinitis [Jiemin qufeng erhaofang zhiliao 
bianyingxing biyan linchuang yanjiu]. Shanghai Journal of Traditional 
Chinese Medicine [Shanghai Zhongyiyao Zazhi], 44(3), 32-34. 
16.  Huang 2006b 
Huang, Z. Y. (2006). Bimin nasal irrigation for the treatment of 71 cases of 
allergic rhinitis [Biminshui zhiliao biantai fanyingxing biyan 71 li]. Guangxi 
Journal of Traditional Chinese Medicine [Guangxi Zhongyi Yao], 29(2), 21-
22. 
17.  Jiang 1997 
Jiang, Z. J. (1997). Clinical effects of Yufengjianbitang in perennial allergic 
rhinitis [Yufengjianbitang zhiliao changnianxing bianyingxing biyan liaoxiao 
guancha. Chinese Journal of Primary Medicine [Zhongguo Ji Ceng Yixue], 
4(4), 36-37. 
18.  Jin 2010 
Jin, H. M. (2010). Clinical observation of Kemin decoction in treating 
perennial allergic rhinitis [Kemintang zhiliao changnianxing bianyingxing 
biyan linchuang guancha]. Chinese Journal of Traditional Chinese Medicine 
and Pharmacy [Zhonghua Zhongyiyao Zazhi], 25(12), 2192-2193. 
19.  Jung 2011 
Jung, J. W., Kang, H. R., Ji, G. E., Park, M. S., Song, W. J., Kim, M. H., . . . 
Min, K. U. (2011). Therapeutic effects of fermented red ginseng in allergic 
rhinitis: A randomized, double-blind, placebo-controlled study. Allergy, 
Asthma & Immunology Research, 3(2), 103-110. 
20.  Lenon 2012 
Lenon, G. B., Li, C. G., Da Costa, C., Thien, F. C. K., Shen, Y., & Xue, C. C. 
L. (2012). Lack of efficacy of a herbal preparation (RCM-102) for seasonal 
allergic rhinitis: A double blind, randomised, placebo-controlled trial. Asia 
Pacific Allergy, 2(3), 187-194. 
21.  Li 2012c 
Li, Q. L. (2012). Differential treatment of 52 cases of allergic rhinitis 
[Bianzheng zhiliao guominxing biyan 52 li liaoxiao guancha]. Zhejiang 
Chinese Medicine Journal [Zhejiang Zhongyi Zhazhi], 47(10), 717-718. 
22.  Li 2012b 
Li, R. (2012). Integrated Chinese medicine and Western medicine for the 
treatment of 80 cases of children with allergic rhinitis [Zhongxiyao jiehe 
zhiliao ertong guominxing biyan 80 li liaoxiao guancha]. Chinese Journal of 
Clinical Rational Drug Use [Linchuang Heli Yongyao], 5(4), 69.  
23.  Li 2008 
Li, S. L. (2008). Clinical efficacy of combined Chinese medicine and Western 
medicine for 30 cases of allergic rhinitis [Zhongxiyi jiehe zhiliao 
bianyingxing biyan 30 li linchuang guancha]. Guiding Journal of TCM 
[Zhongyi Zhidao Bao], 3, 50-53.  
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24.  Liang 2011 
Liang, S. Q. (2011). Clinical observation of modified Spleen qi deficiency 
Buzhongyiqitang for the treatment of perennial allergic rhinitis [Jiawei 
buzhongyizitang zhiliao feiqiquxing changnianxing bianyingxing biyan de 
linchuang zhiliao guancha]. China Health Industry [Zhongyi Weisheng 
Chanye], 8(5), 100-101.  
25.  Lin 2013 
Lin, S. (2013). Clinical observation on 60 cases of children with allergic 
rhinitis treated by integrative medicine [Zhongxiyi jiehe zhiliao xiaoer 
guominxing biyan 60 li linchuang guancha]. Fujian Journal of Traditional 
Chinese Medicine, 44(2), 14-15. 
26.  Liu 2004b 
Liu, G., & Song, R. H. (2004). A clinical observation on the therapeutic 
effects of a combined therapy with dibiling nose dropping and septum 
rectifying operation on allergic rhinitis [Dibiling peihe shoushu jiaozheng 
bizhongge pianqu zhiliao bianyingxing biyan de linchuang guancha]. Chinese 
Journal of Otorhinolaryngology of Integrated Traditional and Western 
Medicine [Zhongguo Zhongxiyi Jiehe Erbiyanhouke Zazhi], 12(1), 20-21. 
27.  Liu 2001 
Liu, Q. P., Liu, J. H., Li, Y. L., & Ge, Y. H. (2001). Nourishing Liver Yin in 
the treatment of allergic rhinitis [Yangyin pingganfa zhiliao biantai 
fanyingxing biyan]. Journal of Beijing University of Traditional Chinese 
Medicine [Beijing Zhongyiyao Daxue Xuebao], 24(2), 68-69. 
28.  Lu 2011 
Lu, B., Chang, K., Wang, H. J., Guo, J. J., & Chen, J. (2011). Regulating Ying 
and Wei in the treatment of 60 allergic rhinitis cases [Tiaohe yingweifa zhiliao 
guominxing biyan 60 li liaoxiao guancha]. Shanxi Journal of Traditional 
Chinese Medicine [Shanxi Zhongyi], 27(3), 10-11. 
29.  Lu 2003 
Lu, B. Q., Sun, Y. F., Guo, Y. L., Xu, Q. W., & Zhou, X. J. (2003). A clinical 
observation on the therapeutic effects of a combined therapy with nasonex and 
bimin formula on allergic rhinitis [Neishuna bipenwuji lianhe zhongyao 
biminfang zhiliao bianyingxing biyan de linchuang guancha]. Chinese Journal 
of Otorhinolaryngology of Integrated Traditional and Western Medicine 
[Zhongguo Zhongxiyi Jiehe Erbiyanhouke Zazhi], 11(6), 272-274.  
30.  Lu 2009 
Lu, J. (2009). Observation of Chinese and Western medicine for the treatment 
of 30 cases of perennial allergic rhinitis [Zhongxiyao heyong changnianxing 
bianyingxing biyan 30 li guancha]. Journal of Practical Traditional Chinese 
Medicine [Shiyong Zhongyiyao Zazhi], 25(6), 380-381. 
31.  Lu 1998 
Lu, P., Shi, Y. M., & Xu, L. G. (1998). Integrative medicine clinical study of 
children with allergic rhinitis [Zhongxiyi jiehe zhiliao xiao'er guominxing 
biyan linchuang yanjiu]. Chinese Journal of Integrated Traditional and 
Western Medicine [Zhongguo Zhongxiyi Jiehe Zazhi], 18(7), 437. 
32.  Luo 2013 
Luo, G. W. (2013). Qingretongqiaotang self-limiting treatment of pediatric 
wind-heat type of allergic rhinitis [Zini Qingretongqiaosan zhiliao xiaoer 
feijing fengrexing guominxing biyan]. Journal of Emergency in Traditional 
Chinese Medicine [Zhongguo Zhongyi Jizhen], 22(12), 2095-2096. 
33.  Matkovic 2010 
Matkovic, Z., Zivkovic, V., Korica, M., Plavec, D., Pecanic, S., & Tudoric, N. 
(2010). Efficacy and safety of Astragalus membranaceus in the treatment of 
patients with seasonal allergic rhinitis. Phytotherapy Research, 24(2), 175-
181. 
34.  Peng 2001 
Peng, S. L., Zhong, Q., & Huang, Q. S. (2001). Clinical observation of 
Biminling treatment in 36 allergic rhinitis cases [Biminling zhiliao 
bianyingxing biyan 36 li linchuang guancha]. Chinese Journal of Information 
on Traditional Chinese Medicine [Zhongguo Zhongyiyao Xinxi Zazhi], 8(3), 
58-59. 
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35.  Peng 2004 
Peng, S. L., Zhong, Q., & Yuan, X. H. (2004). Clinical observation on 42 
cases of perennial allergic rhinitis treated by Sheti Zhiqiu granules 
[Shetizhiqiu keli zhiliao changnianxing bianyingxing biyan 42 li linchuang 
guancha]. Journal of Traditional Chinese Medicine [Zhongyi Zazhi], 45(11), 
836-837. 
36.  Qin 2006 
Qin, H. (2006). The study of the clinical curative effect of the traditional 
Chinese medicine Biyanyihao granule for infusion in the treatment of PAR 
[Zhongyao biyan yihao chongji zhiliao changnianxing bianyingxing biyan de 
linchuang yanjiu]. (Masters), Heilongjiang University of Traditional Chinese 
Medicine [Heilongjiang Zhongyiyao Daxue], Heilongjiang, China. 
37.  Qiu 2012 
Qiu, W. Y. (2012). The allergic rhinitis TCM dialectical law and clinical 
research of Xiaoqinglong decoction treatment. (Masters), Guangzhou 
University of Chinese medicine, Guangzhou, China. 
38.  Shen 2004 
Shen, F., & Chen, X. N. (2004). Xiaofeng granule treatment of allergic rhinitis 
in 80 cases [Xiaofeng chongji zhiliao bianyingxing biyan 80 li]. Liaoning 
Journal of Traditional Chinese Medicine [Liaoning Zhongyi Zazhi], 31(1), 54.  
39.  Shi 2014 
Shi, H. Y., Zhuang, Y., & Wang, X. Y. (2014). Effect of Yupingfeng dropill 
in treatment of allergic rhinitis. Chinese Journal of Chinese Materia Medica, 
29(22), 105-106. 
40.  Shi 2012 
Shi, Q. Y., & Zhao, Y. (2012). The therapeutic effect of Xiangju capsule of 
perennial allergic rhinitis observation [Xiangju jiaonang zhiliao changnian 
guominxing biyan de liaoxiao guancha]. Medical Innovation of China 
[Zhongguo yixue chuangxing], 9(22), 105-106. 
41.  Sun 2014a 
Sun, R. H. (2014). Clinical observation of treatment of Tongqiao biyan 
capsules in allergic rhinitis [Tongqiao biyan jiaonang zhiliao guominxing 
biyan de linchuang guancha]. Guangming Traditional Chinese Medicine 
[Guangming Zhongyi], 29(12), 2578-2588. 
42.  Tang 2008 
Tang, Y. Y., Song, K., Zeng. K.S., & Yang, M. F. (2008). Clinical 
observation on the therapeutic effects of supplemented four gentlemen 
decoction on perennial allergic rhinitis in the pattern of Spleen-Qi deficiency 
[Jiawei sijunzitang zhiliao piqixuxing changnianxing bianyingxing biyan de 
linchuang liaoxiao yanjiu]. Chinese Journal of Otorhinolaryngology of 
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5.2. Characteristics of included studies 
5.2.1. Design of studies 
All the 62 clinical studies were claimed as RCTs. The majority of them (59 studies) employed 
two-arm design whilst only three Chinese studies used three-arm (Chen 2004; Xie 2009; Zhang 
1996) and one in four-arm trial (Xiao 2015). There was no cross-over clinical trial included. 
 
Forty-three out of 62 trials were single centre studies. Nine RCTs were multicentre clinical 
trials, five trials in two centres (Gao 2009; Lenon 2012; Lu 2011; Peng 2004; Wu 2012a), two 
trials in three centres (Wu 2009; Zhao 2009), one trial in four centres (Zou 2012) and one in 62 
centres (Baba 1995). Six studies did not provide sufficient information (Cao 2007; Hong 2005; 
Lu 1998; Peng 2001; Xie 2009; Zhang 1996). Although the rest of four papers did not report 
the details, the trials were most likely performed in one centre as three of them only had one 
author completed the trials (Jiang 1997; Li 2008; Xin 2005) and two authors in the other trials 
were from the same hospital (Liu 2004). 
 
More than one eighth of the included studies (11 out of 62) were supported by at least one 
external funding such as funded by national, provincial, local government, hospital or university 
grants (Huang 2010; Jung 2011; Lenon 2012; Liu 2001; Lu 2011; Qiu 2012; Tang 2008; Wang 
2000a; Wu 2009; Zhao 2009; Zheng 2007). Two trials were partially supported by the 
pharmaceutical manufacturers (Baba 1995; Xue 2003b). The other 49 studies did not report the 
funding sources. 
 
5.2.2. Sample sizes 
The sample sizes of the included studies were various, ranging from 20 to 564 participants with 
an average of 106 participants per trial. Thirty-seven trials had sample sizes between 20 and 
100 (both inclusive). Seventeen studies had sample sizes over 100 but less than 200 (Chen 2014; 
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Chen 2004; Gao 2009; Hong 2005; Huang 2006b; Lin 2013; Liu 2001; Lu 1998; Lu 2003; Lu 
2011; Luo 2013; Shen 2004; Wu 2009; Wu 2012a; Xie 2009; Zhao 2009; Zou 2012). There 
were eight studies with sample sizes that exceeded 200 (Baba 1995; Guo 2010; Qiu 2012; Shi 
2012; Xiao 2015; Yan 2011; Zhang 2007; Zhou 2005). 
 
5.2.3. Setting 
Among 62 trials, 51 studies were performed in mainland China and eleven studies were 
conducted outside mainland China, including four in Australia (Hu 2002; Lenon 2012; Xue 
2003a; Xue 2003b), one in Croatia (Matkovic 2010), one in Hong Kong (Zhao 2009), one in 
Japan (Baba 1995), two in Taiwan (Jiang 2012; Liu 2010), one in South Korea (Jung 2011) and 
one in Switzerland (Zhao 2010). 
 
Thirty-two studies clearly indicated that only outpatients enlisted from hospitals participated in 
the trials. Patients in four trials were recruited solely from outpatient clinics, three trials in 
Australia (Lenon 2012; Xue 2003a; Xue 2003b) and one in Switzerland (Zhao 2010) 
respectively.  Only one study stated that both outpatients and inpatients were included in the 
trial (Hong 2005). Only Bao 2013 cited participants were recruited from inpatients of hospital. 
Fifteen studies did not mention whether outpatients or inpatients were involved however, they 
indicated that the patients were recruited from hospitals, including one in Australia (Hu 2002), 
one in Japan (Baba 1995), one in South Korea (Jung 2011), one in Hong Kong (Zhao 2009) and 
eleven in mainland China (Cao 2014; Chen 2012; Chen 2014; Liu 2001b; Lu 1998; Shi 2012; 
Sun 2014a; Qin 2006; Qiu 2012; Wu 2012; Zou 2012). Nine studies conducted in mainland 
China did not specify where the participants were recruited from, outpatients or inpatients (Cao 
2007; Chen 2004; Jiang 1997; Li 2008; Liu 2004; Peng 2001; Xie 2009; Xin 2005; Zhang 
1996). 
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5.2.4. Types of participants 
The included studies randomised 8,470 participants and analysed 8,395. Their ages ranged from 
two to 82 years. Two studies did not clearly report the ages of participants (Huang 2006b; Zhang 
2007b). Three studies only indicated the mean of the participants’ ages and the range of ages 
was not provided (Lenon 2012; Matkovic 2010; Wu 2012a).  
 
Nine studies included children only (Cao 2014; Chen 2012; Li 2012c; Lin 2013; Lu 1998; Lu 
2011; Luo 2013; Wu 2009; Zheng 2007) and 30 studies focused on adults only (Bao 2013; Cao 
2007; Chen 2011; Chen 2014; Han 2002; Hong 2005; Hu 2002; Huang 2008a; Jiang 1997; Jin 
2010; Jung 2011; Li 2012b; Liang 2011b; Lenon 2012; Liu 2004; Matkovic 2010; Peng 2001; 
Peng 2004; Shi 2014; Tang 2008;  Wu 2012; Xiao 2015; Ye 2015; Xin 2005; Xue 2003a; Xue 
2003b; Zhang 2007; Zhao 2009; Zhong 2013; Zhou 2005). Twenty-three studies mixed the 
children and adults (Baba 1995; Chen 2004; Gao 2009; Guo 2010; Huang 2010; Jin 2010; Li 
2008; Liu 2001; Lu 2003; Lu 2009; Qin 2006; Qiu 2012; Shen 2004; Shi 2012; Sun 2014a; 
Wang 2000a; Xie 2009; Yan 2011; Yang 2004; Zhang 1996; Zhao 2012; Zhou 2001b; Zou 
2012).  
 
For the included studies conducted in mainland China, 56 out of 62 diagnosed their participants 
according to Chinese Medical Association’s Criteria for Allergic Rhinitis which were 
developed in 1990 and further revised in 1997 and 2004. Only four of them adopted the 
diagnostic criteria specified in the textbooks (Bao 2013; Li 2012c; Sun 2014a; Zhou 2005). 
Two studies (Lenon 2012; Liang 2011) performed outside of China developed their own 
diagnostic criteria. All the diagnostic criteria included a number of signs and symptoms as well 
as one objective test (e.g. skin prick test or a specific IgE test) to determine participants’ allergy.  
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Twenty-eight of them investigated the effects of CHMs for patients with PAR (Baba 1995; Bao 
2013; Chen 2004; Hu 2002; Huang 2008; Huang 2010; Jiang 1997; Jin 2010; Jung 2011; Li 
2008; Liang 2011b; Lin 2013; Liu 2001; Lu 2009; Lu 2011; Peng 2004; Qin 2006; Shi 2012; 
Shi 2014; Tang 2008; Xie 2009; Xin 2005; Yan 2011; Zhang 1996; Zhang 2007b; Zhao 2009; 
Zhong 2013; Zou 2012) and five studies focused on patients with SAR only (Lenon 2012; 
Matkovic 2010; Qiu 2012; Xue 2003a; Xue 2003b). Three studies indicated both SAR and PAR 
patients were recruited in the trials (Hong 2005; Li 2012; Shen 2004). The rest 26 studies did 
not specify SAR or PAR and they may include both types of AR. 
 
Most included studies did not differentiate the AR syndromes when recruiting participants. 
Only 24 studies adopted differential diagnosis according to CM theories and applied a fixed 
formula to treat patients with a particular syndrome. Ten of them focused on Lung and Spleen 
Qi deficient syndromes (Cao 2014b; Chen 2012; Chen 2014; Li 2012c; Li 2012b; Qin 2006; 
Qiu 2012; Shi 2014; Yan 2011; Zou 2012), five for Lung Qi deficiency (Lin 2013; Lu 2011; 
Shi 2012; Sun 2014a;  Zhang 2007b), two for Spleen Qi deficiency (Liang 2011; Tang 2008), 
one for phlegm retention (Gao 2009), four for Lung Qi deficient cold type (Bao 2013; Huang 
2008; Zhao 2012; Zhong 2013), and two for heat in Lung meridian syndrome (Jin 2010; Luo 
2013). Three studies recruited patients with any syndromes of AR but treated them individually 
with modified Chinese herbal formulae according to their syndromes (Li 2008; Lu 2009; Zhou 
2005).  
 
5.2.5. Types of interventions 
A total of 62 CHMs were evaluated in the treatment groups. Three studies used single Chinese 
herbs, including fermented red ginseng (Ginseng et Rhizoma Radix Rubra) (Jung 2011), Huang 
Qi (Astragali Radix) (Matkovic 2010), and volatile oil of Magnoliae Flos (Xin Yi) (Wu 2009). 
The rest of 59 included studies used 59 different Chinese medicinal formulae, consisting of 564 
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Chinese herbs, in the treatment groups. Five trials (Liang 2011; Cao 2014, Li 2012b; Huang 
2010 and Ye 2015) used two formulae; while Li 2012a and Lu 2009 employed three formulae 
for three different syndromes. 
 
The forms of Chinese herbs used in these included studies were various, orally (decoction, 
capsule, granule or liquid) and/or externally (nasal drop or spray). Fifty-three studies adopted 
oral administration only. Twenty-four of them used formulae in the decoction form (Chen 2011; 
Chen 2014; Gao 2009; Hong 2005; Huang 2008a; Jiang 1997; Jin 2010; Li 2008; Li 2012b; Li 
2012c; Liang 2011b; Liu 2001; Lu 1998; Lu 2003; Lu 2009; Lu 2011; Luo 2013; Qiu 2012; 
Peng 2001; Tang 2008; Yan 2011; Zhang 2007b; Zhong 2013; Zhou 2005). Sixteen studies 
applied the granule form of CHMs in the treatment group (Baba 1995; Cao 2007; Chen 2004; 
Huang 2010; Lenon 2012; Liang 2011b; Lin 2013; Liu 2010b; Matkovic 2010; Peng 2004; Qin 
2006; Shen 2004; Xie 2009; Yang 2004; Zhang 1996; Zhao 2012). The formulae in 11 studies 
were in the capsule form (Cao 2014b; Han 2002; Hu 2002; Jung 2011; Shi 2012; Sun 2014a; 
Wu 2012; Xue 2003a; Xue 2003b; Zhao 2009; Zou 2012). Two studies (Guo 2010; Bao 2013) 
used the oral liquid form of Chinese herbs. Four studies used CHMs externally in nasal drop 
form (Huang 2006; Liu 2004; Wang 2000a; Wu 2009) and four trials employed nasal spray 
(Chen 2012; Zhang 1996; Zheng 2010; Zhou 2001b). The Xin 2005 study applied both 
decoction and nasal droplet forms of CHMs for treatment. 
 
The interventions in control groups consisted of placebo (seven trials), WM (e.g. anti-histamine 
drugs) (48 trials), immunotherapy (two trials), surgery (one trial), radiofrequency (two trials), 
and acupuncture (two trials). The most commonly used anti-histamine drugs were Cetirizine, 
Loratadine or Desloratadine, Hismanal and Chlorphenamine maleate tablets. 
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When co-intervention was not involved in the trials, seven studies compared CHM with placebo 
(Baba 1995; Hu 2002; Jung 2011; Lenon 2012; Matkovic 2010; Xue 2003a; Zhao 2009). 
Another 37 studies compared CHMs with Western medicine as control. Among them, 27 
studies compared CHM with oral WM (Bao 2013, Cao 2007; Chen 2014; Gao 2009; Guo 2010; 
Han 2002; Hong 2005; Huang 2008a; Huang 2010; Jiang 1997; Jin 2010; Liang 2011b; Liu 
2001; Lu 2011; Luo 2013; Peng 2001; Peng 2004; Qin 2006; Qiu 2012; Shen 2004; Sun 2014a; 
Yan 2011; Yang 2004; Ye 2015; Zhang 1996; Zhang 2007b; Zhong 2013); only one (Wu 2009) 
used nano-liposome nasal drops for the control, whilst there were six studies which used nasal 
sprays as a comparator (Chen 2012; Huang 2006b; Wang 2000a; Zheng 2007; Zhou 2001b; 
Zou 2012); one trial (Xin 2005) involved CHM oral plus external versus WM oral plus nasal 
spray as comparators; and two studies compared CHM with radiofrequency (Chen 2004; Xie 
2009).  
 
When co-interventions were involved in the included RCTs, 17 studies plus one comparison 
from three multi-arm RCTs (Chen 2014; Xie 2009; Zhang 1996) evaluated the additional effects 
of CHMs. Chen 2014 and Xie 2009 compared Chinese herbs plus radiofrequency with same 
radiofrequency alone and Zhang 1996 compared Chinese herbs plus immunotherapy with same 
immunotherapy alone. 
 
Among 17 studies, six used both oral and external applications of WM in the control group (Li 
2008; Li 2012c; Lin 2013; Lu 2003; Lu 1998; Shi 2012). Lu 2009 compared CHM plus WM 
spray with WM sprays only. Xiao 2015 conducted a four-arm trial, two comparisons relevant 
to this review were evaluated: one was to compare effects of Chinese herbal decoction plus 
acupuncture with WM (oral and external) and the same acupuncture with WM; the other was 
to compare CHM with WM (oral and external) versus the same WM alone. When used 
externally in the nasal cavity, one study compared Chinese herbal drops plus surgery with same 
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surgery procedure (Liu 2004b). The rest of the studies compared CHM with WM oral versus 
the same WM (Cao 2014b; Chen 2011; Li 2012b; Shi 2014; Tang 2008; Wu 2012a; Zhao 2012; 
Zhou 2005). 
 
Treatment periods in the included studies varied from two weeks to three months. All the 
included trials followed up the participants until the end of the treatments. Follow-up periods 
after treatment ranged from two weeks to one year. Nine studies followed up the patients for 
one year (Chen 2004; Han 2002; Hu 2002; Jin 2010; Liu 2001; Lu 2003; Peng 2004; Zhang 
1996; Zhou 2005). Six studies (Hong 2005; Huang 2010; Shi 2012; Xiao 2015; Ye 2015;  Zhong 
2013) followed up for six months. Zheng 2007 followed up to four months. Another two studies 
(Cao 2007; Luo 2013) followed up patients for three months. The follow-up period of the Lu 
1998, Lin 2013; Wu 2012a and Xie 2009 trials were two months. Four studies (Li 2012b; Liang 
2011; Qiu 2012; Xin 2005) followed up the patients for one month. Qin 2006 followed up to 
three weeks while Bao 2013; Gao 2009 and Xue 2003b only followed up for two weeks. Thirty 
trials did not provide information on follow-up. Two trials indicated that long-term follow-up 
was applied however, no details were stated (Zhang 1996; Zhou 2005).  
 
5.2.6. Types of outcome measures 
All the included studies involved in one or more primary and/or secondary outcome measures. 
For the purpose of evaluation, the last treatment is defined as immediate follow-up, one week 
(inclusive) to six months (exclusive) after the last treatment as short-term follow-up, six months 
(inclusive) to 12 months (exclusive) after the treatment period as intermediate-term follow-up. 
Long-term follow-up is regarded as one year or above after treatment. There are five outcome 
measures reported as follows: 
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i. Improvement of symptoms  
Majority of included studies assessed the immediate, short-term, intermediate-term and/or long-
term effects on the improvement of global symptoms (by effective rates) and severity of 
symptoms (by individual symptom scores, and/or total symptom scores). 
 
Twenty-seven studies used an effective rate to show the immediate effects of global symptom 
improvement by comparing the symptom scores before and after treatment (Baba 1995; Bao 
2013; Cao 2014b; Chen 2011; Chen 2012; Chen 2014; Gao 2009; Guo 2010; Huang 2008a; Li 
2008; Lu 2009; Lu 2011; Peng 2001; Qin 2006; Shen 2004; Shi 2014; Sun 2014a; Tang 2008; 
Wang 2000a; Wu 2009; Xin 2005; Yan 2011; Yang 2004; Zhang 2007; Zhao 2012; Zhou 
2001b; Zou 2012). Four trials (Hu 2002; Yan 2014; Yang 2004; Zhao 2009) did not apply any 
scales/scores to examine the improvement of symptoms. Lenon 2012; Xue 2003a and Xue 
2003b rated patients' overall response to treatment according to a seven-point scale at the end 
of treatment period. Lenon 2012 also rated global symptoms according to a five-point scale in 
their studies. Four trials (Hu 2002; Yan 2014; Yang 2004; Zhao 2009) did not apply any scales 
or scores to examine the improvement of symptoms.  
 
Seventeen trials evaluated the short-term effects. Three trials rated at two weeks after the last 
treatment (Bao 2013; Gao 2009; Xue 2003b), while one trial rated three weeks after treatment 
(Qin 2006). Five trials evaluated at one month after the treatment period (Chen 2014; Li 2012b; 
Liang 2011b; Qiu 2012; Xin 2005). Four trials assessed at two months after Chinese herbal 
treatment (Lin 2013; Lu 1998; Wu 2012a; Xie 2009). The Zhang 1996 conducted a three-arm 
trial in which the investigators rated one of study for four months, while another of Zhang 1996 
was assessed for one year. The immunotherapy treatment for the one-year evaluation was 
completed at eight months. Two trials were rated three months after treatment (Cao 2007; Luo 
2013). Only Zheng 2007 conducted follow-up four months after treatment. Intermediate-term 
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evaluation (six months after treatment) was performed in six trials (Hong 2005; Huang 2010; 
Shi 2012; Xiao 2015; Ye 2015; Zhong 2013). Nine studies assessed the long-term (one year 
after treatment) effects (Chen 2004; Han 2002; Hu 2002; Jin 2010; Lin 2013; Liu 2001; Lu 
2003; Peng 2004; Zhou 2005). The rest of the studies conducted immediate follow-up after 
treatment. 
 
Owing to the variety of the criteria for evaluating this outcome, the Chinese medicinal formulae 
were rated as effective if the effective rate was greater than 20%. The effective rate was 
calculated as (scores before treatment – scores after treatment) /scores before treatment x 100%. 
 
The severity of symptoms was reported as the individual symptom scores and/or the total 
symptom scores. The individual symptom scores were presented as mean ± standard deviation 
(SD) for immediate effects in nine trials (Chen 2014; Jung 2011; Lu 2011; Matkovic 2010; Shi 
2014; Wu 2009; Zhao 2009; Zheng 2013; Zou 2012) and short-term effects in eight studies 
(Bao 2013; Cao 2007; Gao 2009; Lenon 2012; Liu 2004b; Lu 1998; Peng 2001; Qin 2012). The 
Peng 2004 study showed the findings with the reduction of scores. Two studies illustrated the 
findings as total scores for immediate (Hu 2002; Liu 2004b), two trials for intermediate effects 
(Huang 2010; Zhong 2013) and one for long-term effects (Hu 2002). Total symptom scores by 
mean ± SD were reported for immediate effects in 10 trials (Gao 2009; Huang 2008a; Jung 
2011; Liu 2001; Matkovic 2010; Wang 2006b; Xue 2003a; Xue 2003b; Zou 2012; Zhong 2013). 
The Jiang 1997 studies listed the number and percentage of patients with decreased scores in 
individual symptoms. Out of 62 studies, only Chen 2012 conducted lab tests to assess IgE and 
IL4 values. 
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ii. Quality of life 
Six studies assessed the CHM effects on quality of life using RQLQ or mini-RQLQ with 
presentation of results in mean ± SD (Hu 2002; Jung 2011; Lenon 2012; Matkovic 2010; Xue 
2003a; Xue 2003b), or SF-36 by mean ± SD in Gao 2009, or percentage of changes in scores 
in Zhao 2009. 
 
iii. Medication consumption 
Five trials counted rescue medication consumption (Hu 2002; Lenon 2012; Xue 2003a; Zhao 
2009). However, three trials Hu 2002, Lenon 2012 and Xue 2003a reported the percentage of 
improvement of extra medication scores. The Xue 2003b and Zhao 2009 studies only stated 
that they recorded the relief medications but no scores were reflected.  
 
iv. Serum IgE level 
Eleven studies tested total serum IgE level, nine for immediate effects (Chen 2012; Hu 2002; 
Jung 2011; Liu 2010b; Matkovic 2010; Xue 2003a; Zhang 1996; Zhao 2009; Zhou 2001b); one 
study evaluated for short-term effects (Zhang 1996) and one for long-term effects (Han 2002). 
Among them, the Matkovic 2010, Xue 2003a and Zhao 2009 studies did not provide any data. 
The Zhou 2001b trial only reported results for 26 out of 93 patients in the treatment group. The 
Zhang 1996 study examined serum IgE immediately after two-month CHM treatment whilst 
the immunotherapy was not finished. Data were only provided for CHM group with the 
comparator measurement. 
 
v. Adverse events 
Thirty trials provided information on adverse events. An adverse event is regarded as a minor 
case when the patient was still able to complete the trial. In the same vein, an adverse event is 
considered as a major case when the patient had to withdraw from the trial due to the unpleasant 
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reactions. All the withdrawn cases are categorised as major cases even if the reasons of 
withdrawal were not provided. Most of reported adverse events were minor cases.  
 
Fifteen studies found adverse events in both treatment and control groups (Baba 1995; Bao 
2013; Chen 2014; Han 2002; Hu 2002; Huang 2008a; Jung 2011; Lenon 2012; Lu 1998; Peng 
2004; Wang 2000a; Xue 2003a; Xue 2003b; Zhao 2009; Zhou 2001b). Among them, Huang 
2008a  trial did not provide any data. Five trials did not observe any adverse events in treatment 
group but some in control groups ( Gao 2009; Guo 2010; Huang 2010; Luo 2013; Shen 2004). 
The investigators in Chen 2004, Hong 2005, Liang 2011b, Shi 2014, Sun 2014a, Xie 2009, 
Zhong 2013 and Zou 2012 studies observed no adverse events during the trial periods. Adverse 
events in the treatment group were noted in one study (Lu 1998) but no information was 
provided on the control group. Matkovic 2010 and Shi 2014 did not specify the adverse events 
stated in the trials for each group. The Wu 2009 study generally described the adverse events; 
however, no details were reported. The rest of 32 studies did not report the adverse events.  
 
5.3. Assessment of risk of bias 
The risk of bias of each included study was evaluated according to the criteria listed in 4.1.4. 
The graph and summary of “risk of bias” assessment are illustrated in Figure 10 and Figure 11 
respectively. Each aspect of the risk of bias assessment is detailed from 5.3.1 to 5.3.5. 
 
Figure 10. Graph of risk of bias of 62 included RCTs 
101 
 
 
Figure 11. Summary of risk of bias of 62 included RCTs 
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5.3.1. Allocation (selection bias)  
All the included studies reported that participants were randomly assigned into treatment and 
control groups. Nineteen out of 62 studies provided randomisation allocation methods. Random 
number table was listed as a means of randomised allocation in 10 trials (Bao 2013; Chen 2011; 
Chen 2012; Chen 2014; Huang 2010; Jin 2010; Qin 2006; Qiu 2012; Wu 2009; Xie 2009), the 
computer-generated random number in nine studies (Bai 2012; Cao 2007; Gao 2009; Hu 2002; 
Jiang 2012; Liu 2001; Xue 2003a; Xue 2003b; Zhao 2009).  
 
In terms of ratio, 1:1 ratio randomisation was used in 17 studies (Bao 2013; Cao 2007; Cao 
2014b; Gao 2009; Huang 2008a; Li 2012b; Li 2012c; Lin 2013; Lu 2011; Luo 2013; Shi 2014; 
Shi 2012; Sun 2014a; Wu 2012a; Zhao 2012; Zhong 2013, Zou 2012), 1:1:1 ratio randomisation 
in one trial (Liang 2011b) and 2:1 ratio randomisation in one study (Matkovic 2010). Two 
studies (Huang 2006b; Lu 2011) indicated that stratified randomisation was used however no 
further details were provided. Only one study reported the method for concealment of allocation 
that is, using sealed envelopes to allocate the random numbers to participants (Shi 2012). The 
rest of 40 trials did not describe the methods used for performing randomisation. 
 
5.3.2. Blinding (performance bias and detection bias)  
Eight studies employed double-blinding (Baba 1995; Hu 2002; Jung 2011; Lenon 2012; 
Matkovic 2010; Xue 2003a; Xue 2003b; Zhao 2009) and only one study used single-blinding 
(Cao 2014b) strategy. Two studies clearly indicated that no blinding was employed in the trial 
(Qin 2006; Bao 2013). The rest of 52 studies did not provide any information on blinding.  
 
Seventeen studies (Bai 2012; Cao 2014b; Huang 2008a; Jiang 1997; Jin 2010; Li 2008; Li 
2012b; Li 2012c; Liang 2011b; Lin 2013; Lu 2009; Luo 2013; Sun 2014a; Yan 2011; Yang 
2004; Zhang 2007b; Zhao 2012) only had one author for their published papers and six studies 
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were research work for Masters or PhD degrees with single authors (Chen 2012a; Gao 2009; 
Liu 2010b; Qin 2006; Qiu 2012; Zhong 2013). It is impossible for one investigator to perform 
blinding for treatment and outcome assessment. 
 
5.3.3. Incomplete outcome data (attrition bias)  
The attrition bias was only assessed for the immediate effects. Majority of studies (61 out of 
62) had the same number of participants randomised and analysed in the results for the global 
symptom improvement. Among them, only Lu 1998 study clearly stated that all the 105 
participants completed the trial which indicated that there were no missing data. Only Wu 2009 
reported the results of laboratory tests for part of participants.  
 
Fourteen trials reported a total of 111 withdrawals/drop-outs (Baba 1995; Cao 2014b; Gao 
2009; Hu 2002; Huang 2010; Jung 2011; Lenon 2012; Liang 2011b; Matkovic 2010; Wu 2012a; 
Xue 2003a; Xue 2003b; Zhang 2007; Zhao 2009). All except three studies (Lenon 2012; Liang 
2011; Zhao 2009) provided reasons for withdrawals/drop-outs, including loss of follow-up, 
withdrawal of consent, discontinued treatment, side effects of interventions and poor 
compliance. However, only six studies applied the intention-to-treat method to their data 
analysis (Hu 2002; Lenon 2012; Matkovic 2010; Xue 2003a; Xue 2003b; Zhao 2009) and the 
rest did not address the missing data in the analysis. 
 
5.3.4. Selective reporting (reporting bias)  
None of the included studies reported their protocol prior to publishing their clinical trials; 
therefore it is unclear if the included studies selectively reported the results. In the SR, the data 
in the results of the included studies were compared with those in methods section to determine 
if selective reporting existed. Selective reporting may be involved in three trials as they stated 
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that a certain number of patients with completed data were reported (Cao 2007; Peng 2001; 
Peng 2004). 
 
5.3.5. Other potential sources of bias  
A total of 55 studies exhibited a significant baseline imbalance in participants’ age during 
allocation and were rated with “unclear risk” for allocating participants of mixed ages from six 
to 76 years. Only seven studies (Baba 1995; Hu 2002; Jung 2011; Lenon 2012; Matkovic 2010; 
Xue 2003a; Xue 2003b) recruited adults from 18 years of age onwards for selection of studies. 
In the funding of the projects, external grants supported 11 trials. All but three trials (Lenon 
2012; Liu 2001; Xue 2003b) reported that CHMs were more effective than comparators. One 
trial stated an equal efficacy to the comparator used in the study (Jiang 1997). The high rate of 
reporting positive effects of CHMs may be biased with contribution from the external funding.  
 
5.4. Clinical effects of CHM for AR 
5.4.1. CHM versus placebo 
In this category of comparison, seven trials compared oral administration of CHM with placebo 
(Baba 1995; Hu 2002; Jung 2011; Lenon 2012; Matkovic 2010; Xue 2003a; Zhao 2009).  
 
i. Improvement of symptoms 
Among seven studies, the physicians in the Hu 2002 and Zhao 2009 studies evaluated the 
patients’ overall improvement without using any scales/scores. Thus, their results were not 
included in the meta-analysis. The Baba 1995 trial used an effective rate to evaluate the 
immediate global symptom improvement according to the change of the severity of symptoms. 
The Chinese herbal group was more effective than the placebo group (RR 1.97; 95% CI 1.47 
to 2.65).  
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Two studies assessed severity of nasal symptoms (Jung 2011; Xue 2003a), only Xue 2003a 
rated patients' overall response to treatment using a seven-point scale instead of changed scores 
before and after treatment. When post hoc analysis was applied, both Jung 2011 and Xue 2003a 
studies depicted significant difference for CHM when assessed by patients (SMD -0.61; 95% 
CI -1.00 to -0.22). The heterogeneity was nil (I2 = 0%) (Figure 12). 
 
 
Figure 12. Severity of nasal symptoms (assessed by patients, immediate follow-up post hoc analysis) for CHM 
versus placebo 
 
Patients in three studies (Lenon 2012; Xue 2003a; Jung 2011) assessed the severity of their 
nasal symptoms in immediate follow-up of their treatment. No significant results between two 
groups were demonstrated (SMD -0.38; 95% CI -0.85 to 0.09). Heterogeneity was substantial 
(I2 = 63%) (Figure 13). 
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Figure 13. Severity of nasal symptoms (assessed by patients, immediate follow-up) for CHM versus placebo 
 
Two trials (Hu 2002; Matkovic 2010) presented the changes in sneeze and runny nose scores at 
the immediate follow-up which favoured CHM for sneezing. The pooled data showed that the 
Chinese herbs were more effective than placebo for relieving sneeze (SMD 0.79; 95% CI 0.36 
to 1.22) (Figure 14) but not for runny nose (SMD 0.62; 95% CI -0.10 to 1.35). The heterogeneity 
for the latter was substantial (I2 = 65%) (Figure 15). 
Figure 14. Changes in sneeze score (immediate follow-up) for CHM versus placebo 
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Figure 15. Changes in runny nose (immediate follow-up) for for CHM versus placebo 
 
The Hu 2002 study also illustrated that Chinese herbs significantly reduced more scores of nasal 
congestion (MD 27.92; 95% CI 12.24 to 43.60), itchy nose (MD 0.98; 95% CI 0.39 to 1.58) 
and itchy eyes (MD 28.33; 95% CI 12.42 to 44.24) than placebo at the end of 12-week 
treatment.  
 
The Zhao 2009 trial reported the individual symptom scores after four weeks' treatment. 
Significant difference between two groups was only shown in itchy ears with a favour towards 
placebo (MD 0.34; 95% CI 0.06 to 0.62). Symptoms recurred in the placebo group except for 
nasal congestion in the CHM group (Shi-Bi-Lin) were still decreasing. However, no detailed 
data were available. Meta-analysis was not applied to these outcomes. 
 
In addition, the Hu 2002 study further assessed the changes in individual symptom scores for 
long-term effects (one year after treatment). The authors claimed changes in runny nose (MD 
27.51; 95% CI 11.37 to 43.65) and sneeze score (MD 24.85; 95% CI 7.21 to 42.49) in Biminne 
group were more significant than placebo group.  
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Three trials evaluated the patient-rated for severity of nasal symptom score (Jung 2011; Lenon 
2012; Xue 2003a). CHM and placebo had no significant difference in the outcome measure 
(SMD -0.38; 95% CI -0.85 to 0.09). The heterogeneity was substantial (I2 = 63%) (Figure 16). 
Figure 16. Severity of nasal symptoms (assessed by patients, immediate follow-up) for CHM versus placebo 
 
The specialist-rated total nasal symptom scores in Xue 2003a favoured CHM (MD -0.60; 95% 
CI -1.02 to -0.18). For non-nasal symptoms assessed by specialist, no significant difference was 
also detected (MD -0.30; 95% CI -0.65 to 0.05). Similarly, no significant difference for CHM 
and placebos was demonstrated when assessed by patients for their non-nasal symptoms (MD 
-0.28; 95% CI -0.64 to 0.08).  
 
The Matkovic 2010 study assessed the global symptom scores for SAR which indicated that 
Huang Qi (Astragali Radix) was less effective than placebo at the end of six-week treatment 
(MD 0.77; 95% CI 0.62 to 0.92).  
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ii. Quality of life 
All seven studies except Baba 1995 evaluated quality of life. RQLQ/mini-RQLQ was popularly 
used in five studies (Hu 2002; Jung 2011; Lenon 2012; Matkovic 2010; Xue 2003a). Only the 
Zhao 2009 trial used SF-36 questionnaire. 
 
The changes in overall RQLQ scores at the immediate follow-up from three studies (Hu 2002; 
Jung 2011; Matkovic 2010) were pooled. The meta-analysis showed the Chinese herbs and 
placebo had similar effects on the change of RQLQ scores (SMD 0.11; 95% CI -0.14 to 0.36). 
No heterogeneity was reflected (I2 = 0%). The changed scores in each domain could not be 
compared for these three studies due to lack of data. The Hu 2002 trial also followed up with 
RQLQ after one year of treatment. There was no significant difference between two groups 
(Figure 17). However, no detailed data were provided. 
 
Figure 17. Changes in total RQLQ score (immediate follow-up) for CHM versus placebo 
 
At the end of eight-week treatment, Xue 2003a compared the total scores for RQLQ Section 
One (symptoms and activities related to SAR) and RQLQ Section Two (impact of SAR on 
emotional aspects). Placebo was statistically significant for RQLQ Section One (MD -0.66; 
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95% CI -1.20 to -0.12), however RQLQ Section Two (MD 1.00; 95% CI 0.30 to 1.70) proved 
CHM had an effect.  
 
The Zhao 2009 trial compared Chinese herbal (Shi-Bi-Lin) and placebo effects on percentage 
change from baseline scores for eight domains of SF-36. However, the effects between two 
groups were not compared. 
 
iii. Medication consumption  
Four trials counted rescue medication consumption during the trial (Hu 2002; Lenon 2012; Xue 
2003a; Zhao 2009). Rescue medications were used by participants to relieve severe AR 
symptoms which could not be managed by the interventions during the trial period. The Hu 
2002 study illustrated the use of rescue medication were reduced significantly in Biminne group 
compared to placebo for both immediate (MD 63.03; 95% CI 27.63 to 98.43) and long term 
follow-up (MD 39.41; 95% CI 17.27 to 61.55), respectively. The pooled data from the Xue 
2003a and Lenon 2012 revealed no significant difference in relief medication scores in Chinese 
herbal and placebo groups during the treatment period  (MD -3.13; 95% CI -7.10 to 0.84) 
(Figure 18). The Zhao 2009 trial indicated 13 patients in Shi-Bi-Lin group and 11 patients in 
placebo group took extra concurrent medication to control PAR symptoms but no scores were 
provided. Xue 2003a noted no significance difference detected between the active and the 
control, no data were available for further analysis. 
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Figure 18. Medication consumption score for CHM versus placebo 
 
iv. Total serum IgE level 
Five studies assessed the total serum IgE level right after the treatment period (Hu 2002; Jung 
2011; Matkovic 2010; Xue 2003a; Zhao 2009). However, the Hu 2002 trial only reported the 
median as well as lower and upper quartiles. All the Matkovic 2010, Xue 2003a and Zhao 2009 
studies claimed that there were insignificant differences in changing IgE levels between two 
groups but no data were provided. Thus meta-analysis could not be performed. The Jung 2011 
trial did not show significant difference in the total serum IgE level between ginseng and 
placebo at the end of four-week treatment (MD 16.39; 95% CI  -11.41 to 44.19). 
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v. Adverse events 
Almost all seven trials reported on adverse events. Baba 1995 trial reported six mild and one 
moderate case (digestive problems, headache, facial oedema, stomatitis, and belching) in 
treatment group, and five mild and two severe cases (eye dryness, thirst, and digestive 
problems) in control group. Both groups had one case presenting with a mild increase in 
aspartate aminotransferase (AST) and alanine transaminase (ALT). The Hu 2002 study had 
three cases (nausea, bloating, flatus, headache, sore eyes and sore nose) in treatment group and 
four cases (diarrhoea, vomiting, dizziness, rash on eyes, headache, vomiting, nose bleeding and 
spreading facial brown pigmentation) in control group. These mild to moderate adverse events 
were “considered to be possibly, probably or definitely related to study medication”. However, 
no treatment was required for these adverse events. Two patients withdrew from the control 
group due to stomach upset and dull abdominal pain. The Jung 2011 trial reported one mild 
hepatic dysfunction (an increase in AST) in treatment group whilst in control group, a patient 
had an increase in total bilirubin and another patient had an increase in AST. The Lenon 2012 
trial reported six cases (constipation, tiredness, itchiness around the mouth, dry nose at night 
and skin rash) in treatment group and 9 cases (nausea, tiredness, headache, dry nose at night, 
stomach upset and reflux) in control group.  Ten participants in the Matkovic 2010 study 
reported 15 adverse events which included pharyngitis (seven), rhinosinusitis (four), 
enterocolitis (one), nausea (one), lacunar angina (one) and vulvitis (one); all signs were not 
connected to any intervention. However, no information on participants’ grouping was 
available. Six patients from treatment group and five from control group experienced adverse 
events in the Xue 2003a trial. They experienced mild bloating, ingestion, stomach ache and/or 
dry nose which did not require any additional treatment. Only one patient in treatment group 
had severe skin rash and leg oedema which led to withdrawal from the trial. The Zhao 2009 
trial reported 12 patients in treatment group and 10 in control group experienced abdominal 
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pain, diarrhoea, sore throat, skin itchiness and dry mouth. These adverse events were unrelated 
to the intervention used. 
 
  
114 
 
5.4.2. CHM versus Western medicine 
A total of 37 studies compared CHM to Western medicine. Both Chen 2004 and Xie 2009 
employed three-arm studies thus only CHM versus Western medicine component are included 
in this section.  
 
A total of 27 trials assessed CHM against oral WM (Bao 2013, Cao 2007; Chen 2014; Gao 
2009; Guo 2010; Han 2002; Hong 2005; Huang 2008a; Huang 2010; Jiang 1997; Jin 2010; 
Liang 2011b; Liu 2001; Lu 2011; Luo 2013; Peng 2001; Peng 2004; Qin 2006; Qiu 2012; Shen 
2004; Sun 2014a; Yan 2011; Yang 2004; Ye 2015; Zhang 1996; Zhang 2007b; Zhong 2013). 
Zhang 1996 compared CHM oral to immunotherapy. Six trials compared CHM with WM nasal 
sprays only (Chen 2012; Huang 2006b; Wang 2000a; Zheng 2007; Zou 2012, Zhou 2001b). 
Only one (Wu 2009) used nano-liposome nasal drops for the control. Only one trial involved 
CHM oral plus external versus WM oral and nasal spray as comparators (Xin 2005) while two 
studies compared CHM with radiofrequency (Chen 2004; Xie 2009).  
 
i. Improvement of symptoms 
Seven non-classified AR studies evaluated global symptom improvement with immediate 
follow-up when comparing CHM with oral WM (Lu 2011; Shen 2004; Sun 2014a; Wang 
2000a; Wu 2009; Zheng 2007; Zhou 2001b). Another eight studies for PAR fall under this 
category (Guo 2010; Huang 2008a; Liu 2001; Peng 2004; Qin 2006; Yan 2011; Zhang 2007b; 
Zou 2012). The overall pooled data demonstrated CHM had better significant effects over WM 
(RR 1.13; 95% CI 1.09 to 1.17) with substantial heterogeneity (I2 = 75%). Subgroup analysis 
of global symptom improvement for immediate follow-up demonstrated CHM was more 
effective than WM group in treatment of non-classified AR (RR 1.21; 95% CI 1.14 to 1.28) as 
well as for PAR (RR 1.08; 95% CI 1.02 to 1.13). The heterogeneity for the latter is regarded as 
substantial (I2 = 84%) and the former was moderate at (I2 = 41%) (Figure 19). 
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Figure 19. Global symptom improvement (immediate follow-up) for CHM versus WM 
 
In short-term follow-up of AR treatment, ten studies for non-classified AR were also identified 
(Cao 2007; Chen 2012; Gao 2009; Guo 2010; Luo 2013; Peng 2001; Qiu 2012; Yang 2004; Ye 
2015; Zheng 2007), while for PAR four studies were included (Liang 2011b; Xie 2009; Xin 
2005; Zhang 1996). Effects of CHM in the short-term for non-classified AR was significant as 
reflected in the meta-analysis (RR 1.09; 95% CI 1.04 to 1.14) with low heterogeneity (I2 = 7%). 
However, for PAR, CHM did not demonstrate clinical effects when compared to WM (RR 1.40; 
95% CI 0.82 to 2.39) with substantial heterogeneity (I2=83%). Overall, meta-analysis for short-
term treatment in both groups showed CHM manifested positive symptom improvement in AR 
treatment (RR 1.12; 95% CI 1.04 to 1.21). However, heterogeneity is moderate (I2 = 53%) 
(Figure 20). 
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Figure 20. Global symptom improvement (short-term follow-up) for CHM versus WM 
 
Four studies assessed global symptom improvement for intermediate follow-up (Hong 2005; 
Luo 2013; Huang 2010; Zhong 2013). Both Hong 2005 and Luo 2013 did not classify AR, 
while Huang 2010 and Zhong 2013 were PAR studies. Data for non-classified AR group 
showed a favourable global symptom improvement for patients using CHM (RR 1.24; 95% CI 
1.10 to 1.39). No heterogeneity (I2 = 0%) was detected. However, for PAR, no significant 
difference was shown (RR 1.44; 95% CI 0.75 to 2.74), with substantial heterogeneity (I2 = 
74%). Overall, meta-analysis demonstrated CHM had stronger clinical effects over WM for 
global symptom improvement (RR 1.21; 95% CI 1.08 to 1.37). Moderate heterogeneity was 
reflected (I2 = 32%) (Figure 21). 
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Figure 21. Global symptom improvement (intermediate follow-up) for CHM versus WM 
 
Pooled data did not show any significant difference in global symptom improvement between 
CHM and WM for either PAR (RR 0.90; 95% CI 0.77 to 1.05) or non-classified AR (RR 1.13; 
95% CI 0.95 to 1.33) over long-term follow-up in four studies (Han 2002; Chen 2004; Jin 2010; 
Liu 2001). However, heterogeneity was substantial for PAR studies (I2 = 78%) (Figure 22). 
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Figure 22. Global symptom improvement (long-term follow-up) for CHM versus WM 
 
A further post hoc subgroup analysis conducted for global symptom improvement with the use 
of CHM versus anti-histamines for both non-classified AR and PAR indicated that CHM was 
more effective than anti-histamines for improving global symptoms improvement (RR 1.07; 
95% CI 1.01 to 1.12) with immediate follow-up with heterogeneity at I2 = 48% in the pooled 
data. However, results did not show significant difference for non-classified AR (RR 1.08; 95% 
CI 0.98 to 1.19) and PAR (RR 1.06; 95% CI 0.99 to 1.12) specifically. The heterogeneity for 
the non-classified AR and PAR studies only were substantial (I2 = 71%) and low (I2 = 28%), 
respectively (Figure 23). 
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Figure 23. Global symptom improvement (immediate follow-up) post hoc analysis for CHM versus anti-
histamines 
 
Similar positive results prevailed for short-term follow-up for the use of CHM comparison to 
anti-histamines. For short-term follow-up, six non-classified AR studies (Cao 2007; Gao 2009; 
Luo 2013; Peng 2001; Yang 2004; Ye 2015), two PAR studies (Li 2012b; Liang 2011b) and 
one SAR study (Qiu 2012) were evaluated. Overall pooled data demonstrated CHM manifested 
significant difference over anti-histamines in global symptom over short-term (RR 1.19; 95% 
CI 1.07 to 1.33) with considerable heterogeneity (I2 = 74%) (Figure 24).  
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Figure 24. Global symptom improvement (short-term follow-up) post hoc analysis for CHM versus anti-
histamines  
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Intermediate period evaluation of global symptom improvement involved two studies (Huang 
2010 and Zhong 2013). There was no significant difference between CHM and WM (RR 1.52; 
95% CI 0.58 to 3.99) (Figure 25). 
 
Figure 25. Global symptom improvement (intermediate follow-up) post hoc analysis for CHM versus anti-
histamines 
 
Summarily, meta-analysis results for global symptom improvement for CHM versus WM 
before post hoc analysis indicated for immediate (RR 1.13; 95% CI 1.09 to 1.13; I2 = 75%), 
short-term (RR 1.12; 95% CI 1.04 to 1.21; I2 = 53%), intermediate (RR 1.21; 95% CI 1.08 to 
1.37; I2 = 32%) and long-term effects (RR 1.00; 95% CI 0.89 to 1.12; I2 = 77%), respectively. 
Global improvement for AR symptoms was significant with immediate, short-term and 
intermediate effects but not in the long-term. The post hoc analysis indicated for CHM versus 
anti-histamines over immediate (RR 1.07; 95% CI 1.01 to 1.12; I2 = 48%), short-term (RR 1.21; 
95% CI 1.07 to 1.37; I2 = 78%) and intermediate effects (RR 1.52; 95% CI 0.58 to 3.99; I2 = 
88%). CHMs were superior over anti-histamines in immediate and short-term duration. 
 
As different WMs were used in the control group, subgroup analyses were performed according 
to WM. Subgroup analyses for all the oral western medications involved in the control groups 
that involve anti-histamines included Cetirizine (Huang 2010; Jiang 1997; Liu 2001; Lu 2011; 
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Qin 2006; Shen 2004; Yan 2011); Loratadine (Bao 2013; Gao 2009; Guo 2010; Liang 011; Luo 
2013; Peng 2004; Qiu 2012; Sun 2014a; Ye 2015; Zhang 2007b; Zhong 2013), Ketotifen (Cao 
2007; Peng 2001), Hismanal (Jiang 1997; Han 2002) and Triprolidine (Qin 2006; Yang 2004).  
 
In Figure 26, Subgroup 2 consists of CHM external (Magnolia Flos volatile oil nano-liposome 
nasal drops) versus WM oral medication in one study (Wu 2009). Subgroup 3, CHM external 
versus WM external (nasal spray) were used (Wang 2000a; Zhou 2001b). Only Zou 2012 in 
Subgroup 4 used CHM oral versus WM external (nasal spray).  
 
The use of Magnolia Flos volatile oil nano-liposome nasal drops in Wu 2009 in Subgroup 2 
exhibited significant difference over Cetrizine (RR 1.24; 95% CI 1.11 to 1.39) ( Figure 26, 
2.5.2) after the last treatment. The use of CHM external in comparison with WM external in 
Subgroup 3 exhibited effects at the end of treatment period (RR 1.63; 95% CI 1.14 to 2.32) 
(Figure 26, 2.5.3).  
 
In Subgroup 4, oral administration of Tuomintongqiao capsule (includes six CHMs) was more 
effective than external application of Montelukast nasal drops (RR 1.27; 95% CI 1.05 to 1.54) 
(Figure 26, 2.5.4) in Zou 2012. Overall, meta-analysis of global symptom improvement for 
immediate follow-up demonstrated CHMs had a significant impact in treatment of AR. (RR 
1.12; 95% CI 1.05 to 1.20). Heterogeneity is substantial (I2 = 71%) (Figure 26). 
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Figure 26. Global symptom improvement (immediate follow-up) with subgroup analysis for CHM versus WM 
 
In the subgroup analysis, global symptom improvement (short-term follow-up) demonstrated 
favourable effects of CHM over WM (RR 1.13; 95% CI 1.03 to 1.24). Substantial heterogeneity 
is at (I2 = 65%). No significant difference was depicted for CHM when taken in different forms 
such as external versus WM external (RR 1.17; 95% CI 0.95 to 1.44), immunotherapy (RR 
0.95; 95% CI 0.70 to 1.30) and radiofrequency (RR 0.82; 95% CI 0.59 to 1.14) for improving 
global symptom over the short-term period. However, CHM exhibited more effectiveness over 
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the use of oral anti-histamines (RR 1.15; 95% CI 1.03 to 1.28) with a substantial heterogeneity 
(I2 = 73%) (Figure 27). 
 
 
Figure 27. Global symptom improvement (short-term follow-up) with subgroup analysis for CHM versus WM 
 
Contradictory outcome is portrayed in the data for intermediate evaluation of global symptom 
improvement. CHM was significant as manifested in study of Hong 2005 (RR 1.23; 95% CI 
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1.05 to 1.44) for CHM oral in comparison with WM oral and WM external, but not for anti-
histamine use in Huang 2010, Luo 2013 and Zhong 2013 (RR 1.27; 95% CI 0.98 to 1.63). 
However, pooled data analysis depicted CHM had more significant effects in improving global 
symptom when compared to WM in the intermediate period (RR 1.23; 95% CI 1.06 to 1.42) 
with moderate heterogeneity (I2 = 50%) (Figure 28). 
 
 
Figure 28. Global symptom improvement (intermediate follow-up) with subgroup analysis for CHM versus WM 
 
Pooled data for global symptom improvement over long-term follow-up demonstrated no 
significant difference (RR 0.95; 95% CI 0.74 to 1.22) with substantial heterogeneity (I2 = 77%) 
(Figure 29).  
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Figure 29. Global symptom improvement (long-term follow-up) with subgroup analysis for CHM versus WM 
 
For severity of symptoms, three trials compared the severity of the different AR symptoms at 
the end of the treatment period using mean value with SD (Lu 2011; Peng 2004; Wu 2009). In 
comparison with WM, the pooled data indicated that CHM had no significant effects on sneeze 
(SMD -0.51; 95% CI -1.20 to 0.17) (Figure 30), runny nose (SMD -0.47; 95% CI -1.05 to 0.10) 
(Figure 31) and nasal congestion (SMD -0.44; 95% CI -1.11 to 0.23) (Figure 32). Only severity 
for itchy nose score demonstrated positive results with a favour to CHM (SMD -0.28; 95% CI 
-0.48 to -0.07) (Figure 33). The heterogeneity for sneeze, runny nose and nasal congestion was 
considerable except for itchy nose score, I2 = 90%, I
2 = 86% and I2 = 89%, respectively. No 
heterogeneity was applicable for itchy nose I2 = 0% (Figure 33).  
127 
 
 
 Figure 30. Severity of sneeze score (immediate follow-up) for CHM versus WM 
 
 
Figure 31.Severity of runny nose (immediate follow-up) for CHM versus WM 
 
 
Figure 32. Severity of nasal congestion (immediate follow-up) for CHM versus WM 
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Figure 33. Severity of itchy nose (immediate follow-up) for CHM versus WM 
 
Only Cao 2007 assessed patients’ severity of symptom score in short-term follow-up, while 
Zhong 2013 evaluated severity in the intermediate period. Results showed that in the short term, 
CHM had less effects when compared to oral Ketotifen in Cao 2007 with sneeze (MD 0.73; 
95% CI 0.21 to 1.26), runny nose (MD 1.17; 95% CI 0.62 to 1.72), nasal congestion (MD 0.74; 
0.22 to 1.27) and itchy nose (MD 0.62; 95% CI 0.10 to 1.14). Positive trend is depicted in the 
data of Zhong 2013 when severity of symptoms was evaluated on Qufengtongqiao formula for 
PAR after intermediate duration of treatment. A positive effect was demonstrated in CHM for 
the severity of AR symptoms when compared to Desloratadine for a period of six months: 
sneeze (MD -0.60; 95% CI -1.08 to -0.11), nasal congestion (MD -0.83; 95% CI -1.33 to -0.34), 
itchy nose (MD -0.68; 95% CI -1.17 to -0.19) and runny nose (MD -0.91; 95% CI -1.40 to -
0.41). 
 
Four studies assessed global symptom score at the end of treatment period (Bao 2013; Huang 
2006b; Peng 2004; Zou 2012). There was no significant difference in global symptom score 
between CHM and WM oral groups (SMD -0.87; 95% CI -1.79 to 0.05) right after the treatment 
period. Considerable heterogeneity was reflected (I2 = 90%) (Figure 34). The same trend is also 
observed in short-term assessment of global symptoms except for Qiu 2012 where syndrome 
differentiation was employed in the trial (Figure 35). Positive global symptom outcome was 
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depicted in CHM group compared to WM in Qiu 2012 (SMD -2.87; 95% CI -3.27 to -2.48). 
Insignificant difference for non-classified AR was observed in the meta-analysis for Cao 2007; 
Gao 2009 and Peng 2001 (SMD 0.11; 95% CI -0.74 to 0.96). Overall pooled data demonstrated 
no effect was exerted by CHM following a short-term period (SMD -0.63; 95% CI -2.22 to 
0.95). A high heterogeneity is depicted (I2 = 98%) (Figure 35). 
 
Figure 34. Global symptom score (immediate follow-up) for CHM versus WM 
 
Figure 35. Global symptom score (short-term follow-up) for CHM versus WM 
 
Both Huang 2010 and Zhong 2013 assessed total symptom score for CHM versus WM for PAR 
in the intermediate period (six months after treatment). It appeared that CHM did not exert 
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significant difference in the symptom score associated with PAR subgroup when compared to 
WM oral (SMD -0.33; 95% CI -1.88 to 1.22). Substantial heterogeneity exists (I2 = 94%) 
(Figure 36).  
 
 
Figure 36. Global symptoms score (intermediate follow-up) for CHM versus WM 
 
No studies reported data on total symptom scores for long-term follow-up. 
 
ii. Quality of life 
Only one trial Gao 2009 assessed the effects on quality of life using SF-36. The scores in the 
eight domains of SF-36 and Chinese herbs (Lingguizhugan decoction) showed more 
improvement than Loratadine tablet for PAR patients with phlegm retention at the end of two 
weeks’ treatment. The following three domains: physical functioning (MD 2.77; 95% CI 0.49 
to 5.05), role limitations due to physical health problems (MD 6.82; 95% CI 0.90 to 12.74) and 
general health (MD 6.25; 95% CI 0.28 to 12.22) were significant. There were no significant 
differences between two groups in the other five domains which included, bodily pain (MD 
2.81; 95% CI -2.09 to 7.71), vitality (MD 1.04; 95% CI -5.32 to 7.40), social functioning (MD 
4.38; 95% CI -0.30 to 9.06), role limitations due to emotional problems (MD 8.42; 95% CI -
2.96 to 19.80) and mental health (MD 1.89; 95% CI -4.10 to 7.88). 
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iii. Medication consumption 
None of these 37 studies recorded the use of rescue medication. 
 
iv. Total serum IgE level 
The total serum IgE level was evaluated in four trials (Chen 2012; Han 2002; Zhang 1996; Zhou 
2001b). However, the Han 2002 study reported the Chinese herbs could reduce serum IgE level 
(iu/ml) significantly in a long-term (one year after treatment period) with comparison to 
Hismanal tablet (MD -64.50; 95% CI -69.64 to -59.36). Both Chen 2012 and Zhang 1996 
reported no significant difference between CHM and WM in the IgE levels for the immediate 
follow-up (MD -401.96; 95% CI -982.59 to 178.67) and short-term follow-up (MD 18.20; 95% 
CI -48.97 to 85.37) (Figure 37). 
Figure 37. Total serum IgE levels assessed over different follow-up periods for CHM versus Western medicine 
 
v. Adverse events 
Twenty included studies reported information on adverse events and the rest of the studies did 
not report any. 
 
132 
 
The meta-analysis was performed for the nine studies with data in both groups (Gao 2009; Guo 
2010; Han 2002; Hong 2005; Huang 2010; Peng 2004; Shen 2004; Wang 2000a; Zhou 2001b) 
using the ITT method. The post hoc subgroup analysis showed that CHM groups had less minor 
adverse events than WM groups (RR 0.20; 95% CI 0.08 to 0.49); however, there was no 
significant difference in major adverse events between two groups (RR 0.31; 95% CI 0.05 to 
1.92) (Figure 38). 
 
Figure 38. Adverse events with post hoc analysis for CHM versus WM 
 
Common adverse events in control groups were lassitude, somnolence (sleepiness), dry mouth 
and dry nose. Three cases in Gao 2009 study experienced lassitude and somnolence which 
related to the use of Loratadine tablet. The Guo 2010 trial reported nine adverse events in 
control group including five cases with somnolence, one with headache, two with dry mouth 
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and one with nausea. The Huang 2010 study found seven cases including four with dry mouth, 
somnolence and lassitude, two with headache and dizziness, and one gastrointestinal 
discomfort. No additional treatment was provided to these adverse events. Three cases (one 
case with somnolence and two cases with dry mouth and dry nose) were reported in the Shen 
2004 study. The Zhou 2001b trial found 31 cases with dry nose and 11 patients having high 
blood pressure with an increase of heartbeat and blood pressure. The Huang 2008a study 
observed rare adverse events in treatment group and some somnolence, lassitude and dry mouth 
in control group. However, no detailed data were provided. The Wu 2009 trial reported pain in 
nasal cavity; however, no detailed information was given.  
 
Four trials reported adverse events in both groups (Han 2002; Peng 2004; Wang 2000a; Bao 
2013). Han 2002 study observed one with stomach ache in treatment group and one with 
diarrhoea in control group. The Peng 2004 trial reported two patients in treatment group had 
dry mouth and dry nose (one case with blood in nasal discharge). Eight patients in control group 
experienced adverse events including five with lassitude and somnolence, two with nausea and 
vomiting, and one with mild skin itchiness. The Wang 2000a study found one adverse event 
(pain in nose) in treatment group whilst three (distending headache) in control group. No 
additional treatment was provided in these trials. Bao 2013 reported dry mouth, somnolence, 
and heart palpitation in both groups; however, no detailed data was provided. The rest of of the 
four trials reported no adverse events were associated with the therapeutic course. 
 
In the three-arm studies (Zhang 1996, Chen 2004 and Xie 2009), both Zhang 1996 and Xie 
2009 did not report any adverse event in their evaluation, only Chen 2004 cited no side effects 
were observed during the therapeutic course. 
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5.4.3. CHM plus co-intervention versus placebo plus same co-intervention 
Only one study (Xue 2003b) employed the use of acupuncture as co-intervention to two groups. 
 
i. Improvement of symptoms 
Severity of nasal symptoms was assessed by patients and specialist for the treatment of SAR in 
this study. In terms of severity of nasal symptom, the data demonstrated CHM combined with 
acupuncture had no significant difference over placebo and acupuncture when assessed by both 
patient (MD 0.08; 95% CI -0.42 to 0.58) and specialist (MD 0.12; 95% CI -0.39 to 0.62) at the 
end of the treatment period. Similarly for non-nasal symptoms when assessed by patients (MD 
-0.08; 95% CI -0.58 to 0.42) and specialist (MD 0.02; 95% CI -0.49 to 0.52) alike, CHM did 
not exert additional effects in comparison to placebo when it is employed with acupuncture as 
co-intervention. 
  
ii. Quality of life 
With co-intervention (acupuncture), Xue 2003b did not find any significant difference in RQLQ 
Section One or Section Two scores between two groups (Section One: MD 0.15; 95% CI -0.36 
to 0.65; Section Two: MD -0.35; 95% CI: -0.85 to 0.15).  
 
iii. Medication consumption 
The data from the Xue 2003b study reported that it did not observe any significant difference 
in relief medication scores in both groups during the treatment period. No detailed data were 
provided. 
 
iv. Total serum IgE level 
No IgE level was measured in this study. 
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v. Adverse events 
The Xue 2003b study reported that three patients from the treatment and control group 
experienced mild gastrointestinal discomfort (bloating, indigestion and stomach ache) and 
bruising from acupuncture. No additional management was required for these minor adverse 
events. 
 
5.4.4. CHM plus co-intervention versus same co-intervention only 
A total of 17 trials were evaluated for the effects of CHM with co-intervention versus the same 
co-intervention only (Cao 2014b; Chen 2011; Li 2008; Li 2012b; Li 2012c; Lin 2013; Liu 
2004b; Lu 1998; Lu 2003; Lu 2009; Shi 2012; Shi 2014; Tang 2008; Wu 2012a; Xiao 2015; 
Zhao 2012; Zhou 2005). Xiao 2015 conducted a four-arm trial of which two of the comparisons, 
CHM with WM (oral and external) versus same WM only; CHM with acupuncture and WM 
(oral and external) versus same acupuncture and WM only. The rest studies compared CHM 
plus Western medicine with the same Western medicine only.  
 
Another three included studies (Chen 2004; Xie 2009; Zhang 1996) are three-arm trials. One 
of their comparisons, that is, CHM plus immunotherapy compared with same immunotherapy 
alone in Zhang 1996, CHM plus radiofrequency versus same radiofrequency alone in Chen 
2004 and Xie 2009, were also included in this category.  
 
In terms of the co-interventions, seven studies used both oral and external applications of WM 
in the control group (Li 2008; Li 2012b; Li 2012c; Lin 2013; Lu 2003; Lu 1998; Shi 2012). 
When used externally in the nasal cavity, one study compared Chinese herbal drops plus surgery 
with same surgery alone (Liu 2004b).  
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i. Improvement of symptoms 
Global symptom improvement for immediate follow-up was assessed in nine trials namely, Cao 
2014b; Chen 2011; Chen 2014; Li 2008; Li 2012c; Liu 2004b; Shi 2014; Tang 2008 and Zhao 
2012. Meta-analysis demonstrated CHM plus co-intervention displayed a favourable tendency 
with a significant difference over the same co-intervention only (RR 1.26, 95% CI 1.05 to 1.51). 
However, substantial heterogeneity existed (I2 = 82%) (Figure 39). 
 
 
Figure 39. Global symptom improvement (immediate follow-up) for CHM plus co-intervention versus same co-
intervention only 
 
Four trials (Li 2012b; Lin 2013; Wu 2012a; Xie 2009) assessed global symptom improvement 
over a short-term period. Significant effects of CHM with co-intervention over same co-
intervention when used alone were strongly featured (RR 1.27; 95% CI 1.15 to 1.39). No 
heterogeneity was depicted in the meta-analysis (I2 = 0%) (Figure 40). 
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Figure 40. Global symptom improvement (short-term follow-up) for CHM plus co-intervention versus same co-
intervention only 
 
A six-month follow-up period was undertaken to evaluate the effects in two clinical trials (Shi 
2012; Xiao 2015). Xiao 2015 conducted a four-arm trial, of which two of the arms were 
applicable in two subgroups namely, CHM with WM oral and external versus same WM (oral 
and external only); CHM with acupuncture and WM oral versus same acupuncture and oral 
WM only. Both clinical trials demonstrated no significant difference over WM oral and 
combined acupuncture treatment as well as comparison with same WM oral and external at (RR 
1.13; 95% CI 0.96 to 1.35) and (RR 1.08; 95% CI 0.97 to 1.22), respectively. Overall, meta-
analysis demonstrated that CHM was superior when combined with WM for global symptom 
improvement in the intermediate period (RR 1.08; 95% CI 1.02 to 1.14). No heterogeneity for 
the pooled data was shown (I2 = 0%) (Figure 41). 
 
 
Figure 41. Global symptom improvement (intermediate follow-up) for CHM plus co-intervention versus same 
co-intervention only 
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Four studies assessed their patients for long-term follow-up of one year (Chen 2004; Lu 2003; 
Zhang 1996; Zhou 2005). Overall data showed CHM exerted significant difference over WM 
in the long-term period following treatment (RR 1.30; 95% CI 1.19 to 1.42) with heterogeneity 
at 0% (Figure 42). 
 
 
Figure 42. Global symptom improvement (long-term follow-up) for CHM plus co-intervention versus same co-
intervention only 
 
Owing to the differences in the co-interventions used in the 17 trials plus three comparisons 
from multi-arm trials, post hoc subgroup analyses were carried out. Seven subgroups were used 
to differentiate the use of different co-interventions combined with CHM, including Subgroup 
1: CHM oral with WM oral versus same WM oral only (Cao 2014b; Chen 2011; Shi 2014; Tang 
2008; Xiao 2015; Wu 2012a; Zhao 2012; Zhou 2005); Subgroup 2: CHM oral with WM (oral 
and external) versus same WM (Li 2008; Li 2012b; Li 2012c; Lu 1998; Shi 2012); Subgroup 
3: CHM  external plus surgery versus same surgery only (Liu 2004b); Subgroup 4: CHM oral 
with WM external versus WM oral and WM external only (Lu 2003); Subgroup 5: CHM oral 
combined radiofrequency versus same radiofrequency only (Chen 2004; Xie 2009); Subgroup 
6: CHM combined with acupuncture and WM oral vs same acupuncture and WM oral (Xiao 
2015); and Subgroup 7: CHM external with immunotherapy versus same immunotherapy only 
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(Zhang 1996). Among them, Xiao 2015 was assigned in subgroup 1 and 6 as it was a four-arm 
trial involving two relevant comparisons. 
 
Among the different subgroups for immediate review after treatment, subgroup 2 (RR 1.22; 
95% CI 1.06 to 1.40) (Figure 43, 4.5.2) and subgroup 3 (RR 1.42; 95% CI 1.06 to 1.91) (Figure 
43, 4.5.3) featured CHM with WM co-intervention were more effective in improving global 
symptom right after AR treatment. Pooled data of the different subgroups demonstrated CHM 
with combined other therapies were superior to same therapies when used on its own (RR 1.32; 
95% CI 1.06 to 1.64). However, substantial heterogeneity is embedded in the trials (I2 = 84%) 
(Figure 43). 
 
 
Figure 43. Global symptom improvement (immediate follow-up) post hoc subgroup analysis for CHM plus co-
intervention versus same co-intervention only 
 
Positive results are depicted for short-term outcome in global symptom improvement for CHM. 
Subgroups 1, 2 and 5 indicated CHM combined with WM were more effective in improving 
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overall symptoms than WM in this segment of post hoc analysis (RR 1.27; 95% CI 1.16 to 1.40) 
(Figure 44, 4.6.1 to 4.6.3). No heterogeneity was detected (I2 = 0%) (Figure 44). 
 
Figure 44. Global symptom improvement (short-term follow-up) post hoc subgroup analysis for CHM plus co-
intervention versus same co-intervention only 
 
When assessed over intermediate period up to six months; CHM coupled with WM also exerted 
significant effects when compared to WM only. Meta-analysis of these subgroups showed 
CHM combined group was more effective in global symptom scores at the end of the 
intermediate period (RR 1.08; 95% CI 1.02 to 1.14) with a low heterogeneity (I2 = 0%). (Figure 
45). 
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Figure 45. Global symptom improvement (intermediate follow-up) post hoc subgroup analysis for CHM plus co-
intervention versus same co-intervention only 
 
When assessed over long-term, global symptom improvement was highly positive with CHM 
combined group over different Western medicine co-interventions used alone (RR 1.23; 95% 
CI 1.15 to 1.32) (I2 = 0%). No significant difference was detected for either CHM plus WM 
oral and external) versus same WM alone (RR 1.43; 95% CI 0.99 to 2.06) or CHM combined 
with radiofrequency versus radiofrequency only (RR 1.19; 95% CI 0.97 to 1.45) (Figure 46).  
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Figure 46. Global symptom improvement (long-term follow-up) post hoc subgroup analysis for CHM plus co-
intervention versus same co-intervention only 
 
Subgroup analysis was conducted for non-classified AR and PAR trials with and without 
syndrome differentiation. Two non-classified AR studies (Li 2012c; Zhou 2005) involving 
syndrome differentiation demonstrated significant difference existed when CHM plus co-
intervention was compared to same co-intervention only (RR 1.21; 95% CI 1.13 to 1.30). 
Similarly, combined therapy in the trials without syndrome differentiation provided benefits to 
AR sufferers than same other therapy alone (RR 1.27; 95% CI 1.13 to 1.43). The heterogeneity 
for with and without syndrome differentiation AR subgroups was I2 = 0% and I2 = 63%, 
respectively (Figure 47). 
 
Out of 17 studies, eight were involved in PAR clinical trials. Among the eight trials, only two 
trials employed the use of syndrome differentiation in CM to treat the patient in the trials (Li 
2008; Tang 2008) while six PAR studies did not employ the use of syndrome differentiation 
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(Chen 2004; Lin 2013; Shi 2012; Shi 2014; Xie 2009; Zhang 1996). Both PAR trials with and 
without syndrome differentiation demonstrated positive outcomes in CHM combined group for 
improving global symptom, (RR 1.26; 95% CI 1.02 to 1.56) and (RR 1.27; 95% CI 1.09 to 
1.49); respectively. Meta-analysis of the studies in the PAR and AR subgroup showed CHM 
were highly effective in improving AR global symptom as an adjunct therapy (RR 1.24; 95% 
CI 1.09 to 1.49). However, substantial heterogeneity is reflected in the pooled data (I2 = 56%) 
(Figure 47). 
 
 
Figure 47. Global symptom improvement for PAR and non-classified AR subgroup analysis for CHM plus co-
intervention versus same co-intervention only 
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Only one study Chen 2014 evaluated the changes of symptom score in immediate follow-up in 
the AR associated four-symptom category. Pooled data of immediate follow-up treatment 
showed that Cetirizine alone could reduce more symptom scores compared to combined group: 
changes in nasal congestion (MD -2.10; 95% CI -2.55 to -1.65), sneeze (MD -2.80; 95% CI -
3.31 to -2.29), itchy nose (MD -2.03; 95% CI -2.48 to -1.59) and runny nose score (MD -2.52; 
-3.01 to -2.04). 
 
Two studies were evaluated global symptom score for immediate follow up after treatment 
(Chen 2014; Shi 2014). CHM with WM co-intervention exerted more effects than WM co-
intervention (SMD -1.39; 95% CI -1.93 to -0.85). However, substantial heterogeneity was 
observed (I2 = 64%) (Figure 48). 
 
 
Figure 48. Global symptom score (immediate follow-up) for CHM plus co-intervention versus same co-
intervention 
 
The global symptom score over short-term follow-up for Lu 1998 demonstrated CHM 
combined group had significant difference over WM co-intervention alone (MD -8.50; 95% CI 
-9.72 to -7.27). 
 
Another study (Lu 1998) also evaluated the outcome on the changes of scores but during short 
term follow-up. WM could reduce more scores for nasal congestion score (MD -4.36; 95% CI 
-5.07 to -3.65), sneeze (MD -8.01; 95% CI -9.17 to -6.84) and runny nose (MD -5.29; 95% CI 
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-6.11 to -4.46) than the CHM combined group. There was no significant difference for turbinate 
hypertrophy between the two groups (MD 0.00; 95% CI -0.38 to 0.38).  
 
ii. Quality of Life 
None of the included studies in this category assessed the quality of life after treatment. 
 
iii. Medication consumption 
No assessment was performed on the use of rescue medication in all 17 trials. 
 
iv. Total serum IgE level  
Only one study (Zhang 1996) compared CHM plus dust mite immunotherapy with same 
immunotherapy only and reported serum IgE level (Zhang 1996). Zhang 1996 tested the total 
serum IgE level for the CHM group right after two-month treatment but examined it for the 
control group at four months since the beginning of the immunotherapy. Thus, their results were 
not comparable.  
 
v. Adverse events 
Out of the 17 trials plus three comparisons from another three multi-arm trials, Lu 1998 reported 
four subjects suffered from stomach upset but did not mention whether they were in CHM 
combined with WM group or WM control group; one study (Shi 2014) reported no adverse 
effects were observed during the trials.  The remaining 15 studies (Cao 2014b; Chen 2011; Li 
2008; Li 2012b; Li2012c; Lin 2013; Liu 2004b; Lu 2003; Lu 2009; Shi 2012; Tang 2008; Wu 
2012a; Xiao 2015; Zhao 2012; Zhou 2005) did not report any information related to adverse 
effects in their studies.  
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For those comparisons from the three multi-arm RCTs, the adverse events were not reported 
specifically for each arm. Therefore, the relevant information was reported under “v. Adverse 
events” of 5.4.2 CHM versus Western medicine.  
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5.5. Principal herbs used in RCTs  
The total number of CHMs used in the RCTs treatment group was 552. All the trials used herbal 
formulations with the exception of three studies which employed the use of single herb to 
evaluate the effects on AR (Jung 2011; Matkovic 2010; Wu 2009). The rest of 59 included 
studies applied 59 different Chinese medicinal formulae. Six studies (Liang 2011b; Cao 2014b; 
Li 2012c; Li 2012b; Huang 2010; Ye 2015) used two formulae; while Lu 2009 employed three 
formulae for three different syndromes. Table 16 summarises the formulae names and the 
number of herbs in the 62 included studies. 
 
Table 16. List of formulae and total number of herbs used in the included RCTS 
No. Study I.D. Number of herbs Formulae 
1. Baba 1995 8 Tsumura Sho-seiryu-to granule 
2. Bao 2013 8 Xiaoqinglong tang ampule 
3. Cao 2007 3 Cang'erzi granule 
4. Cao 2014b 8 Chuanxinlian tablets and Yupingfengsan granule 
5. Chen 2012 8 Xingbiwenningjiaoji 
6. Chen 2004 13 Yupingfeng decoction 
7. Chen 2014 3 Yupingfengsan granule 
8. Chen 2011 9 Yupingfengsan powder 
9. Gao 2009 3 Modified Lingguizhugan decoction 
10. Guo 2010 8 Qufengzhiyang liquid 
11. Han 2002 10 Bushenwenfei capsule 
12 Hong 2005 9 Fufangbiyan decoction 
13. Hu 2002 11 Biminne capsule 
14. Huang 2008a 10 Bimin nasal drops 
15. Huang 2006b 7 Wenfeizhiliu pills 
16. Huang 2010 4 Jieminqufeng erhao granule/Jieminqufeng yihao granule 
17. Jiang 1997 8 Yufeng jianbi decoction 
18. Jin 2010 12 Kemin decoction 
19. Jung 2011 1 Fermented red ginseng capsule 
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No. Study I.D. Number of herbs Formulae 
20. Lenon 2012 8 RCM-102 
21. Li 2012b 11 Cang’erzi san with Yupingfengsan 
22. Li 2012c 35 
Qufengtongqiao Tang modified/ Bufeiqixuxing 
modified/Wenbupishen Huoxuetongqiao modified 
23. Li 2008 10 Xiaoqinglongtang & Yupingfengsan powder 
24. Liang 2011 14 Jiawei Buzhongyiqitang 
25. Lin 2013 7 Yupingfengsan extract 
26. Liu 2004b 8 CHM formula to nourish Yin & calm Liver 
27. Liu 2001 5 Dibiling nasal drops 
28. Lu 2011 8 CHM formula 
29. Lu 2003 10 Bimin formula 
30. Lu 2009 9 Modified Guizhi  decoction 
31. Lu 1998 9 
Modified Wenfeishiliu/Buzhongyiqi decoction/Jingui 
Shenqi decoction 
32 Luo 2013 12 Qingretongqiao san 
33. Matkovic 2010 1 Astragali extract 
34. Peng 2001 12 Biminling decoction 
35. Peng 2004 7 Shetizhiqiu  granule 
36. Qin 2006 13 Biyan granule 
37. Qiu 2012 12 Xiaoqinglongtang Jiawei 
38. Shen 2004 4 Yupingfengsan droppil 
39. Shi 2014 8 Xiangju capsule 
40. Shi 2012 5 Tongjiaobiyan Jiaonang 
41. Sun 2014a 9 Xiaofeng granule 
42. Tang 2008 6 Sijunzitang 
43. Wang 2000a 6 Tuimin nasal drops 
44. Wu 2012a 1 Flos Magnoliae volatile nano-liposome nasal drops 
45. Wu 2009 10 Xin Qin Keli 
46. Xiao 2015 11 Yupingfengsan decoction 
47. Xie 2009 5 Chinese herbal granule 
48. Xin 2005 14 Qi-boosting CHM 
49. Xue 2003a 18 CHM extract capsule 
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No. Study I.D. Number of herbs Formulae 
50. Xue 2003b 18 CHM extract capsule 
51. Yan 2011 11 Modified Yupingfengsan 
52. Yang 2004 9 Xinqin capsule 
53. Ye 2015 13 Guizhitang Jia Huangmafuzixixin tang 
54. Zhang 1996 7 Tongqiaobiyan granule 
55. Zhang 2007b 6 Biyan granule 
56. Zhao 2012 6 Xingbiningjiaoji 
57. Zhao 2009 9 Jianbi mix 
58. Zheng 2007 6 Shi-Bi-Lin extract capsule 
59. Zhong 2013 9 Xinzhi nasal drops 
60. Zhou 2001b 16 CHM formula 
61. Zhou 2005 6 Tuomintongqiao capsule 
62. Zou 2012 5 Qufengtongqiaotang 
 
 
The top ten most frequently used Chinese herbs in the RCTs were Huang Qi (Astragali Radix) 
(in 41 studies), Fang Feng (Saposhnikoviae Radix) (in 39 studies), Xin Yi (Magnoliae Flos) (in 
31 studies), Bai Zhu (Atractylodis Macrocephalae Rhizoma) (in 31 studies), Cang Er Zi 
(Xanthii Fructus) (in 27 studies), Gan Cao (Glycyrrhizae et Rhizoma) (in 26 studies), Bai Zhi 
(Angelicae Dahuricae Radix) (in 26 studies), Xi Xin (Asari Radix et Rhizoma) (in 24 studies), 
Dang Shen (Codonopsis Radix) (in 17 studies), Wu Wei Zi (Schisandrae Chinensis Fructus) 
(in 13 studies) (Figure 49).  
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Figure 49. Top 10 herbs used in RCTs in the systematic review 
 
5.6. Discussion 
The current review identified 62 included studies for CHMs compared with placebo or Western 
medicine, with or without co-interventions. An overview of the clinical effects of CHM in the 
management of AR is outlined in Table 17. 
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Table 17. Summary of clinical effects of CHM in the management of AR  
 
Comparisons 
No. of RCTs 
Global symptom 
improvement 
(No. of RCTs) 
Quality 
of life 
Rescue 
medication 
use 
IgE 
Adverse 
events 
CHM vs Placebo 7 
+ 
(n=1) 
- 
+ 
(n=4) 
N/A 
mild 
(n=7) 
CHM vs 
Western 
medicine 
37 
+ 
immediate (n=15) 
short-term (n=14) 
intermediate (n=4) 
N/A N/A - 
mild 
(n=20) 
CHM  + co-
intervention vs 
Placebo + co-
intervention 
1 N/A - N/A N/A 
mild 
(n=1) 
CHM + co-
intervention vs 
same co-
intervention only 
17 
Plus one 
comparison of 
Chen 2004, 
Xie 2009, 
Zhang 1996 
and Xiao 2015  
+ 
immediate (n=9) 
short-term (n=4) 
intermediate (n=3) 
long-term (n=4) 
N/A N/A - 
mild 
(n=2) 
Notes: N/A: data not available; - : no significant difference between two groups; +:  favours CHM intervention. 
 
CHM for the management of AR was evaluated on five domains in the SR. In the category of 
CHM vs placebo, only Baba 1995 evaluated global symptom improvement based on the 
changes in the severity nasal symptom, Sho-seiryu-to was found to have significant difference 
when compared to placebo. Positive global symptom improvement was demonstrated in studies 
conducted across the immediate (n=15), short-term (n=14) and intermediate (n=4) follow-ups. 
CHM used in these trials indicated strong clinical effects over Western medicine. Positive 
outcomes for CHM were also featured strongly over Western medicine. The use of CHM in 
oral or external exhibited its clinical effects over WM oral and/or external except for controls 
such as radiofrequency and immunotherapy. In the category of the CHM plus co-intervention 
versus same co-intervention only, unequivocal clinical effects were demonstrated across all 
periods evaluated. When employed with or without syndrome differentiation for both PAR and 
non-classified, there was a clear indication of favour towards CHM experimental group. 
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Limited number of studies in the subgroup for combined therapy of radiofrequency for Chen 
2004 and subgroup CHM plus acupuncture and WM oral verus same acupuncture and WM oral 
rendered insiginificant outcomes. When CHM is combined with other therapies, CHM exerted 
strong and prolonged clinical effects over all durations for treatment as an adjunct therapy.   
 
For quality of life assessment, only six studies (Hu 2002; Jung 2011; Lenon 2012; Matkovic 
2010; Xue 2003a; Zhao 2009) in the category CHM versus placebo and one in CHM plus 
intervention versus placebo plus same co-intervention evaluated the participants after treatment. 
CHM was found to be comparable to placebo in Hu 2012, Jung 2011, Lenon 2012 and Matkovic 
2010. It was also discovered that CHM exerted positive impact on SAR in managing the 
emotional aspects of SAR which Xue 2003a assessed in section two of RQLQ. Only the Zhao 
2009 trial used SF-36 questionnaire 
 
Only four studies in the CHM versus placebo category and one trial in CHM plus intervention 
versus placebo plus same co-intervention only category evaluated the consumption of rescue 
medication. The pooled data indicated that rescue medication usage were not significant when 
CHM was compared to placebo groups, with or without co-intervention. None of the rest of the 
trials utilised rescue medication in their assessment. 
 
The assessment of the total IgE serum was conducted by five studies in CHM versus placebo 
category, four of the studies reported insignificant differences in the levels of IgE between the 
groups. Similarly, for CHM plus co-intervention versus same co-intervention category, data for 
control were not provided in Zhang 1996. Further meta-analysis could not be carried out owing 
to lack of information.  
 
Nearly half of the RCTs reported on adverse events, with 30 out of 62 reported information on 
adverse events in either the control and/or treatment or in both groups. In the CHM versus 
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placebo category,  trials reported adverse events; seven trials reported in the category of CHM 
versus placebo; 20 studies in CHM versus WM, one study in category of CHM versus co-
intervention versus placebo plus same co-intervention and 2 studies in the category CHM plus 
co-intervention versus same co-intervention only. In terms of adverse symptoms experienced 
by the participants, minor adverse events were observed in the CHM group were headache, 
stomach upset and oedema in treatment groups. However, in regards to the control groups, the 
use of WM appeared to exert stronger adverse effects on general unwellness ranging from 
fatigue, somnolence, and dry mouth syndrome to epistaxis. Systemic effects were observed 
with patients experiencing elevated blood pressure and palpitations with WM. CHM seemed 
safer as reflected in the meta-analyses; however, the lack of data in at least 50% of the studies 
may render an inaccurate analysis. Caution is required in the interpretation in this aspect. 
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Chapter 6  Results II – Review of experimental studies 
 
Based on the findings from SR, five herbs were selected from the top ten herbs most frequently 
used list from the investigation which include; Huang Qi (Astragali Radix), Fang Feng 
(Saposhnikoviae Radix), Xin Yi (Magnoliae Flos), Cang Er Zi (Xanthii Fructus), Xi Xin (Asari 
Radix et Rhizoma). The WHO has developed monographs of some selected medicinal plants; 
of which only two of the herbs Huang Qi and Xin Yi have been included in the WHO 
monographs. This chapter reports the review outcomes in the mechanisms of actions of herbs 
in recently published literature of experimental studies as well as WHO selected herbs. This 
chapter examines the immunopharmacological efficacies of five popular herbs used for 
treatment of AR in CM; exploring their phytochemical, pharmacological and pharmacokinetic 
effects and pathways that extend beyond nasal allergy. Toxicological evidence of herbs such as 
Cang Er Zi and Xi Xin is also reviewed.  
 
6.1. Mechanisms of actions of WHO-endorsed herbs  
The chemical compounds and the pharmacological actions of Huang Qi and Xin Yi provided 
in WHO monographs are summarised in the table below (Table 18). 
 
Table 18. Mechanisms of actions of WHO selected herbs 
Herbs Chemical Compounds Pharmacological actions References 
Huang Qi 
(Astragali 
Radix) 
Triterpene saponins  
(Astragalosides I-X and  
isoastragalosides I-IV) 
Polysaccharides 
 Immunopotentiating effects 
 Immunostimulant activities 
 Cardiovascular effects 
 Anti-viral effects 
WHO (1999) 
Xin Yi 
(Magnoliae 
Flos) 
Magnolol 
Honokiol 
Isoquinoline 
Alkaloid 
Magnocrarine 
Cadinol 
1,4-cineole 
p-cymene 
β-eudesmol 
Geraniol 
 Anti-allergic effects 
 Anti-asthmatic effects 
 Anti-bacterial effects 
 Anti-gastric effects 
 Anti-inflammatory effects 
 Anti-vascular effects 
 Anti-oxidative effects 
 Anxiolytic effects 
 Cardiovascular effects 
 Muscle relaxant effects 
(WHO, 2009) 
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The compound of Xin Yi, magnolol was discovered multiple effects: anti-vascular resistant, 
anti-asthmatic, anti-bacterial, anti-gastric, anti-inflammatory antioxidative, anxiolytic and a 
muscle relaxant (WHO, 2009). Huang Qi manifested cardiovascular effects, 
immunopotentiating, immunostimulatory and antiviral activities (WHO, 1999). In terms of 
cardiovascular protection, magnolol appears to have an impact on coronary circulation and 
vascular resistance. Although no change to the blood pressure and coronary flow velocity was 
detected, but decreased blood pressure vascular resistance was significant with 10-4 g/kg (WHO, 
2009). Magnolol also could inhibit norepinephrine-induced phasic and tonic contractions in rat 
thoracic aorta in vitro. Huang Qi also exhibited cardiovascular activity. Enhanced contractility 
and contraction amplification of models’ hearts were detected. Latent inverted and biphasic T 
waves and prolonged S-T intervals response after intraperitoneal injection of Huang Qi were 
observed three to four hours in dogs (WHO, 1999). Saponins in Huang Qi exerted inotropic 
effects on cultured murine myocardial cells, suggesting a modulation of sodium and potassium 
ATPase exchange uptake (WHO, 1999).  
 
The combined compounds, honokiol and magnolol extracted from the bark of Xin Yi, both 
inhibited the growth of Actinomyces visccosus ATCC 19246, Streptococcus mutans Ingbritt and 
Streptoccoccus sobrinus 6715 with a low dose of bacterium concentration. The extract of the 
bark Xin Yi and magnolol were also able to inhibit the growth of Helicobacter Pylori. Anti-
microbial activities of both compounds have marked effects (MIC, 25.0 μg/ml) against 
Actinobacillus, Actinomycetemcomitans, Porphyromonas gingivalis, Prevotella intermedia, 
Micrococcus luteus and Bacillius subtilis but not against Shigella flexineii, Staphylococcus 
epidermidis, Eneterobacter aerogenes, Proteus vulgaris, Escherichia coli and Pseudomonas 
aeruginosa (WHO, 2009).  
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Anxiolytic activity and muscle relaxant were also produced with honokiol and magnolol. 
Honokiol was discovered to possess 2.5 to 5.2 times more potency in anxiolytic effects than 
magnolol although both compounds could enhance the potentiating effect of γ-aminobutyric 
acid on [3H]flunitrazepam binding with EC50 value of 0.61 μM and 1.6 μM (WHO, 2009). 
Honokiol was the main chemical compound to contribute to the anxiolytic effect. Sedation, 
ataxia, muscle relaxation and a loss of righting reflex were also associated with magnolol in 
vitro with intraperitoneal administration (0.0-500 mg/k bw) (WHO, 2009). Other effects 
highlighted in the WHO monographs were discussed within the subpoints. 
 
6.2. Anti-inflammatory and anti-allergic effects 
Not all the herbs were screened for its chemical phenotypes on immunomodulatory effects. This 
was due to the limited studies that had undertaken analysis on the chemical structure of herbs. 
However, many studies have studied the chemical phenotypes and its contribution to the 
biological systems of diseases. Three herbs namely; Xi Xin, Xin Yi and Fang Feng were found 
to suppress cytokines-mediated inflammatory cascades. Inflammation is a common 
denominator in many chronic diseases and allergic diseases alike. 
  
Fang Feng contains naturally-occurring chromones namely; prim-O-glucosylcimifugin (GC), 
4Ꞌ-O-β-D-glucosyl-5-O-methylvisamminol (GV), cimifugin (C), sec-O-glucosylhamaudol 
(GH), and 5-O-methylvisamminol (MV) (Chin, Jung, Chae, Yoon, & Kim, 2011; Dai et al., 
2008; Okuyama et al., 2001). Coumarins, especially both furanocoumarins and 
pyranocoumarins were also available in the roots of this plant. GC, C, MV and coumarin 
anomalin, appeared to exert considerable inhibition in major inflammatory pathways such as 
NF-κB, mitogen activated protein kinases (MAPKs), CREB and NO production. Anti-
inflammatory effects of Fang Feng in arthritic rats revealed significant decline in the arthritis 
score for pain and swelling with a reduction of the inflammatory cytokines levels, although 
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suppression of the TNF-α and IL-1β was only observable on rats with a higher dose of Fang 
Feng (Kong et al., 2013). PGE2, a by-product of the cyclooxygenase (COX) pathway, was also 
decreased in both sera and joints. Evidence suggested Fang Feng deactivated NF-κB binding, 
facilitated by the suppressions of signal-transduction inflammation and induced by TNFα-
mediated phosphorylation of ERK, JNK and p38 which were amplified (3.2, 2.8 and 2.6 fold, 
respectively) in both collagen-induced arthritic rats and human fibroblast-like synoviocytes 
(Kong et al., 2013). The inhibition of phosphorylated MAPKs phosphorylation-extracellular 
signal-regulated kinases (- ERKs), c-Jun NH (2) terminal kinase (JNK), and p38 was due to the 
action of GC. Among all the MAPK subtypes, p-JNK, was discovered most effectively 
suppressed.   
 
Interestingly, although the chromone GC in Fang Feng was an effective inhibitor of NO and 
iNOS production, however when compared to C and MV, both the former and latter were by 
far stronger than GC in exerting anti-inflammatory effects (B. Zhao, Yang, Yang, & Liu, 2012). 
Fang Feng chromones and anomalin (a pyranocoumarin), were highly effective against acute 
and chronic inflammation. GC, in particular, counteracted the lipopolysaccharides (LPS)-
induced inflammation in severe pulmonary inflammatory disorder manifested in acute 
respiratory distress syndrome (N. Chen, 2013). In vivo and in vitro results demonstrated GC 
attenuated LPS-induced cytokine levels; TNF-α, IL1β and IL6 were far lower in the GC group 
as compared to the control group (B. Zhao et al., 2012). Aside from Fang Feng anomalin-
mediated inhibitions on inducible nitric oxide synthase (iNOS), COX-2, TNF-α and IL6, 
anomalin was also responsible for the deactivation of the transcriptional onset of NF-κB 9 in 
LPS-induced RAW 265.7 cells (S. Khan et al., 2011). Cytoplasmic expressions of IκBα were 
drastically reduced, along with subunits of NF-κB, p50, p65 and c-rel being translocated, 
indicative of anomalin obliterating NF-κB-DNA binding activities. Although anomalin was 
able to interrupt protein synthesis of IκBα phosphorylation, there was no inhibitory effect on 
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the protein-initiating factor, eIG2α phosphorylation. Notably, anomalin was also effective 
against acute and chronic inflammation associated with hyperalgesia and allodynia. It is 
common in allodynia, elevated expressions of MARK-ERK and p38 signalling and nuclei 
translocation correspond to activation of the CREB pathway (Crown et al., 2006). The release 
of these pro-inflammatories cytokines and pro-nociceptive mediators induced prolong pain in 
chronic inflammation. Anomalin interference in the cell-signal transduction particularly NF-
κβ, MARK-ERK and p-38 expressions was exponentially reduced, in effect abolishing the 
CREB-DNA phosphorylation activity (S. Khan, Shehzad, Chun, & Kim, 2013). 
 
Similarly, GV, GC, C and GH also exhibited evidence of being matrix metalloproteases (MMP) 
inhibitors (L. Li et al., 2015). Both matrixins such as MMP-2 and MMP-9 are responsible for 
clearing collagens fragments generated by collagenases in tissues repair and remodelling. 
Enhancement of both MMP-2 and MMP-9 activities induced by the IL8 secretion were inherent 
biomarkers of cancers (Riveiro et al., 2010). GV, GC, C and GH indicated a clear dose 
dependent inhibition in in vitro MMP-assay, IC50 at 15.6, 108.87, 313.25 and 344.4 μM, 
respectively (L. Li et al., 2015). GV was the strongest inhibitor of MMP-2. Yet in another study 
reported amongst the 11 herbs tested, Fang Feng was obvious in suppressing MMP-9 (M. H. 
Lee et al., 2008).  
 
Both Xi Xin and Xin Yi are famed for its effectiveness in treating nasal allergy in CM. 
Methyleugenol (MEG), a genotoxic and cytotoxic compound in Xi Xin, manifested early phase 
anti-allergic effects by targeting signalling domains in mast cell activation. MEG effectively 
suppressed IL4, a cytokine driver for Th2 differentiation, influencing its effect on mucus 
secretion, IgE production and curtailing TNF-α expression of endothelial molecules adhesion 
and granulocyte migration in late phase inflammation of AR (Tang et al., 2015). Traditional 
theory of IgE receptor signalling established that antigen binding of FϲεRI β and γ chains at the 
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onset acute inflammation was initialised by a Scr tyrosine kinase Lyn phosphorylation at 
immune-receptor tyrosine-based activation motifs (ITAMs) and resulted in the recruitment of 
spleen tyrosine kinase (Syk), in effect, triggering the enzymatic phosphorylation of Scr kinases 
and transmembrane adaptor linker for activation of T cells via ERK complexes. Recently, other 
Src-family kinases, Hck and Fyn were discovered to be also involved in the signalling cascade 
other than Syk and Lyn (MacGlashan Jr, 2008). MEG inhibitory effect on Syk incapacitated 
the paired-phosphorylation of Lyn and Syk in the IgE downstream cascade, however Lyn was 
not inhibited (Tang et al., 2015). This correlates with findings that Lyn kinase which in fact, 
was not abundantly available to FсεRI and was considered a rate-limiting molecular species, 
whereas Syk was a highly expressed signalling element, varied with levels associated with IgE-
mediated histamine release (MacGlashan Jr, 2008). Moreover, primary signalling domain for 
IgE receptor signalling rested in Syk, not Lyn, with the latter positive signalling via FсεRI 
ITAMs and Syk depended on much its availability to receptors, responsiveness to IL3 and Fyn 
catalytic activity (Bruhns, Frémont, & Daëron, 2005). In addition, MEG also diminished the 
rate limiting step of arachidonate cascade in leukotriene biosynthesis as well as supressing 
COX-2 expression and 5-lipoxygenase (LOX) phosphorylation, which in the process halted 
prostaglandin and leukotriene activities (Tang et al., 2015). This anti-allergic action of MEG 
imparted a vasodilator effect in AR and allergic asthma and could potentially block the 
anaphylactic effects of prolonged bronchoconstriction. In essence, MEG impeded Syk 
molecular signalling and disrupted the Lyn/Sky phosphorylation pathway, this molecular 
inhibitory mechanism on Syk could serve as a “switch” to turn off acute onset of AR and allergic 
diseases. 
 
The volatile oils of Xin Yi in particular, VOMbp also possessed an immunological-regulatory 
effect on mast-cell histamine release (Kuan, 2011; T. Q. Xiong, Qin, & Shen, 2006). Oral 
administration of 0.01-1.0 g/kg body weight of aqueous extract of Xin Yi derived from both the 
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flowers and the bark significantly inhibited IgE-passive cutaneous anaphylactic reaction 
(WHO, 2009). Levels of plasma histamine in vitro inhibited the release from rat peritoneal mast 
cells and prevented systemic anaphylaxis in rats. Arthus reaction associated with types III 
hypersensitivity was also reversed due to the presence of magnolol in Xin Yi (WHO, 2009). 
This anti-inflammatory action could be used to treat depositions of antigen-antibody 
complexes.   
 
The process of mast-cell histamine release, cytokines-mediated isotype class switching to IgE 
inducted by IL4 and IL13 and IL5-induced eosinophilic infiltration are all pathological 
processes of AR, asthma as well as in other allergic diseases. Although both IL4 and IL13 are 
implicated in IgE production, IL13 is not specifically involved in Th2 differentiation. IL13 
essentially functions with IL4 to induce alternative macrophage activation, repair epithelial 
tissue, fibrosis and produce mucous production. In essence, IL4 acts as Th2 differentiation 
agent, whereas IL13 drives downstream effector responses (Kasaian et al., 2013). VOMbp 
apparently could induce inverse biomarkers IL4 in both early and late inflammatory phases. 
Early phase response to VOMbp upregulated IL4 with a reduction of IL13 in the peripheral 
blood, conversely, a reverse phenomenon was observed in the late phase reaction with 
decreased IL4 and elevated IL13, both attenuated IgE and impeded histamine release (Kuan, 
2011). The anti-inflammatory effects of VOMbp seems to reinforce the biologic characteristics 
of IL4 and IL13 inhibiting the allergic cascade, although the VOMbp molecular kinetics is not 
understood in this aspect.  In addition, oral administration of 0.01-1.0 g/kg body weight of 
aqueous extract of Xin Yi derived from both the flowers and the bark also significantly inhibited 
IgE-passive cutaneous anaphylactic reaction (WHO, 2009). The discovery of the inverse 
antagonist on IL13 and IL4 effect of VOMbp on mast cell-derived histamine levels in the 
peripheral blood, inhibition of anaphylaxis and the reversal of Arthus reaction could present a 
promising novel drug in inverse dual cytokine-antagonist in controlling IgE production and 
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anti-mast cell-histamine release in AR. The down-regulation of cytokine actions of Fang Feng, 
Xi Xin and Xin Yi could serve as a drug target intervention for acute and chronic 
inflammatories. 
 
6.3. Analgesic and antinociceptive effects 
The isolated structures of C, GH, GC and GV chromones of Fang Feng were responsible for 
the analgesic effects (Okuyama et al., 2001). Hamaudol with its algycone portion as well as 
ledebouriellol and divaricatol (both pyranochromones) also imparted an opioidergic effect by 
increasing pain threshold in vivo when administered with a high dose of GH (Chin et al., 2011). 
Evidence of prolonged pain threshold suggested the analgesic effects of Fang Feng 
corresponded to the anti-inflammatory effects. It was speculated that the opioidergic effect 
could be related to the mode of action on an opioid receptor in the central nervous system and 
its pathway, not on the peripheral nervous system pain-associated inflammation generally 
produced on the peripheral sensory nerve as naloxone counteraction of pain threshold in LPS-
induced pyrexia in vivo (Okuyama et al., 2001). Fang Feng effectively deferred at a later time. 
The antinociceptive effects for acute model persisted for six hours after two hours of treatment 
while for the chronic models, the effects lasted for five days.  
 
Pain signals stem primarily from voltage gated sodium (Na+) channel. Naν1.8 and Nav1.9, are 
expressed selectively in damage sensing peripheral neurons (Wood, Boorman, Okuse, & Baker, 
2004) while Nav1.7 is expressed in the dorsal root ganglia and sympathetic neurons (Black, 
Frézel, Dib-Hajj, & Waxman, 2012). Nav1.7, tetrodotoxin-sensitive (TTX-S), fast activating 
and fast-inactivating Na+ channel, is closely related to congenital insensitivity to pain owing to 
loss-of-function mutations in SCN9A (a Nav1.7 gene encoder) and is linked to pain in 
erythromelalgia as well as paroxysmal extreme pain disorder (Black et al., 2012). Pain is a 
comorbidity often associated with chronic inflammation. Analgesic evidence for Cang Er Zi 
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was notable in marked reduction of writhing and formalin-induced licking time in murine 
models at late phase response but not at the early phase. (Huang et al., 2011). The nociceptive 
effects could in part be due to decreased levels of iNOS and COX-2 expressions and the radical 
scavenging, reducing activity and liposome protection exerted by the phenolic compounds in 
Cang Er Zi, although the molecular mechanisms on pain channel are not understood. Similar 
analgesic effects were also present in Fang Feng, which was attributed to the chromones 
compounds in the roots of the herbs (Kreiner, Pang, Lenon, & Yang, 2016). In Xi Xin, MEG 
tonically inhibited Nav1.7 with resting state at a holding potential of -120mV and inactivated 
state at a holding potential of -60mV, in a concentration and voltage dependent manner.  
Peripheral nerve Nav1.7 was inhibited with an IC50 of 295 μmol/L at a -100mV holding 
potential. In order to gain the therapeutic effect of RA-MEG in emitting an average tonic 
inhibitory outcome, the receptivity of the receptor interaction to the concentrations of MEG 
was 1:1. Higher concentration of MEG evoked greater potency of inhibition at higher stimulus 
frequencies. Interestingly, Xi Xin exhibited the same effect as anticonvulsive drugs at 
interacting with Nav1.7 channel inactivation state in negative potentials and displayed double 
the depolarizations in concentration dependent manner and recovery from inactivation state in 
the Nav1.7 channel was also slower with higher concentration. These results suggested Xi Xin 
might effectively inhibit the sustained or transient high frequency bursts in peripheral nerve 
commonly associated with neuropathic pain (Z. J. Wang, Tabakoff, Levinson, & Heinbockel, 
2015).   
 
No clinical studies have directly evaluated Xin Yi and Huang Qi for any therapeutic effects for 
analgesia and antinociceptive conditions. 
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6.4. Anti-oxidative and anti-proliferative effects 
The modulatory effects of Astragaloside-IV (AS-IV) in Huang Qi, magnolol in Xin Yi and 
MEG in Xi Xin were able to confer both neuroprotective and anti-oxidative effect. Oxidative 
stress is a result of excessive production of ROS. ROS accumulation often causes oxygen and 
glucose deprivation in cortical neurons, hippocampus and/or cerebrum, triggering an 
inflammatory reaction commonly seen in cerebral ischemia, hypoxia and memory deficits 
associated with dementia (S. Y. Kim et al., 2015). The neuroprotective effects of AS-IV in 
Huang Qi improved spatial learning and memory deficits in rats with chronic cerebral 
hypoperfusion. 8-hydroxy-2’-deoxyguanosine expression, an oxidative DNA damage marker 
commonly associated with aging and dementia; astrocyte as well as activated microglia in 
hippocampus were reduced markedly in AS-IV treated rats (20 mg/kg dose) (S. Y. Kim et al., 
2015).  Further reduction of detectable loss of hippocampal neurons and the thickness of this 
region also offered a glimpse of the efficacy of AS-IV in diminished memory models. Notable 
levels of superoxide dismutase (SOD) indicated increased ROS activities and presence of 
elevated malondialdehyde (MDA) also presented lipid peroxidation, which could cause protein 
modification in the DNA strands. At a transcriptional level, AS-IV was able to regulate activity 
of nuclear factor erythroid 2 (Nrf2), a regulator of anti-oxidant genes which binds to anti-
oxidant response element (ARE), a promoter region of cytoprotective genes (Gu et al., 2015). 
Nrf2 is a master regulator of the cytoprotective genes responsible for exerting a dual effect. 
Activation of Nrf2 is mediated by the epidermal growth factor receptor (EGFR) signalling 
pathway, responsible for proliferation, growth and survival of cells (Abbas et al., 2012). 
Subsequent ubiquitination of Nrf2 is triggered by a disassociation from cyctolic inhibitor of 
Nrf2, an adaptor protein, facilitated by Nrf2Ser-40 phosphorylation (Abbas et al., 2012). This 
mechanism activates ARE gene expression that essentially promoted cell apoptosis, decreased 
Nrf2 and cell survival. On the other side of the coin, unrestrained activation of Nrf2 as a result 
of accumulation of Nrf2 in nucleus could reverse the effect of cell apoptosis and increase cell 
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survival. AS-IV revealed strong effects in inducing Nrf2 Ser-40 phosphorylation and nuclear 
localization and promoted ARE dependent genes while inhibiting ROS accumulation in cortical 
neurons. It was suggested that the activation of Nrf2 was dependent on the “transactivation” of 
EGF-EGFR signalling network as evidenced by the increased heparin-binding-EGF growth in 
AS-IV treated neurons, thus inhibiting oxygen and glucose deprived or re-oxygenated models, 
promoting ROS scavenging ability and activating Nrf2 in the wake of promoting apoptosis (Gu 
et al., 2015).  
 
Aberrant levels of the antioxidant defence system in SOD, glutathione, catalase and glutathione 
peroxidase are hints of imbalance between these anti-oxidants and ROS. This imbalance 
triggers mutagenic transcription, promotes atherogenicity, activates cytokines downstream 
inflammation and produces plague depositions (Pisoschi & Pop, 2015). Neuronal hypoxic and 
ischemic cells, when treated with MEG, experienced an increase of radical scavenging activity 
with IC50 13.7 μM (Choi et al., 2010). In comparison to vitamin C at 3.6 μM, MEG by far 
exerted a stronger anti-oxidative effect. Anti-oxidant enzymes, SOD and catalase were 
upregulated in vitro, with abnormal levels of superoxide ions and ROS substantially suppressed, 
this facilitated a reduction of cerebral infarct volume. The anti-oxidative effect of MEG in Xi 
Xin could be the key to deterring further cerebral cellular damage in lipids peroxidation and 
protein degradation induced by accumulation of ROS in ischemia and post–ischemic 
reperfusion injuries.  
 
Hypoxia-induced cell injury in cortical neurons-astrocyte generally exposed cells to lactose 
dehydrogenase A release, commonly associated with induced apoptosis, affected invasive and 
spheroid growth tumours, reduced expression of MMPs and cancer-stem like cells markers 
(Maftouh et al., 2014). Treatment with 10 and 100 μM significantly reduced potassium cyanide-
induced lactose dehydrogenase release in in vitro. In addition, in septicaemia, in vivo models 
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administered with magnolol before and after induction of sepsis by cecal ligation and puncture, 
survival rates remarkably improved with the pretreatment models (WHO, 2009). Overall 
intensity of lipid peroxidation in plasma, liver and lungs of the models was reduced.  
 
Magnolol in Xin Yi also appeared to exhibit antioxidative effect extending cardioprotective 
activities. Myocardial ischemia and reperfusion injury was discovered to have been 
substantially reduced when early administration (10 minutes) before the incidence of left 
coronary artery occlusion (45 minutes) (WHO, 2009). The duration and the severity of the 
occlusion reduced the mortality and the ventricular fibrillation. After one hour of perfusion, 
levels of SOD anion and myeloperoxidase production as well as both primary indexes for 
neutrophil infiltration in ischaemic myocardium, reduced the infarct size. In addition, effects of 
magnolol was able to counter a common side effect of balloon angioplasty known as restenosis 
(an intimal rethickening in the arterial wall) (WHO, 2009). In vitro results on cholesterol fed 
models with injection of 1 μg/kg body weight of magnolol over six weeks discovered inhibition 
of copper-induced low density lipoprotein oxidation in cholesterol fed models and reduced 
atheroma formation in the thoracic aortas. Intimal response was also reduced in high cholesterol 
models. 
 
These potentiated active compounds of Huang Qi, Xi Xin and Xin Yi could provide a novel 
therapy for neurodegenerative, myocardial and ischemic diseases. 
 
Cellular proliferation is synonymous in cancers and metastases. Naturally occurring compound 
(-)-xanthatin in Cang Er Zi, exhibited potent anti-proliferative effects in cancer cells. Cytogenic 
aberrations are results of amplification or deletion of topoisomerase (topo) IIα that cause 
chromosomal translocation or deregulation of gene expression (Jarvinen & Liu, 2003). It is an 
enzymatic biomarker for cellular proliferation in cancers, responsible for DNA cleavage during 
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genes transcription and the mitotic remodelling of chromatin in the cell cycle. Expression of 
topo IIα was influenced by p53 and retinoblastoma susceptibility gene product, pRB, with the 
latter exerting a bi-functional role in stimulating and deregulating topo IIα cleavage via stimuli-
induced GADD45γ protein while the former exerted a deregulatory role on topo IIα in cell cycle 
at G1/S boundary (Kellner, Maxwell, Jensen, Gieseler, & Rudolph, 2002). Interestingly, (-)-
xanthatin was discovered to catalytically inhibit topo Iiα and induce DNA damage in vitro in 
human breast cells and activating GADD45γ, of which was stabilised by generated ROS. DNA-
SC conformation was relaxed and after 12-hour exposure to (-)-xanthatin, chromatin 
remodelling surfaced with the formation of γH2AX (a marker of DNA double strand break). It 
was posited that ROS generation was an important mediator factor for (-)-xanthatin’s anti-
proliferative activities via induction of GADD45γ (Takeda et al., 2013). In addition, (-)-
xanthatin was also antagonistic against the effects of etoposide. Although the potential of Cang 
Er Zi compound (-)-xanthatin may be heralded as a new chemotherapeutic drug intervention 
for cancers, however its pharmakinetic and its toxicokinetic mechanisms have yet to be 
investigated further. 
 
Natural occurring chemical compounds could provide a drug scaffold for existing cancer 
therapy. Panaxynol, an active component of Fang Feng root displayed traits of reinforcing 
conventional drug treatment for human mammary adenocarcinoma. The discovery of in vitro 
tests in combined therapy with chemotherapeutics; camptothecin (CAM), paclitaxel (PTX) and 
Fang Feng achieved a synergistic effect in the IC50 value. IC50 is a measure of the drug 
concentration causing a 50% inhibition of a desired activity in the cellular mechanism (Kuo, 
Lin, Huang, Shu, & Tsai, 2002). Synergistic effects with the combined treatment of 
chemotherapeutic agents, CAM or PTX on the four cancer cells demonstrated Fang Feng 
extracts effectively reduced the IC50 values of CAM and PTX in K562 and HL60, PTX in MCF7 
and MDA-MB-468 cells as compared to chemotherapeutic agent(s) alone and increased the 
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percentage of proliferative activity (Tai & Cheung, 2007). Co-administration of Fang Feng with 
a lower dose of chemotherapeutic agents could effectively achieve the same anti-proliferative 
effect as compared to a high cytotoxic dose of CAM or PTX for treatment of cancer. Complete 
inhibitory effects were observed in vitro at 100 μM of panaxynol with evidence of cell cycle 
arrest from G0/G1 phases to S and G2/M phases was observed. Remarkably, the ratio of cyclin 
E mRNA was also significantly decreased in vitro. Co-administration with Fang Feng extracts 
and chemotherapeutics exhibited no cytotoxicity or side effects in in vitro. However, this 
antagonistic effect on cell proliferation is highly dependent on the dosages of Fang Feng 
extracts and the chemotherapeutic agents. 
 
6.5. Immunoregulatory effects 
The immunoregulatory effect of Fang Feng polysaccharides on the spleen proliferation index 
and spleen index as well as on the macrophage and its phagocytic rate showed marked 
difference in spleen proliferation index marker (H. Liu et al., 2008). No significant difference 
was observed in the spleen index even though spleen proliferation index were higher than the 
control. An obvious increase of the phagocytic rate and macrophage index in mice coincided 
with the increased doses, 250, 500 and 1000 mg/kg of Fang Feng polysaccharides administered. 
Lymphocytes subsets ratio for CD3+CD4 increased from 27.28 ± 2.30% (250 mg/kg dose) to 
45.82 ± 1.54% (1000 mg/kg), while CD3+CD8+ was significantly as high as 17.44 ± 1.78% 
(250 mg/kg dose) but decreased by 13.22 ± 1.34% (1000 mg/kg dose). Significant differences 
were detected in subsets CD4+CD8+ ratio from 1.58 ± 0.18% (250 mg/kg dose) to 3.49 ± 0.29% 
(1000 mg/kg dose), as well as CD19+ from 10.42 ± 2.40% (250 mg/kg dose) to 15.15 ± 2.32% 
(1000 mg/kg dose) (H. Liu et al., 2008).  
 
The polysaccharides of Huang Qi confirmed in in vitro and in vivo, at concentrations of 10 
mg/ml increased T-cell function of mononuclear cells derived from cancer patients (WHO, 
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1999). The immunopotentiating effect in T-cell deficient cancer patients was fully corrected in 
vitro. Huang Qi polysaccharides were found to be able to reverse cyclophosphamide-induced 
immunosuppressant effect in rats. Enhanced IL2 activity generated lymphokine-activated killer 
cell activities in vitro (WHO, 1999). Further phagocytic activities also induced the antibody to 
a T-dependent antigen and polysaccharides are responsible for Th cells activities in both normal 
and immunosuppressed models. When countering cobra venom on immune function of treated 
mice and guinea pigs, treatment with Huang Qi polysaccharides increased levels of complement 
and neutrophil phagocytic activities as well as levels of neutrophils granular substances (WHO, 
1999). Aside from immunopotentiating effects, the immunostimulatory effects were observable 
when human adults were treated with 15.6 g of oral dose of Astragali root for 20 days (WHO, 
1999). Increased IgM, IgE, cAMP concentrations were detected. Huang Qi was also highly 
effective against coxsackievirus B myocarditis with enhanced natural killer cells response. The 
overall effects also stimulate interferons which are associated antiviral activities. 
 
No clinical studies evaluated immunoregulatory effects on Cang Er Zi, Xin Yi and Xi Xin. 
 
6.6. Anti-asthmatic effects 
A shift of Th1 predominance to Th2 is a typical characteristic of airway hypersensitivity, 
inflammation, hyperresponsiveness and airway remodelling observed in exacerbation of AR 
with comorbidity of asthma. Influx of proinflammatory Th2 cytokines LI4, IL5 and IL13 
initiate eosinophilic responses to proliferate mast cells and secrete chemoattractants, promoting 
the induction of B-cells towards IgE production. Prolonged amplification of these self-antigenic 
response triggered Treg cells. The phenotypic characteristics of Treg cells lie in 
CD4+CD25+Foxp3 whose key role is to suppress the activation and the effector functions of 
other, self-reactive and potentially pathogenic lymphocytes (Abbas et al., 2012). The reductive 
effect of Huang Qi on airway hyperresponsiveness was marked with the suppression of IL4, 
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IL5 and IL13 and increased Th1 cytokine INF-γ, elevated leukocytes, eosinophils, 
lymphocytes, macrophages and neutrophils levels as well as CD4+CD25+Foxp3+Tregs in 
bronchoalveolar lavage fluid. Reduction of collagen deposits, peribronchial fibrosis and 
mucous secretion in active murine models. Treg cells were increased by 17.9% at an oral dose 
of 10 mg/kg (Jin et al., 2013). It was posited that the bidirectional regulatory effects on 
cytokines could be due to the complex constituents of the Astragali polysaccharides in Huang 
Qi, thereby resulting in modulation of the hypersensitive airway structure.  
 
As yet, the strongest anti-asthmatic effect was exerted by AS-IV, a major active constituent of 
Huang Qi, at mRNA level with expressions of Foxp3 (transcription factor) and peroxisome 
proliferation-activated receptor-γ (PPAR-γ). PPAR-γ is a nuclear receptor subtype responsible 
for regulating inflammatory cytokines cascade, with a secondary regulatory role in IgE and IgG 
production and GATA-3 and T-bet (both transcription factors) expressions in cell 
differentiation (Abbas et al., 2012). The latter transcription factors are master regulators of Th1 
and Th2 cell differentiation. Increased expressions of PPAR-γ in bronchial submucosa, airway 
epithelium, and smooth muscles are commonly associated with asthma (Woerly et al., 2003). 
AS-IV decreased GATA-3 and increased the activity of PPAR-γ in asthmatic simulated models. 
The increase of activity of PPAR-γ implied a possible reversal of Th2 to Th1 to downregulate 
the effector cells and cytokines infiltration in airway allergy through inhibition of Th2 cytokines 
(S. M. Chen, 2014). The efficacy of Huang Qi was equivalent to rosiglitazone, a PPAR-γ 
agonist, in vitro (S. M. Chen, 2014).  
 
Remodelling of the bronchial muscle in asthma is a typical response of the cytokines and 
chemokines as a result of mast cells activation and degranulation causing increased of deposits 
of extracellular matrix proteins (Bara, Ozier, Tunon de Lara, Marthan, & Berger, 2010). 
Calcium activities in tracheal smooth muscle were affected with decreased potassium outward 
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currents. Magnolol, a compound in Xin Yi, was discovered to reversibly increase the amplitude 
of the potassium outward flow and effectively increase the conductance of calcium activated 
potassium channels with effective concentration value of 1.5 μM of magnolol (WHO, 2009).  
 
Xi Xin has longed been used for its anti-asthmatic effects in CM. There have been no studies 
that evaluated the anti-asthmatic effects of Xi Xin.  Studies on anti-asthmatic effects of Xi Xin 
are always coupled with other herbs in formulae to determine its efficacy. In addition, no 
clinical studies have been conducted on Cang Er Zi and Fang Feng for anti-asthmatic effects. 
 
6.7. Toxicological evidence  
Of the five herbs, only two of the herbs, Cang Er Zi and Xi Xin, were found to possess toxic 
compounds. Dose-related toxicities and side effects of Cang Er Zi have arisen in recent 
literature (L. L. Chen, 2013; Yao, 2006; Yu et al., 2013). Diterpenoids glycosides, atractyloside 
(ATR) and carboxytractyloside (CATR) are the main toxic constituents. ATR and CATR 
toxicities often result in high dose-related incidences causing kidney damage which manifests 
haematuria, albuminuria, abnormal renal function and acute renal failure. Yu et al. (2013) 
demonstrated no acute toxicity was manifested at low dosages, however at higher dosages, 
acute toxicity was obvious for both raw and stirred-fried Cang Er Zi (Jiao Ban Chao Cang Er 
Zi, 搅拌炒苍耳子). Chronic toxicity was indicated in the fluctuating changes of blood nitrogen 
urea, serum creatinine with pathological changes in congestion and focal necrosis in the liver, 
renal tubules, lungs and heart after prolonged administration in both medium and high dosage 
mice groups. Obvious side effects of thrombocytopenia also emerged. The investigators (Yu et 
al., 2013) concluded that a single of administration of even 10 times the permitted highest daily 
dosage of Cang Er Zi (3 g to 10 g) as legislated by Chinese Pharmacopeia 2015 (Chinese 
Pharmacopoeia Commission, 2015) is safe. This experiment elucidated an observation that the 
lack of dose-dependent toxicity response relationship might have precluded the exposure time 
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and the possible toxicological pathways of both ATR and CATR of Cang Er Zi were not 
clarified. Despite its cytotoxic nature, Cang Er Zi still offers much potentiated use in the 
treatment of cancers and tumours. 
 
Xi Xin is currently still used in the clinical practice of CM in China, Japan, Singapore, South 
Korea and Taiwan, although it is scheduled in Australia and parts of Europe such as Holland 
and England (Z. Z. Zhao et al., 2008). Xi Xin is indicated in the classical text Shennong’s 
Classics of Materia Medica (Shen Nong Ben Cao Jing, 神农本草经) to release the exterior 
pathogen, dispel wind cold, clear nasal cavities warm the Lung and expectorate the lavages in 
the bronchial system (R. Hu, 2015). These connotative descriptions parallel respiratory 
conditions such as respiratory and comorbid conditions such cold, chronic sinusitis, cough, 
dyspnoea in chronic obstructive pulmonary disease, lavage congestion in lungs, and AR 
comorbid headache. Although Xi Xin genus belongs to the Aristolochia family, 
chromatographic fingerprint of this herb did not detect aristolochic acid I (AA-I) (Wagner, 
Bauer, Melchart, Xiao, & Staudinger, 2011). AA-I is a toxic component primarily responsible 
for drug-induced nephropathy, also known as Chinese herbal nephropathy (Rietjens, Martena, 
Boersma, Spiegelenberg, & Alink, 2005). However, recent literature study discovered that there 
are trace AA-I ranging from 3.1 mg to 26.6 mg in chromatography screening (Y. Liu, Gao, 
Wang, & Zhang, 2010), its amount is in fact negligible. It is confounding that both studies Y. 
Liu et al. (2010) and Wagner et al. (2011) revealed conflicting results on the toxicity of Xi Xin. 
Z. Z. Zhao et al. (2008) conducted a thorough study on the levels of AA-I in the different 
portions of Xi Xin in liquid chromatography–mass spectrometry and the comparisons of the 
potency of AA-I in different extracts. The aerial parts of Xi Xin was found to contain higher 
levels of AA-I than the roots and methanol extracts contained more AA-I than water extracts 
(Z. Z. Zhao et al., 2008).  
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The chemical constituents present in Xi Xin are estragole, MEG, elmicin, safrole, asaricine, 
croweacin and kakuol (Drew et al., 2002).  The implicating toxic agents in Xi Xin are mainly 
due to safrole and MEG (C. Chen et al., 2009; Chiang et al., 2011). Both constituents are 
commonly found in foods; safrole derived from essential oils of sassafras, nutmeg, sweet basil, 
garden basil, tarragon, cinnamon, nutmeg, star anise, black pepper and methyleugenol from 
pimento, nutmeg, lemongrass, tarragon, basil, star anise and fennel (Rietjens et al., 2005).   
 
Both safrole and MEG constituents share derivatives of alkenylbenzene and are both nephrotic 
and hepatic carcinogenic agents. MEG dose of 100 mg/kg and safrole 0.5% dose (in a dose 
dependent manner) were discovered to be carcinogenic when the glutamate pyruvate 
transaminase delta manifested marked increase in glutamate pyruvate transaminase mutations 
and Spi- mutant frequency as well as positive proliferating cell nuclear antigen, a monoclonal 
antibody marker for preneoplastic lesions in the liver cells. A GC→CG transversion mutation 
in the treated male rats and an AT→TA transversion mutation in the female rats were observed, 
although incidence rates were not statistically significant compared to control (Jin et al., 2013). 
Safrole-glutamate pyruvate transaminase-mutant spectra also detected mutant changes with the 
predominant type of AT:GC transition being significantly present in the genome (Jin et al., 
2011). Both these toxic agents could induce cytotoxicity and genotoxicity causing renal and 
hepatic failures. 
 
Acute toxicity signs and symptoms manifested were convulsions, torpor, breathlessness and 
lack of appetite. Although water extraction was administered in high dosage, no obvious 
intraocular toxic reaction was detected with acute poisoning. The long-term toxicity of Xi Xin 
on hepatotoxicity and nephrotoxicity was also further evaluated in vivo, which demonstrated 
the degree of renal damage was relative to the dosage administered in two Chinese studies (W. 
X. Chen, 2009; J. J. Li, 2007). Severe hyperplasia, fibrosis, renal congestion and large amount 
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of inflammatory cell infiltration with marked renal tubular necrosis. Severe weight loss and 
reduction of appetite were associated with Xi Xin toxic signs and symptoms. Blood urea 
nitrogen (BUN) and creatinine (Cr) are primary markers for nephrotoxicity. BUN tests the 
clearance rate of the kidney by determining nitrogenous element in the bloodstream, Cr refers 
to the metabolic by-product of muscle metabolism excreted by urea. The category of the light-
dosage rat models’ biomarkers of BUN and Cr were similar to the control group. This indicated 
that light doses of Xi Xin extracts might take longer time for nephrotoxicity to take effect. 
Nephrotoxicity induced by Xi Xin was reversible in both medium and high dosage in vivo 
models. Morphological samples revealed only inflammatory cell infiltration with no delayed 
toxic reactions. Xi Xin-induced hepatotoxicity also corresponds to the relative dosage as 
investigated in another study (J. J. Li, 2007). Long-term administration with high dosage in rat 
models manifested an increase of the total bilirubin levels with little effect on the synthetic liver 
function. Severe pathological changes in high dosage group manifested large inflammatory cell 
infiltration and necrosis tissue in the liver, reversibility of hepatic injury was achieved once the 
administration of Xi Xin stopped. Long-term effects Xi Xin-induced renal and hepatic toxic 
injury were reversible within two weeks of cessation, regardless of the dosage (W. X. Chen, 
2009; J. J. Li, 2007). 
 
The instructive dosage of Xi Xin was noted in the Shennong’s Classics of Materia Medica -(Xi 
Xin Bu Guo Qian, 细辛不过钱), which highlighted that dosage used in formulation should not 
exceed 3 g (R. Hu, 2015). Current Pharmacopoeia of China 2015 editon stipulated Xi Xin 
dosage should be administered within 1 to 3 g (Chinese Pharmacopoeia Commission, 2015). 
The toxic mechanism in relation to the dosages could essentially be compounded the types of 
extractions in the preparation of this herb. Three types of extractions were tested on the mice: 
supercritical extract, volatile oil extract and water extract, measuring the median lethal dose 
(LD50). Dose-response experimental results demonstrated LD50 and CI limit of volatile oil and 
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supercritical fluid extraction were 86.9 g kg-1.d-1 (62.2~120.8 g kg-1.d-1) and 7.4 g kg-1.d-1 
(6.3~8.7 g kg-1.d-1). Among the three compositions tested, water extraction was not able to fulfil 
LD50 of 30 g kg
-1.d-1. This was found to be equivalent to 76.92 times of a 70 kg adult daily dried 
herb consumption (R. R. Li, Yang, Ding, Qin, & Li, 2012). In CHM, herbal decoction in water 
extract is regarded as the golden standard for consuming and preparing CHM. The strategy in 
pairing herbs or formulating herbs which involve a toxic herb in CM is based on the principle 
of mutual counteraction (Xiang Wei) where the toxicity of herbs are reduced or neutralised 
when paired with another herb. In the case of Xi Xin, pairing with Dan Shen (Salviae 
Miltorrhizae Radix et Rhizoma), Chi Shao (Paeoniae Radix Rubra) or Wu Wei Zi (Schisandrae 
Chinensis) is recommended (Sionneau, 1997). Depending on the syndromes, these herbs have 
longed been used to supress the toxicity. In addition, boiling of decoction for Xi Xin requires 
45 minutes to totally eliminate the toxic substances (C. Chen et al., 2009). Therefore, the water 
extraction method confirmed the toxicity of Xi Xin was negligible to impart nephropathy. In 
spite of the positive evidence that low dosages of Xi Xin and Cang Er Zi may not present acute 
toxicity, it is highly encouraged that caution and drug vigilance should be exercised. 
 
6.8. Discussion 
The bioactive chemical components of natural products are essential building blocks for novel 
drug development. For natural products to be defined as therapeutic natural products, four broad 
acceptable definitions include the following: First, it is an unregulated organisms or natural 
materials; second, a FDA-regulated, unmodified natural materials or compounds; third, a 
semisynthetic compound – a naturally occurring compound that has been chemically modified 
and fourth; a purely synthetic medicinal compound inspired by a natural compound (Patridge, 
Gareiss, Kinch, & Hoyer, 2016).  
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By chemical modification, biological and chemical engineering, the naturally occurring 
bioactive compounds can be improved by these methods to produce superior drugs to target 
chronic diseases more effectively.  
 
The review of the five top herbs commonly used clearly underscores the pharmacodynamics 
and the diversity of their bioactive chemical compounds on molecular mechanisms, multiple 
pathways and its regulatory indications. The reception of CHMs for medicinal purposes has 
been instilled by fearmongering stirred by a faction of scientific community or owing to 
ignorance. Yet, to date, new molecular entities that were approved by FDA derivatives from 
natural products: 44% from mammals with the primary species of origin being (in order of 
frequency) bovine, porcine, equine, canine and human, 25% from plant, 16% from bacteria, 
12% from fungi and 30% from bacteria (Patridge et al., 2016). In fact, at least 35 different 
natural-product based new molecular entities that target opioid or neurotransmitter receptors 
accounted 94% derived from plants (Patridge et al., 2016).  
 
The outcomes of this review unveil many other potentiated pharmacological effects of CHM 
used for the management of AR such as anti-inflammation and anti-allergic, anti-nociceptive 
and analgesia, anti-oxidative and anti-proliferative, immunoregulatory and immunostimulatory 
for different biological systems of disease. Toxicological evidence revealed both Cang Er Zi 
and Xi Xin are toxic in regards to their levels of toxicities and their effects on the health system. 
Exposure of AA-I induced mutated adenines in the genome associated with A→T transversion 
at 5′AG (acceptor) splice site accounts for 30%, and 20% represent all other mutations 
(Grollman, 2013). These mutations represent a failure of DNA to repair its strand and account 
for the persistence of lesions in human tissues. Toxicities induced by AA-I are known as AA 
nephropathy. Given the use of Xi Xin and Cang Er Zi, many of cases of AA nephropathy are 
due to linear dose-response relationship established between consumption of herbal remedies 
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(Grollman, 2013) and risk developing chronic renal disease, upper urothelial carcinoma, 
hepatocellular necrosis and liver disease (Grollman, 2013; Yu et al., 2013).  
 
To date, Taiwan has the highest recorded renal-pelvis-urethra AA-I induced mutagenesis owing 
to use of Aristolochia herbs which accounts for one third of the population (Grollman, 2013). 
The main reason for the increase of the incidence of AA-I is iatrogenic, where CM practitioners 
prescribe Aristolochia herbs with little or no knowledge of restrictions and dose-related 
requirements. It is important that ongoing education on the molecular toxic effects of AA-I 
herbs be reinforced to CM practitioners. At the grassroots level, bodies of authorities in relation 
to CM practice need to exercise more stringent surveillance of herbal dispensary, even though 
a restriction on the use of Xi Xin is in place in Australia. All species of Aristolochia are 
prohibited for supply, sale or use in therapeutic goods in Australia under the Standard for the 
Uniform Scheduling of Drugs and Poisons (Therapeutic Goods Administration, 2001). 
However, Aristolochia species especially Xi Xin may still be presented in other CM herbal-
based products for sale in Australia, vigilance has to be exercised. 
 
Although Cang Er Zi is not restricted, it is known for its toxicities yet it has beneficial effects 
in AR. Informed usage of this herb has to be reinforced to prevent unforeseen endemic AA-I 
susceptibilities in patients seeking CM. 
 
With the well-established understanding of the usage of herbs, sustained efforts in research of 
herbs for drug development and education on its application in clinical practice can expand the 
drug resources for treatment of diseases. 
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Chapter 7  Results III – Review of CM classic literature 
 
This chapter reports the outcomes from the principal component and hierarchical cluster 
analyses of the main classical texts for AR-like signs and symptoms and identifies the 
commonly used herbs in the classics. 
 
7.1. Results of literature search 
A total of 1,687 articles were searched from ZHYD and ZGBQS and 294 articles were included 
in the review which identified 163 herbs were used in ancient times for the management of AR 
(Figure 50). 
 
660 articles identified in 
ZHYD
660 articles identified in 1,027 articles identified in 
ZGBCQS
1,027 articles identified in 
1,687 articles identified with 
keywords ‘nose’
1,687 articles identified ith 
key ords ‘nose’
294 articles included294 articles included
163 herbs identified for treatment 
of AR-like signs and symptoms
163 herbs identified for treat ent 
of -like signs and sy pto s
1,393 articles excluded due to 
reasons:
- Diagnosis descriptions only (n=85)
- 鼻生瘜肉谓之齆 (nasal polyps) 
(n=175)
- 鼻渊/鼻渊不止 (rhinosinusitis) 
(n=152)
- 鼻齆鼻渊(rhinosinusitis-induced 
nasal congestion (n=1)
- Acupuncture only (n=25)
- Other nasal pathologies (n=955)
1,393 articles excluded due to 
reasons:
- iagnosis descriptions only (n 85)
-  (nasal polyps) 
(n 175)
- /  (rhinosinusitis) 
(n 152)
- (rhinosinusitis-induced 
nasal congestion (n 1)
- cupuncture only (n 25)
- ther nasal pathologies (n 955)
 
 
 
Figure 50. Search process for ZHYD and ZGBCQS 
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7.2. Descriptions of selected classical texts 
The following table is a summary of classical texts with relevance to AR-like signs and 
symptoms in ZGBCQS (Table 19). 
 
Table 19. Summary of classical texts in ZGBCQS containing AR-like signs and symptoms 
Volumes 
No. of 
Books 
Names of books and sections Periods 
2 7 神农本草经（马继兴辑本） 
Shennong’s Classics of Materia Medica 
5th century 
神农本经（卢复辑本） 
Compendium of Shennong’s Classics of Materia Medica 
17th century 
本草经  
Materia Medica 
17th century 
神农本草经（孙星衍、孙冯翼辑本） 
Shennong’s Classics of Materia Medica 
9th century 
神农本草经（狩谷棭斋辑本） 
Shennong’s Classics of Materia Medica 
9th century 
神农本草经（森立之辑本） 
Shennong’s Classics of Materia Medica 
9th century 
神农本草（王仁俊辑本） 
Shennong’s Classics of Materia Medica 
9th century 
3 3 注解神农本草经 
Annotations of Shennong’s Classics of Materia Medica 
19th to 20th  
century 
神农本经（姜国伊辑本） 
Shennong’s Classics of Materia Medica (American Edition) 
19th century 
神农本经校注  
Notes on Shennong’s Classics 
20th century 
5 5 本草经集注 
Reconstituted Annotations of Materia Medica 
No date 
6 12 新修本草 
Newly Revised Materia Medica (Tang Materia Medica) 
No date 
食疗本草 
Dietetic Materia Medica  
7th century to 8th  
century 
何首乌录 
Records of Polygoni Multiflori Radix 
8th century to  
12th century 
石药尔雅 
Minerology in Medicine 
8th century to  
12th century 
食医心鉴  
Reflections on Food for Medicine 
8th century to 
12th century 
药谱 
Drug Register 
8th century to  
12th century 
7 1 海药本草 
Overseas Materia Medica 
5th century to  
11th century 
7 1 经史证类备急本草  
Annals of Exigent Syndromes Materia Medica 
5th century 
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Volumes 
No. of 
Books 
Names of books and sections Periods 
8 1 经史证类备急本草  
Annals of Exigent Syndromes Materia Medica 
11th century 
9 -11 3 经史证类大观本 
Annals of Syndromic Catalogue of Materia Medica 
12th century 
11-13 1 重修政和经史证类备用本草 
Recompilations of Annals of Exigent Syndromes Materia Medica 
12th century 
 
 
13-14 1 绍兴校定经史证类备急本草（龙谷大学本） 
Shaoxing Materia Medica 
13th century 
14-15 1 绍兴校定经史证类备急本草画卷 
Shaoxing Materia Medica with  Pictorial Inserts 
12th century 
15-16 3 绍兴校定经史证类备急本草（神古克桢本） 
Shaoxing Materia Medica 
No date 
本草衍义 
Elucidations of Materia Medica 
19th century 
图经本草药性总论  
Comprehensive Blueprints of Materia Medica 
12th century 
18 1 图经衍义本草  
Elucidations of Materia Medica Blueprints 
13th century 
19 2 图经衍义本草  
Comprehensive Blueprints of Materia Medica 
13th century 
类编图经集注衍义本草  
Complete Blueprints Assortments of Materia Medica 
No date 
22 7 珍珠囊  
Pearls of Wisdom in Gastrointestinal Doctrine 
No date 
汤液本草  
Doctrines of Herbal Decoction 
13th to 14th 
century 
本草元命苞  
Materia Medica for the Preservation of Life 
13th to 14th  
century 
本草衍义补遗  
Elucidations on the Addendum to the Complete Materia Medica 
14th century 
日用本草（嘉靖四年刻本） 
Conventional use of Materia Medica 
14th century 
日用本草（万历四十八年刻本） 
Conventional use of Materia Medica 
15th century 
饮膳正要  
Dietary Nutrition 
15th century 
24 3 滇南草本（务本堂本） 
Southern Yunnan Materia Medica 
15th century 
滇南本草图说  
Southern Yunnan Herbal Picture Book 
15th century 
滇南本草（云南丛书本） 
Southern Yunnan Materia Medica 
15th century 
24 1 滇南本草（云南刻本） 
Southern Yunnan Materia Medica 
15th century 
25 4 滇南本草（云南刻本） 
Southern Yunnan Materia Medica 
15th century 
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Volumes 
No. of 
Books 
Names of books and sections Periods 
滇南本草(沐忠本)  
Southern Yunnan Materia Medica 
15th century 
药性赋  
Herbal Properties 
15th century 
本草集要 Notes on Materia Medica 15th century 
26 3 新编注解药性赋  
Commentary on Herbal Properties 
15th century 
本草约言  
Covenant of Herbal medicine 
16th century 
食物本草（胡文焕精抄本） 
Food as Medicine 
14th to 17th 
century 
28-37 1 (御製本草品彙精要)本草品彙精要（罗马本） 
Herbal Essentials Collection  
16th century 
38-41 2 本草纲目（金陵本） 
Compendium of Materia Medica 
16th century 
41-47 1 本草纲目（武林本） 
Compendium of Materia Medica 
16th century 
48-52 1 本草纲目（味古斋本） 
Compendium of Materia Medica 
16th century 
53-54 1 神农本经会通  
Mutual Annotation of Shennong’s Classics of Materia Medica 
15th century 
54 3 鼎刻京板太医院校正分类青囊药性赋 
Correction of the classification of Chinese Materia Medica in 
Imperial Academy of Hospital in Beijing 
16th century 
医方药性合编  
Edition of Medical Prescriptions 
16th century 
食品集 
Food Collections 
16th century 
55 5 食鑑本草  
Materia Medica for Dietary Therapy 
16th century 
体仁彙编·十二经络脏腑病情药性 
Benevolence practice – Interactions of medicine and 12 meridians 
and Zang Fu diseases 
16th century 
新刻药证类明 
Illuminations on novel drugs 
16th century 
南产志 
Records of Chinese Materia Medica produced in Southern China 
16th century 
太医院补遗本草歌诀雷公炮製 
Addendum to University Hospital on Decoction of Processed Herbal 
Medicine  
16th century 
56 1 药性粗评  
Debate on Herbal Medicine 
16th century 
56 1 本草发明  
Invention of Materia Medica 
16th century 
58 2 新刻太乙仙製本草药性大全  
Compendium of Mystical Efficacy of Herbal Medicine 
17th century 
饮馔服食谱  
Recipes of Foods and Beverages 
16th century 
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Volumes 
No. of 
Books 
Names of books and sections Periods 
59 
 
3 本草定衡 
Revaluation of Materia Medica 
16th century 
万病回春·药性歌  
Rhymes on Herbal Efficacy -Rejuvenation from Thousand Diseases 
16th century 
伤寒论条辨·本草钞  
Treatise on Shang Han Lun Materia Medica 
16th century 
60 1 本草选  
Herbal Medicine Selection 
17th century 
61 2 药鑑／药鉴  
Governance on Medicine 
17th century 
本草原始（李中立绘图本） 
Origins of Herbal Medicine 
17th century 
62 2 本草原始（永怀堂刻本） 
Origins of Herbal Medicine 
17th century 
炮炙大法  
Art of Processed Medicine 
17th century 
63 3 本草真诠 
Original Exposition of Herbal Medicine 
17th century 
食物辑要  
Edition on Foods 
17th century 
芷园臆草题药 
Impression on Chinese Materia Medica by Zhi Yuan  
17th century 
64 1 本草彙言/本草汇言 
Discourse on Herbal Medicine 
17th century 
67 3 食物本草  
Herbal Foods  
17th century 
野菜博录  
Records of Wild Plants 
17th century 
景岳全书·本草正  
Complete Works of Jingyue 
17th century 
68 4 珍珠囊指掌补遗药性赋  
Pearls of Wisdom Addendum to Fu Herbs 
17th century 
镌补雷公炮製药性解  
Lei’s Supplementary Exposition on Processed Herbs 
17th century 
镌补雷公炮製药性解 
Lei’s Supplementary Exposition on Processed Herbs 
17th century 
养生要括  
Inclusions on Health 
17th century 
69-70 1 神农本草经疏  
Notes on  Shennong’s Classics of Materia Medica 
17th century 
71 1 分部本草妙用  
Sections on Mystical Use of Herbs 
17th century 
71 1 医宗必读·本草征要  
Compulsory Clinical Readings on Herbal Evidence 
17th century 
72-74 3 食物本草（姚可成辑本） 
Herbal Foods 
17th century 
明医选要·药性诗诀  
Choice of Clinical Fame · Poetry on Herbs Efficacy 
17th century 
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Volumes 
No. of 
Books 
Names of books and sections Periods 
山公医旨食物类  
Top Medical Advice on Foods for Medicine 
17th century 
76 3 药镜 
Reflections on Medicine 
17th century 
药品化义  
Drugs of Justice 
17th century 
新锲药性会元 
Potency of New Element 
15th century 
78 3 本草纂要  
Medicinal Compilations 
16th century 
仁寿堂药镜  
Reflections on Compassion and Longevity in Herbal Medicine  
17th century 
新刊校正李东垣官板药性大全 
New Editions on Corrections of Medicinal Properties 
Compilation by Li Dong Yuan 
17th century 
79-83 4 本草品彙精要（大塚本） 
Herbal Collection Essentials 
16th century 
 
本草歌括（八卷本） 
Herbal Rhymes 
14th century 
本草歌括（二卷本） 
Materia Medica Rhymes 
14th century 
本草发挥  
Efficacy of Herbal Medicine 
15th century 
84 3 本草歌括（八卷本） 
Herbal Rhymes 
16th century 
本草纲目类纂必读  
Essential Proses on the Compendium of Materia Medica  
17th century 
食宪鸿秘 
Secrets of Food and Constitution 
18th century 
85-86 2 本草汇 
Transmissions on Herbal Medicine 
17th century 
寿世秘典 
Secret Code of Longevity 
17th century 
87 2 本草彙笺  
Annotations of Materia Medica 
17th century 
经方衍义  
Elucidations of Jing Fang 
17th century 
88 1 本草洞诠 
Complete Exposition on Materia Medica 
17th century 
89-91 1 本草述  
Narrations on Materia Medica 
17th century 
93 1 本草纲目必读 
Compulsory readings of Compendium of Materia Medica 
17th century 
95 4 本草通玄  
Tong Xuan Materia Medica 
17th century 
  农经酌雅 
Discretionary Farmer’s Treatise 
17th century 
  本草崇原  
Origins of Herbal Medicine 
17th century 
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Volumes 
No. of 
Books 
Names of books and sections Periods 
  生草药性备要  
Preparation of Herbal Medicine 
17th century 
96 2 药性纂要  
Compilations on the Efficacy of Medicine 
17th century 
药品辨义  
Debate on Quality of Medicine 
17th century 
98 3 医学启蒙彙编  
Compilations on the Enlightenments of  Medicine 
16th century 
食物本草会纂  
Compilations of Food as Medicine 
16th century 
颐生秘旨  
Secrets of Nourishing Life 
18th century 
99 1 山居本草  
Mountain Herbs 
17th century 
101 2 本经逢原  
Doctrine of Origin 
17th century 
药理近考  
Test on Pharmacology 
17th century 
102 3 杂症痘疹药性合参  
Indications of Small Pox and Herbal Medicine  
17th century 
 
得宜本草分类 The  
Legitimate Herbal Medicine              
18th century 
长沙药解  
Changsha Exposition on Medicine 
18th century 
103 3 夕庵读本草快编 
Fast Composition of Chinese Materia Medica by Xi’an 
17th century 
绛雪园得宜本草 
Jiang Xue Legitimate Herbal Medicine 
18th century 
医林纂要探源  
Original Compilation of Medicine 
18th century 
105 2 药性通考 
Biographical Notes on Medicinal Efficacy 
18th century 
要药分剂  
Analysis of Medicine 
18th century 
108 1 要药分剂补正  
Commendable Analysis of Medicine 
19th century 
 
108 1 食物小录  
Food Records 
18th century 
110 2 法古录  
Following Ancient Records 
18th century 
质问本草  
Questions on Materia Medica 
18th century 
111 1 脈药联珠药性食物考 
Criticism on Apllicaiotn of Pulse, Syndrome and Chinese Materia 
Medica 
18th century 
113 1 毛诗名物图说 
Illustration of Chinese Materia Medica 
18th century 
114 2 增补药性雷公炮製  
Supplementary to Efficacy of Processed Medicine 
19th century 
184 
 
Volumes 
No. of 
Books 
Names of books and sections Periods 
本草述录  
Records of Materia Medica 
19th century 
115 1 本草纲目拾遗  
Corrections of Compendium of Materia Medica 
18th century 
117 2 本草经疏辑要 
Collections of Monastic Herbs 
19th century 
本草正义  
Merits of Herbal Medicine 
19th century 
119 5 本草纂要稿  
Draft Complication of Herbs 
19th century 
四言药赋 
Medicinal Ode in Four Character Verse 
19th century 
类经证治本草  
Category of Herbal Treatment 
19th century 
简易草药草方图说  
Simplified Pictures of Herbal Medicine 
19th century 
药达 
Attainment of Chinese Materia Medica 
19th century 
121 1 本草述钩元 
Origin and Link of Herbal Medicine 
19th century 
124 2 本经续疏·本经序疏要  
Disseminations of Treatise 
19th century 
济荒必备 
The Necessity of Economy 
19th century 
125 1 本草求真  
Truths of Materia Medica 
18th century 
126 2 药性集要便读 
Volumes of Potency of Medicine 
19th century 
锦囊药性赋  
Tips on Potency of Fu Medicine 
19th century 
131 1 植物名实图考长编  
Pictogram of Plants 
19th century 
135 1 务中药性  
Works of Chinese Medicine 
19th century 
135 1 天宝本草 
Heavenly Treasure Herbal Medicine 
19th century 
136 4 神农本草经赞  
Merits of Shennong’s Classics of Materia Medica 
19th century 
药性摘录  
Records of Herbal Extracts 
19th century 
本草省常  
Common herbs 
19th century 
随息居饮食谱  
Increasing Spectrum of Home Diet 
19th century 
137 1 本草经考注  
Notes on Materia Medica 
19th century 
138 1 本草再新   
Revival of Materia Medica 
19th century 
139 4 本草汇编 19th century 
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Volumes 
No. of 
Books 
Names of books and sections Periods 
Collection of Materia Medica 
本草明览 
Overview on Herbs 
19th century 
药性蒙求  
Annotations on Herbal Efficacy 
19th century 
本草汇纂 
Discourse on Herbal Medicine 
19th century 
142 1 本草纲目易知录  
Understandings of Compendium of Materia Medica 
19th century 
143 3 本草正论  
Discussions on Materia Medica 
19th century 
稽古摘要  
Summary of the Practice 
19th century 
本草简明图说 
Facsimile of Materia medica 
19th century 
144 4 草木便方  
Benefit of Herbal Medicine 
19th century 
药要便蒙新编 
Overview of Herbs and its Usage 
19th century 
本草害利 
 Effects of Herbs 
19th century 
本草衍句  
Disseminations on the Materia Medica  
19th century 
146 3 虫荟  
Entomology 
19th century 
本草问答  
Questions and Answers on Herbs 
19th century 
本草韻语  
Rhymes on Herbal Medicine 
19th century 
148 1 分类草药性 
Studies on Types of Herbal Efficacy 
20th century 
148 10 每日食物却病考  
Eliminating Disease Utilising Daily Foods 
20th century 
分类草药性 
Studies on Types of Herbal Efficacy 
20th century 
本草（清抄本） 
Materia Medica 
20th century 
简明药性 
 Illuminating Herbal Efficacy 
20th century 
九龙虫治病方  
Beetles and Thousands Cures  
20th century 
本草类考  
Types of Herbs 
20th century 
本草分经（张节著本） 
Doctrines on Materia Medica 
20th century 
药性提要歌诀  
Rhymes on Herbal Efficacy 
20th century 
药性要略  
Debate on Herbal Efficacy 
20th century 
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Volumes 
No. of 
Books 
Names of books and sections Periods 
本草知要  
Fundamentals on Materia Medica 
20th century 
149 3 本草释名类聚  
Names of Herbs 
20th century 
本草须知  
Fundamental Knowledge on Herbal Medicine 
20th century 
本草分队  
Types of Herbs 
20th century 
150 6 本草二十四品  
24 Types of Herbs 
20th century 
药谱字类  
Writings on Medicinal Herbs 
20th century 
本草（程龄源著本） 
Materia Medica 
20th century 
备用药物  
The Necessary Medicine 
20th century 
药性新编  
New Edition on the Efficacy of Herbal Efficacy 
20th century 
四言药性分类精要  
Synopsis on Herbal Efficacy 
20th century 
151 4 神农本草经抄今注  
Annotations to the Shennong’s Classics of Materia Medica 
20th century 
本草约编（清抄本） 
Herbal Series 
20th century 
用药法程  
Methods of Using Processed Herbs 
20th century 
药性钞  
Summary on Herbal Efficacy 
20th century 
151 
 
 
3 
 
 
药性探源  
The Origin of Herbal Efficacy 
20th century 
本草歌括详注  
Rhymes on Herbal Medicine 
20th century 
药性骊珠  
Pearls of Wisdom of Herbal efficacy 
20th century 
153 1 本草十三家註  
Thirteen Texts on Herbs 
20th century 
155 3 辞典本草 
Encyclopaedia on Herbs 
20th century 
食物治病新书  
New Edition to Food as Medicine 
20th century 
药名杂钞  
Nomenclature of  Herbs 
20th century 
156 3 神农本草经注论  
Discussions on Shennong’s Classics of Materia Medica 
20th century 
党参新研究  
New Study on Dang Shen 
20th century 
药性精髓  
Essence of Herbs Efficacy 
20th century 
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Volumes 
No. of 
Books 
Names of books and sections Periods 
157 3 本草疏证  
Rectifications in Materia Medica 
20th century 
杂类药性书 
Text on Varied Herbal Efficacies 
20th century 
研药指南 
Manual of Herbal Exposition 
20th century 
158 1 本草求原  
Origin of Materia Medica 
19th century 
159 4 药性选要   
Choosing the Right Herbs for Efficacious Outcome 
20th century 
药名诗 
Poetry on the Nomenclature of Herbs 
19th century 
中国新本草图誌  
China Latest Herbal Facsimile  
20th century 
药物出产辨  
Discussions on Manufacturing Process of  Drugs 
20th century 
160 3 岭南采药录  
Understandings the Use of Herbal Medicine 
20th century 
中国实用药物  
China Clinical Practice In Herbs 
20th century 
药物图考  
Facsimiles of Herbs 
20th century 
161 2 分类饮片新参   
Types of Patent Medicine  
20th century 
国药诠证  
The Heritage of Herbs in China 
20th century 
162 
 
 
3 
 
 
马王堆医书五种  
Five Types of Ma Wang Dui Clinical Text 
3rd century 
武威汉代医简  
Wuwei Han Dynasty Clinical Text 
1st century 
敦煌出土不知名医方二十三种  
Twenty-three Unknown Buddhist Herbal Formulae 
7th century to 
10th century 
163 2 金匮要略方论  
Discussions on Synopsis of Prescriptions of the Golden Chamber 
1st century 
肘后备急方  
Use of Emergency Herbal Formulae 
4th century 
164 1 备急千金要方 
 Treasures in Emergency Formulae 
7th century 
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There are 740 volumes in ZGBCQS containing CHMs. Among them, a total of 129 out of 164 
volumes were singled out to contain information related to AR-like signs and symptoms. 
 
AR-like signs and symptoms classified were found under several genres in ZHYD, with the 
titles of the books classified under Materia Medica 本草类; medical doctrines genres 医经类; 
prescriptions genres 方书类 ; Comprehensive Materia Medica 综合本草 ; 综合方书
comprehensive collections of formulae books 综合方书; comprehensive medical genres 综合
医书类; 温病类 warm diseases 温病类; 伤寒金匮 cold damage and Jin Gui 伤寒金匮; 
comprehensive medicine 综合医书类; clinical and specialisations genres 临证各科类; diet and 
health preservation 养生食疗外治类; clinical discussions and cases 医论医案类; Chinese 
medicine dictionary 中医辞典. Out of 1,156 books in ZHYD, 94 books were found to contain 
information related to AR-like signs and symptoms (Table 20). 
 
Table 20. Summary of classical books in ZHYD containing AR-like signs and symptoms 
Genres No. of books Names of books and sections Periods 
医经类 
Medical Doctrines 
1 黄帝素问宣明论方  
Enlightened Discussion of Suwen in the 
Emperor’s Inner Canon   
3rd to 5th  
century 
本草类 
Materia Medica 
 
综合本草 
Comprehensive  
Materia Medica 
 
13 本草经集注  
Annotations of Materia Medica 
6th century 
 新修本草  
Newly Revised Materia Medica 
7th century 
 本草图经  
Materia Medica Facsimiles 
7th century 
 名医别录  
Alternative records for practice 
11th century 
 证类本草  
Syndromes of Materia Medica 
3rd to 5th  
century 
 本草品汇精要 
Essential Herbal Collections 
16th century 
 本草纲目  
Compendium of Materia Medica 
16th century 
 本草征要  
Materia Medica Evidence 
16th century 
 本草易读  
Comprehensible Materia Medica 
11th century 
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Genres No. of books Names of books and sections Periods 
 本草纲目拾遗 
Supplementary Texts to Compendium  
of Materia Medica 
18th century 
 本草崇原  
Origin of Materia Medica 
17th century 
 炮炙大法  
Comprehensive Handbook on the  
Processing of Drugs 
16th century 
 本草详节  
Interpretations of the Materia Medica 
17th century 
方书类 
Prescriptions  
genres 
综合方书 
Comprehensive 
collections of  
formulae books 
3 太平圣惠方  
Peaceful Holy Benevolent  
Prescriptions 
10th century 
孙真人海上方  
Sage’s Kong Formulae of the Sea 
7th to 10th  
century 
华佗神方 
Hua Tuo’s Divine Formulae 
16th century 
方书类 
Prescriptions  
genres 
综合方书 
Comprehensive 
collections of  
formulae books 
 
17 小品方  
Formulary of Trifles 
16th century 
苏沈良方  
Su Shen Formulae 
5th century 
圣济总录  
Sacred Compilations of  
Disseminations  
10th to 12th 
century 
鸡峰普济方  
Universal Capstone of Formulae 
12th century 
普济本事方 
Universal Formulae 
10th to 12th  
century 
妇人大全良方  
Compendium of Prenatal Formulae 
13th century 
 仁斋直指方论（附补遗） 
Addendum to Pool of Benevolence Formulae 
13th century 
  严氏济生方  
Yan Shi Ji Sheng Formulae 
13th century 
  瑞竹堂经验 
Tested Formulae of Ruizhi Hall 
13th century 
  御药院方  
Royal Hospital Medicine 
14th century 
  世医得效方  
Effective Herbal Formulae in  
Medicine 
13th century 
  是斋百一选方 
Selected Formulae by Wang Qiu Yuan 
13th to 14th 
century 
  传信适用方 
Transmissions in Formulae 
12th century 
  活人事证方后集  
Testimony of the Living Formulae 
12th century 
  卫生易简方  
Easy Formulae for Health 
10th to 13th 
century 
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Genres No. of books Names of books and sections Periods 
  普济方 
Universal Formulae 
15th century 
  
 
奇效良方  
Miraculous Formulae 
14th to 17th 
century 
方书类 
Prescriptions  
genres 
综合方书 
Comprehensive 
collections of  
formulae books 
 
16 医方考 
Medicinal Formulae 
15th century 
仁术便览  
Benevolence Handbook 
16th century 
鲁府禁方 
House of Fu Forbidden Formulae 
16th century 
祖剂  
Ancestral Decoctions 
16th century 
普济方 
Universal Formulae 
12th to 14th 
century 
证治准绳·类方 
Standards of Proven Formulae 
17th century 
扶寿精方  
Formulae for Supporting Longevity 
17th century 
 
医方选要  
Choice Herbal Medicine 
16th century 
 万氏家抄济世良方 
Wan’s Ancestral Formulae 
15th century 
  种福堂公选良方 
Hall of Zhong Fu Choice Formulae 
16th century 
  成方切用 
Explanations on Use of Patent  
Medicine 
18th century 
  太医院秘藏膏丹丸散方剂 
Secret Plaster, Pill and Powder  
Prescriptions in Imperial Academy of 
Hospital 
17th to 18th 
century 
  古方汇精 
Enlightened Discussion of Ancient  
Formulae 
19th century 
  喻选古方试验  
Experienced Selections of Ancient  
Formulae 
19th century 
  不知医必要 
Fundamentals Knowledge of  
Medicine 
19th century 
  医略抄  
Discussions on Medicine 
18th century 
方书类 
Prescriptions  
genres 
综合方书 
Comprehensive 
collections of  
formulae books 
9 历验再寿编  
Essay on Rejuvenation through the  
Ages  
20th century 
救生集  
Chapter on Rescue Medicine 
21th century 
秘方集验  
Classified Formulae 
17th century 
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Genres No. of books Names of books and sections Periods 
 
 
 
 
医方集解  
Medicinal Formulae 
17th century 
 上部病  
Upper Body Disease 
No date 
 续名家方选  
Famous Formulae 
19th century 
 外治寿世方 
External Herbal Formulae Treatment through 
the Ages 
17th to 20th 
century 
  单方验方.回 生 集  
Single Formulae 
No date 
  温病通论  
Discussions on Warm Diseases 
No date 
温病类 
Warm diseases  
genre 
1 伤寒论  
Treatise on Cold Damage Diseases  
18th century 
 
伤寒金匮类 
Cold Damage and  
Golden Chamber  
genres 
综合医书类 
Comprehensive  
medical genres 
6 诸病源候论  
Discussions of Pathogenesis of  
Diseases 
7th century 
周慎斋遗书  
Testimony of Zhou Zhen 
13th to 14th  
century 
证治汇补  
Revision of  Standards 
17th century 
医方集宜  
Formulae Edition 
14th to 17th 
century 
 丹溪治法心要  
Danxi’s Experiential Therapy 
13th to 14th  
century 
  寿世保元  
Longevity and Life Preservation 
17th century 
伤寒金匮类 
Cold Damage and  
Golden Chamber  
genres 
综合医书类 
Comprehensive  
medical genres 
10 古今医统大全  
Complete Compendium of Medical  
Works, Ancient and Modern 
16th century 
万病回春  
Recovery from All Ailments 
16th century 
明医杂著  
Famous Clinical Practice Essays 
17th century 
丹溪手镜  
Danxi’s Handbook of Reflections 
13th to 14th 
century 
张氏医通   
Zhang’s Medical Canon 
17th century 
 医学心悟  
Thoughts on Medical Practice 
18th century 
  冯氏锦囊秘录  
Feng’s Records of Secret Tips 
1tth to 18th 
century 
  医学纲目 
Compendium of Medical Practice 
14th to 18th 
century 
  医学研悦  
Exposition on Medicine 
14th to 17th 
century 
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Genres No. of books Names of books and sections Periods 
  内科通论  
Discussions on Internal Medicine 
19th century 
临证各科类 
Clinical and 
specialisations genres 
6 儿科通论  
Discussion on Pediatrics Medicine 
17th to 20th 
century 
 慈幼便览  
Charitable Guide 
No date 
  原幼心法 
Therapeutic Methods for Paediatrics 
14th to 17th 
century 
  儿科专论 
Discourse on Paediatrics 
No date 
  外科通论  
Discussions on External Medicine 
19th century 
   内科通论  
Discussion on Internal Medicine 
14th to 17th  
century 
养生食疗外治类 
Diet and health 
Preservation genres 
1 巢氏病源补养宣导法 
Chao’s Tonifying and Guiding  
Methods for Diseases 
No date 
养生食疗外治类 
Diet and health 
preservation genres  
4 养生导引秘籍  
Secrets to Health 
14th to 17th  
century 
养生导引法  
Art to Good Health 
14th to 17th  
century 
急救广生集  
Chapters on Emergency Medicine 
19th century 
  临证指南医案  
Manual on Clinical Cases 
18th century 
医论医案类 
Clinical discussions 
and cases 
4 旌孝堂医案  
Manifestations on the Clinical Cases 
No date 
临症经应录  
Records of Clinical Diagnosis 
17th to 20th  
century 
沈菊人医案 
Clinical Cases by Shen Juren 
17th to 20th  
century 
 叶天士曹仁伯何元长医案  
Yetianshi and Caorenbo Clinical  
Diagnosis 
17th to 20th  
century 
中医辞典 
CM Encyclopaedia 
2 专科专病中成药  
Patent Medicine for Specialty  
Medicine 
17th to 20th  
century 
  外用剂  
External Medicinal Decoction 
No date 
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7.3. Scoring outcomes of classical herbal formulae/herbs 
A total of 163 herbs were identified from the combined sources of ZHYD and ZGBCQS, were 
used for the management of AR-like signs and symptoms in ancient times. Ten animal products, 
three minerals and two bodily excretory products (sediment of human urine and horse urine) 
were used for the management of AR-like signs and symptoms. Animal products for AR 
treatment consist of scorpions (Figure 51), dung beetles, earthworms (Figure 52), goats’ lungs 
(Figure 53) and buffaloes’ horns (Figure 54) to treat nasal congestion, a late phase symptom 
manifestation of AR. 
 
Figure 51. Scorpions (Photograph by Kreiner, J.) 
 
 
Figure 52. Earthworms (Photograph by Kreiner, J.) 
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Figure 53. Goats' lungs (X. P. Gu 2016) 
 
 
Figure 54. Buffaloes' horns (China Medicinal Herb Suppliers, 2010) 
 
Many natural products were used to treat nasal congestion. Yellow-coloured canine meat and 
in particular yellow canine skull ash were used. Canine meat was prescribed to address nasal 
congestion arising from deficiency of the Spleen’s transport and transformation as well Kidney 
Yang deficiency. The classical texts described canine meat could invigorate the Qi and 
strengthen the Spleen and Kidney. To relieve nasal blockage, canine skull ash was administered 
by blowing into the nostrils to unblock the orifices. Three minerals Zhu Sha Liu Huang and Shi 
Lü were used to treat nasal congestion by means of blowing through the nostrils. The bodily 
secretory products include sediments of human urine (Figure 55) and horse urine (no picture 
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are available) were used to treat congested nose with runny discharge. Residues from plant soot 
scraped from a boiler (Figure 56) were also featured as one of the remedies for nasal congestion.  
 
 
Figure 55. Sediments of human urine (Baidu wiki, 2015) 
 
 
Figure 56. Plant soot residues scraped from boiler (Bao & Qi 2015) 
 
Bi Chong Shui (nasal irrigation fluid) was described to be used for nasal congestion and the 
content for this fluid was noted as unknown as it was a foreign product introduced from the 
West. The passage even described how the product should be administered for the type of 
condition associated with it (Figure 57). 
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Figure 57. Passage extract on nasal irrigation fluid (Bi Chong Shui) (Photograph by Kreiner, J.) 
 
A combined outcome of the systematic scoring in combined texts of ZGBCQS and ZHYD 
produced outcome on top five herbs used in ancient CM clinical practice were Xi Xin (132 
citations), Xin Yi (70 citations), Bai Zhi (35 citations), Bo He (31 citations) and Gua Di (31 
citations) (Table 21). 
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Table 21. Combined frequency and ranking of herbs from ZHYD and ZGBCQS 
Herbs Frequency of Citations Ranking 
Xi Xin (Asari Radix et Rhizoma) 132 1 
Xin Yi (Magnoliae Flos) 70 2 
Bai Zhi (Angelicae Dahuricae Radix) 35 3 
Bo He (Menthae Haplocalycis Herba) 31 4 
Gua Di (Pedicellus Trichosanthis) 31 4 
Gan Cao (Glycyrrhizae Radix et Rhizoma) 30 5 
Chuan Xiong (Ligustici Rhizoma) 28 6 
Fang Feng (Saposhnikoviae Radix) 28 6 
Huang Qi (Astragali Radix) 27 7 
Cang Er Zi (Xanthi Fructus) 25 8 
Sheng Jiang (Zingiberis Rhizoma Recens) 25 8 
Fu Zi (Aconiti Lateralis Radix Preparata) 22 9 
Tong Cao (Tetrapanacis Medulla) 22 9 
Jie Geng (Platycodonis Radix) 18 10 
Ren Shen (Ginseng Radix) 18 10 
Nan Xing (Arisaematis Rhizoma) 17 11 
Cong Bai (Bulbus Allii Fistulosi) 16 12 
Gan Jiang (Zingiberis Rhizoma) 16 12 
Qiang Huo (Notopterygii Rhizoma et Radix) 16 12 
Mu Tong (Akebiae Caulis) 15 13 
Bai Zhu (Atractylodis Macrocephalae Rhizoma) 14 14 
Pi Ba (Piper Longum) 14 14 
Xiong Huang (Realgar) 14 14 
Chang Pu (Rhizoma Acori Tatarinowii Rhizoma) 13 15 
Ji Li (Tribuli Fructus) 12 16 
Gui (Cinnamom Ramulus) 11 17 
Jing Jie (Schizonepetae Herba) 11 17 
Ju Hua (Chysanthemi Flos) 11 17 
Si Gua Teng Jin Geng (Pedicellis Luffa Retinervus) 11 17 
Zhi Zi (Gardeniae Fructus) 11 17 
  
198 
 
7.4. Principal component analysis of herbs  
The PCA emphasises on the correlation of variables (AR-like signs and symptoms) to the herbs 
used in the management of AR. Squared loadings in the PCA define the correlation between a 
component and a variable. Loadings impart information on the proportion of variance of the 
herbs analysed while the eigenvalues summarise the amount of information (inertia) in the PCA 
dimension. Inertia refers to the total variance of a dataset, which marks the dimension or 
distance of the correlation matrix and it also denotes the importance of the component (Abdi & 
Williams, 2010). The sum of squared coefficients of correlations between a variable (herb) and 
all the components is equal to eigenvalue of 1. When the coefficient of a component is closer 
to the centre of the plot, eigenvalue is generally less than the value of 1. Therefore this means 
the component is less important. Eigenvalue greater than 1 is considered more important. The 
loadings essentially are positioned within the circle of correlations, this correlation is 
determined by the loadings on component space (Abdi & Williams, 2010).  
 
A total of 163 herbs were analysed against 11 AR-like signs and symptoms cited in the classical 
literature: sneeze, congested nose with runny nose discharge, sinusitis, nasal congestion, itchy 
nose, allergic rhinitis, postnasal drip, listlessness, headache with eye pain, pain the nose and red 
nose. These made up the 11 components used to evaluate the effects of the herbs. Only three 
components namely, Component 1 (nasal congestion), Component 2 (congested nose with 
runny nose discharge) and Component 3 (sinusitis); were identified with eigenvalues of more 
than 1, which are 5.357, 1.235 and 1.029, respectively. The variance of the loadings for 
Components 1, 2 and 3 were 48%, 11 % and 9%, respectively. Although Component 3 
eigenvalue is more than 1, its inertia accounts for only 9.4%. Together both Components 1 and 
2 accounted for more than 60% of the variance for the loadings (Table 22). Therefore, the herbs 
with attributes of Components 1 and 2 are likely to imply better effects in the treatment of AR-
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like signs and symptoms specifically, nasal congestion and congested nose with runny 
discharge. 
 
Table 22. Total variance, loadings and eigenvalues of components 
 
The highest loadings with the characteristics of Component 1 are Xi Xin, Xin Yi, Bai Zhi, Bai 
Bu, Cang Er Zi, Chuan Xiong, Huang Qi, Fang Feng, Gua Di, Bo He and Bai Zhu (in 
descending order). All these herbs share characteristics of managing AR-like signs and 
symptoms associated with effective treatment to nasal congestion which are relative to 
Component 1. Negative loading is depicted for Bai Xian Pi in Component 1 which means that 
this herb may not necessarily be effective for the treatment of nasal congestion. Traditionally, 
in CM diagnostics, Bai Xian Pi is used to treat conditions related to oedema. Similarly, herbs 
associated with Component 2 are Chuan Xiong, Bai Xian Pi, Gua Di and Huang Qi (in 
descending order). Both Huang Qi and Gua Di have positive loadings of both Component 1 and 
2 but with stronger influence in Component 1, this could be an indication of its versatility in its 
remedies. These herbs are associated with treatment for other AR signs rather than nasal 
Components 
Initial Eigenvalues Extraction Sums of Loadings 
Total % of 
Variance 
Cumulative 
% 
Total % of 
Variance 
Cumulative % 
1 5.357 48.700 48.700 5.357 48.700 48.700 
2 1.235 11.225 59.926 1.235 11.225 59.926 
3 1.029 9.353 69.279 1.029 9.353 69.279 
4 .782 7.105 76.385    
5 .698 6.341 82.726    
6 .525 4.772 87.497    
7 .416 3.784 91.281    
8 .328 2.983 94.264    
9 .288 2.614 96.878    
10 .222 2.014 98.892    
11 .122 1.108 100.000    
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congestion. It is noted that although Chuan Xiong possesses both Component 1 and 2, it has a 
higher loadings of Component 2 (10.03312) than 1 (2.22028). This could be interpreted that it 
may be more effective in treating other AR-like signs and symptoms than nasal congestion. 
(Table 23). 
 
Table 23. Component loadings matrix of herbs  
Herbs Principal Component 1 Principal Component 2 
Xi Xin (Asari Radix et Rhizoma) 9.0156 -0.41758 
Xin Yi (Magnoliae Flos) 3.51007 -1.17409 
Bai Zhi ( Angelicae Dahuricae Radix) 3.03387 -2.24648 
Bai Bu (Stemonae Radix) 2.96231 -0.28186 
Cang Er Zi (Xanthii Fructus) 2.23757 -0.86863 
Chuan Xiong ( Ligustici Rhizoma) 2.22028 10.03312 
Huang Qi (Astragali Radix) 2.17804 0.37503 
Fang Feng (Saposhinikoviae Radix) 2.09358 -1.7895 
Gua Di (Pedicellus Trichosanthis) 1.99094 0.94858 
Bo He (Mentae Haplocalysis Herba) 1.96368 -2.30418 
Bai Zhu (Atractylodis Macrocephalae Radix) 1.42645 -0.16902 
Bai Xian Pi (Dictamni Cortex) -0.11798 2.77305 
 
In Figure 58, a distinct cluster of herbs is detectable near 0. From this, it can be interpreted that 
this group of herbs all possess the same qualities of treating AR-like signs and symptoms, which 
indicates that these herbs treat sneeze, congested nose with runny nose discharge, rhinosinusitis, 
nasal congestion, itchy nose, allergic rhinitis, postnasal drips, headache, and eye pain, pain the 
nose and red nose with the same effect. Based on the PCA, amid all the herbs evaluated, all 
herbs exhibited similar levels of efficacy but there are few variations in the treatment of the 
AR-like signs and symptoms with the exception of the few herbs such as Xin Yi, Bai Bu, Cang 
Er Zi, Chuan Xiong, Huang Qi, Fang Feng, Gua Di, Bo He and Bai Zhu. Xin Yi, having the 
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second largest loadings PC1 axis, also depicted a high pattern of association with possible 
effective treatment of nasal congestion (Figure 58). 
 
The PC1 on x-axis marks the circle of dimension at 48% while PC2 on y-axis is 11%. The PCA 
depicted the two herbs that demonstrated largest variations in PC1 and PC2, Xi Xin and Chuan 
Xiong; respectively. In fact, the huge inertia of Xi Xin on PC1 marks its dimension away from 
the rest of the herbs indicates a pattern that Xi Xin may feature a strong profile in treating AR-
like signs and symptoms, while Chuan Xiong with higher coordinates on PC2 is inversely 
correlated to Xi Xin in the treatment of AR signs and symptoms (Figure 58).  
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Figure 58. Principal component analysis of 163 herbs from ZHYD and ZGBCQS 
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7.5. Hierarchical cluster analysis of herbs  
The dendrogram is a graphical representation of cluster pattern analysis produced by SPSS 
analytics, which employs the agglomeration schedule to identify a set pattern which 
components or cases (herbs) are grouped together. Scale distance is determined by using 
squared Euclidian distance and between-groups distances to highlight importance of large 
distances and cluster all data points, respectively. The compound clusters are formed by joining 
individual compounds or existing compound clusters with the join point known as node  
(Nonlinear Dynamics, 2016). Based on the hierarchical analytics, three clusters were identified 
with herbs Qing Mo to Chang Pu grouped cluster 1, Pi Ba to Xiong Huang in cluster 2 and 
cluster 3 included only Xin Yi and Xi Xin (Table 24). Cluster 1 demonstrates that all the herbs 
were similar in their effects. Cluster 1 and Cluster 3 indicated no significant clustering with the 
exception that Xin Yi was merged with cluster 1, which may be due to the fact that Xin Yi 
shared the same characteristics in treating AR-like conditions. Yet, cluster 3 was markedly 
dissimilar from the rest of the herbs. Overall, the pattern clusters demonstrated although all the 
herbs are likely to treat AR-like and symptoms, except Xin Yi and Xi Xin are different. Both 
Xi Xin and Xin Yi are regarded as outliers. Although is clustered as an outliers, Xin Yi is 
correlated with cluster 2 herbs such as Pi Ba, Sheng Jiang, Tong Cao, Bo He, Fang Feng, Gua 
Di, Bai Zhi, Gan Cao, Cang Er Zi, Chuan Xiong, Huang Qi, Fu Zi, Jie Gen, Nan Xing, Cong 
Bai, Mu Tong, Gan Jiang, Ren Shen, Qiang Huo and Xiong Huang. This could be interpreted 
that Xi Xin has similar effects on the components 1 and 2 with linkage to the aforementioned 
herbs and Xin Yi (Figure 59). 
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Table 24. Lists of clustered herbs extracted from dendrogram 
Cluster 1 Cluster 2 Cluster 3 
 Fu Di Qing Mo (*) 
 Zhu Ye (Callicarpae 
Formosanae Folium) 
 Ma You (Sesame oil)) 
 Shi Gao (Gypsum Fibrosum) 
 Mai Dong (Ophiopogonis 
Radix) 
 Cong Xian (Garlic juice) 
 Ma Niao (Horse urine) 
 Ze Zi Gen (*) 
 Bi Ma Ren (Ricini Semen) 
 Pi Pa Ye (Eriobotryae Folium) 
 Ya Cao (Commelinae Herba) 
 Da Suan (Garlic) 
 Gao Ben (Ligustici Rhizoma et 
Radix) 
 Zhi Gan Cao (Glycyrrhizae 
Radix et Rhizoma) 
 Zhi Shi (Aurantii Fructus 
Immaturus) 
 Chen Ju Pi (Citri Reticulatae 
Pericarpium) 
 Gan Song (Nardostachyos 
Radix et Rhizoma) 
 Yuan Zhi (Polygalae Radix) 
 Ou Jie Hui (Nelumbinis 
Rhizomatis Nodus-ash) 
 Ting Xiang (Clove) 
 Gan Hu Lu ( Trigonellae Foeni-
graeci) 
 Po Xiao (*) 
 Zao Jiao (Gleditsiae) 
 Da Huang (Rhei Radix et 
Rhizoma) 
 Ji Zi (Chicken) 
 Mu Xiang (Aucklandiae Radix) 
 Shi Xiao (*) 
 Liu Huang (Sulfur) 
 Chuan Wu (Aconiti Radix) 
 Gua Zi Ren (Trichosanthis 
Semen) 
 Huo Po (Magnoliae Officinalis 
Cortex) 
 Jiang Can (Bombyx 
Batryticatus) 
 Cang Tui (Cicadae 
Periostracum) 
 Huo Xiang Ye (Agastaches 
Herba Folium) 
 Da Zao (Jujubae Fructus) 
 Qian Hu (Peucedani Radix) 
 Lian Qiao (Forsythiae Fructus) 
 Yuan Shen (*) 
 Bai Shao (Paeoniae Radix 
Alba) 
 Shu Jiao (*) 
 Tian Dong (Asparagi Radix) 
 Bi Ba (Piperis Longi 
Fructus) 
 Sheng Jiang (Zingiberis 
Rhizoma Recens) 
 Tong Cao (Tetrapanacis 
Medulla) 
 Bo He (Menthae 
Haplocalycis Herba) 
 Fang Feng (Saposhnikoviae 
Radix) 
 Gua Di (Pedicellus 
Trichosanthis) 
 Bai Zhi (Angelicae 
Dahuricae Radix) 
 Gan Cao (Glycyrrhizae 
Radix et Rhizoma) 
 Cang Er Zi (Xanthii Fructus) 
 Chuan Xiong (Ligustici 
Rhizoma) 
 Huang Qi (Astragli Radix) 
 Fu Zi (Aconiti Lateralis 
Radix Praeparata) 
 Jie Geng (Platycodonis 
Radix) 
 Nan Xing (Arisaema Cum 
Bile/Arisaematis Rhizoma) 
 Cong Bai (Bulbus Allii) 
 Mu Tong (Akebiae Caulis) 
 Gan Jiang (Zingiberis 
Rhizoma) 
 Ren Shen (Ginseng Radix et 
Rhizoma) 
 Qiang Huo (Notopterygii 
Rhizoma et Radix) 
 Xiong Huang (Realgar) 
 
 Xi Xin (Asari Radix et 
Rhizoma) 
 Xin Xi (Magnoliae Flos) 
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Cluster 1 Cluster 2 Cluster 3 
 Long Nao Xiang (*) 
 Qing Shou Cao Hua Sheng 
(Hand-fried peanuts) 
 Mu Gua (Chaenomelis Fructus) 
 Gou Tou Hui ( Canine skull-
ash) 
 Ai Ye (Artemisiae Argyi 
Folium) 
 Shi Lü (Jadeite) 
 Yang Fei (Goat’s Lungs) 
 Zhu Ya (Pig’s teeth) 
 Shui Jin (*) 
 Xuan Shen (Scrophulariae 
Radix) 
 Qiang Liang (*) 
 Qing Yu Dan (*) 
 Li Lu (*) 
 Man Jing Zi (Viticis Fructus) 
 Ku Qin (*) 
 Kuan Dong Hua (Farfarae 
Flos) 
 He Zi (Chebulae Fructus) 
 Ji Zi Jing (Chicken essence) 
 Dou Chi (*) 
 Fu Mo (*) 
 Bing Lang (Arecae Semen) 
 Bei Zi (*) 
 Tie Fen (Iron powder) 
 Bei Bu (*) 
 Ku Gua (*) 
 Chai Hu (Bupleuri Radix) 
 Gan Ju (*) 
 Sang Ji Hua Rui (Taxilli) 
 Tie Suo (Iron) 
 Chuan Jiao (*) 
 Quan Xie (Scorpion) 
 Ren Zhong Bai (Human urinary 
sediments) 
 Ma Zi Ren (*) 
 Qiu Yin (Earthworm) 
 Geng Mi (Cooked rice) 
 Yang Sui (*) 
 Zhen Zhu (Margarita) 
 Hai Er Cha (Catechu) 
 Hua Fen (*) 
 Di Yu (Sanguisorbae Radix) 
 Lu Er (*) 
 Qing Niu Jiao (Bubali Cornu) 
 Fu Ling (Poria) 
 Xun Cao (*) 
 Zao Jia (*) 
 Xiao Ji (Cirsii Herba) 
 Zhu Sha (Cinnabaris) 
 Bi Cheng Qie (Litseae Fructus) 
 Lu Xiang (*) 
 Fu Di Mo Shui (*) 
 Shan Zhu Yu (Corni Fructus) 
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Cluster 1 Cluster 2 Cluster 3 
 Dang Gui (Angelicae Sinensis 
Radix) 
 Fan Shi (*) 
 Shi Hu (Dendrobii Caulis) 
 Rou Gui (Cinnamomi Cortex) 
 Su Ye (Perillae Folium) 
 Gou Rou (Canine’s meat) 
 Ku Fan (*) 
 Shao Mo Xue Hui (*) 
 Bi Ma Zi (Ricini Semen) 
 Huang Lian (Coptidis Rhizoma) 
 Qing Niu Xi (*) 
 Cang Zhu (Atractylodis 
Rhizoma) 
 Jiu Qin (Alcohol essence) 
 Xin Yi Ren (*) 
 Bei Mu (Fritillariae 
Ussuriensis Bulbus/ Fritillariae 
Thunbergii Bulbus ) 
 Xiang Fu (Cyperi Rhizoma) 
 Di Huang (Rehmanniae Radix) 
 Ku Shen (Sophorae 
Flavescentis Radix) 
 Tao Ren (Persicae Semen) 
 Bai Fan (*) 
 Lu Xiang (*) 
 Cao Tou Wu (Aconiti 
Kusnezoffii Radix) 
 Huang Dan (*) 
 Ge Gen (Puerariae Lobatae 
Radix) 
 Jing Jie (Schizonepetae Herba) 
 Zhi Zi (Gardeniae Fructus) 
 Ma Huang (Ephedrae Herba) 
 Gui (Cinnamomi Ramulus) 
 Rui He (*) 
 Gui Xin (*) 
 Ban Xia (Pinelliae Rhizoma) 
 Ji Li (Tribuli Fructus) 
 Sheng Ma (Cimicifugae 
Rhizoma) 
 E Bu Shi Cao (Centipedae 
Herba) 
 Gan Shi (*) 
 Ju Hua (Chrysanthemi Flos) 
 Bai Zhu (Atractylodis 
Macrocephalae Rhizoma) 
 Chang Pu (Acori Tatarinowii 
Rhizoma) 
 
* Latin names were not available 
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Figure 59. Dendrogram using average linkage (between groups) rescaled distance cluster combined 
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7.6. Discussion 
Each of the volumes of ZGBCQS may consist of more than one book. It is not uncommon to 
expect that same books in different collections may have the same titles (May et al., 2013). 
However, the content may be presented differently. Both ZHYD and ZGBCQS, the former 
being digital format and the latter in paperback hardcopies, do not contain any index nor a 
structured list of titles of books for access. The ZHYD sorely lacks bibliographic data for the 
purpose of referencing and systematic search (May et al., 2013). The lack of bibliographic data 
in ZGBCQS and index of non-structured list of titles in ZHYD are in part due to nature of the 
articles or writings presented in these texts. Each citation of the articles is a representation of a 
clinical instance which was recorded by the author(s) or author-clinician(s). It is common to 
find disparate writings by author(s) and clinician-author(s) in small parts with excerpts of their 
knowledge and findings recorded in the classical texts years later after the original writer had 
passed on. Many of the texts were compiled together under same titles with contributions from 
different writers with little information of the dates, rendering structured indexing an arduous 
task for research purposes. Moreover, interpretation of these medical texts is also subjected to 
many challenges: vocabulary, semantics, and lexical context. 
  
Chinese medical historical texts, ZHYD and ZGBCQS, both are of great significance and 
relevance in the clinical practice of CM. Connotative descriptions of syndromes in CM stem 
from these texts and are still used in current practice. Although these CM historical diagnoses 
may not fit the framework of modern medicine, its context is still meaningful in disease 
treatment. It provides a backdrop to the types of disease to which the treatments were used, and 
an insight to the types of natural products that were effective. Most importantly, it creates 
opportunities to identify conditions that could parallel modern biological diseases that still lack 
the right drug efficacy.  
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The reliability of retrospective diagnosis derived from these historical texts is dependent on 
several factors: eye-witness testimony; clear descriptions of signs and symptoms of the disease, 
and minimal evidence for modifying description to match medical views of period, presence of 
one or more virtually diagnostic symptoms, and record of any epidemiological observation 
given (Mitchell, 2011). From a CM clinical perspective, the retrospective diagnoses in the CM 
medical texts are able to fulfil the criteria for reliability. It is important to highlight that this 
project does not entail an exercise of textual analysis but to conduct a text mining extracting 
data on the citations of AR-like signs and symptoms.  
 
 A total of 163 herbs were identified for the management for AR-like signs and symptoms in 
the CM classical texts which were closely associated with AR in modern diagnosis. Component 
analysis indicated all the herbs consisted of homogenous characteristics in treating AR-like 
signs and symptoms. This could be interpreted that either all herbs were just as effective in 
treating AR-like symptoms or not at all. Herbs with eigenvalue of greater than 1 on x-axis is of 
a level of significance, namely; Xi Xin, Xin Yi, Bai Zhi, Fang Feng, Huang Qi, Fang Feng, 
Cang Er Zi, Bai Zhu, Bo He, Gan Cao and Gua Di. All of these herbs share prevailing 
characteristics of Component 1 which may address certain traits in addressing AR-like signs 
and symptoms. Only two herbs exhibited great variations; Xi Xin (Component 1) and Chuan 
Xiong (Component 2). The magnitude on the x-axis which highlights the vast distance from the 
rest of the herbs indicates Xi Xin is entirely dissimilar and could potentially consist of 
characteristics of more than addressing AR-like signs and symptoms. The Euclidean distance 
showed a near 10-fold inertia for Chuan Xiong and Xi Xin from the rest of the herbs. The 
effectiveness of Xi Xin has been described as miraculous (Shen Xiao; 神效) in the classical 
texts. It has the attributes of not just treating nasal congestion but the varied types of conditions 
associated with nasal congestion and severe nose blockage such as yellow-green discharge (a 
sign of inflammatory infection) and clear runny nasal discharge. Aside from treating AR-like 
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symptoms, descriptions matching dyspnoea and chest discomfort were also associated with Xi 
Xin. In contrast, Chuan Xiong leans closer to the y-axis with strong influence of Component 2. 
The variation of the component is lesser than Xi Xin, it is differentiated from the other herbs 
based on the proximity to the y-axis in the pattern analysis. The inclusion of Chuan Xiong in 
the classical texts and its variance of 12% is an indication of its limited role in treatment of AR 
compared to Xi Xin.  
 
The HCA in the dendrogram appears to have its own set pattern of clustering herbs for its 
remedies. Almost all the herbs share a similar remedy for AR-like management. A total of 139 
herbs are grouped in cluster 1 with join node of less than 1, indicating little difference amongst 
the herbs in its function for treatment. The graphical representation showed two outliers which 
are on its own; Xi Xin and Xin Yi. Both of these herbs are distinct in its management of 
treatment of AR signs and symptoms. Particularly, these two herbs have also been identified as 
most commonly used herbs used for AR management in the SR of modern clinical studies. It 
would be meaningful to analyse the characteristics of both Component 1 and Component 2 in 
these herbs further either in pharmacological, clinical or genotyping analyses to further 
determine their variations in their respective clusters.  
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Chapter 8  General discussion 
 
This chapter discusses the results of the reviews of clinical studies, experimental and classical 
literature in this project as well as the applicability and quality of the evidence. 
 
8.1. Summary of main results 
The SR provided a deep insight as to the effects of CHM for the treatment of AR in RCTs. A 
total of 62 RCTs were included in the SR according to selection criteria and all except one 
(Jiang 1997) were included in the meta-analyses as it did not apply any continuous or 
dichotomous data for quantifying its results. The comparisons consisted of CHM versus 
placebo, WM or other therapies, with or without co-interventions. The outcome measures 
composed of five domains: improvement of symptoms, quality of life, rescue medication use, 
IgE levels and adverse events. Durations of immediate, short-term, intermediate and long-term 
were also used as yardstick for the measure of the domains when possible. The outcome of this 
review presented mixed results for the clinical effects of CHM. 
 
The scientific community has long regarded the randomised, double-blind, placebo-controlled 
clinical trial as the “gold standard” of scientific methodology for testing therapeutic effects of 
interventions (West et al., 2010). Eight included studies adopted such ideal design. However, 
due to the diverse outcome measures selected across those studies, data synthesis was unlikely 
performed. 
 
Promising results surfaced in the comparison of CHM versus Western medicine. Meta-analyses 
reflected significant clinical effects of CHM for global symptom improvement at immediate 
(15 trials), short-term (14 trials), intermediate (four trials) but not long-term (four trials) follow-
ups. Particularly, subgroup analyses demonstrated CHM was more beneficial for global 
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symptom improvement when compared to orally taken anti-histamines (including Cetirizine, 
Hismanal, Ketotifen, Loratadine, Desloratadine and Triprolidine) for immediate (11 trials) and 
short-term (nine trials) follow-up. It is noted that Hismanal (Astemizole) was discontinued in 
the US in 1999 due to cardiovascular risks and its adverse effects according to the Food and 
Drug Administration (U.S. Food and Drug Administration, 1999). When CHM was combined 
with other therapy in comparison to same other therapy alone, CHM demonstrated more 
additional effects in improving global symptom across all duration of follow-ups.  
 
Although CM provides individualised treatment to patients with a focus on the differentiation 
of syndrome, this protocol was only incorporated in less than 7% of included studies (four out 
of 62 RCTs). Due to the limited studies, it is not surprising that synthesised data could not 
illustrate CHM combined group’s effects for subgroup studies involving syndrome 
differentiation when compared to those studies without syndrome differentiation.  
 
In terms of quality of life, CHM was highly favourable for PAR in physical functioning, 
physical role and general health. IgE levels tended to favour WM, however, there was no direct 
correlation between the total serum IgE concentration and the symptom improvement. Further 
meta-analysis could not be conducted on use of rescue medication (95% of studies), quality of 
life (94% of studies) and IgE domains (98% of studies) as a lack of data existed in the RCTs. 
No severe adverse events were noticed across all the included studies. 
 
The overall findings of the SR of RCTs demonstrated that CHM might be effective and safe for 
AR management when used orally on its own or as an adjunct therapy to WM. However, it is 
important to note that the positive results could essentially be interfered by high/unclear risk of 
bias in the studies. The promising results should be interpreted with great caution. 
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The text mining exercise of classical texts provided an invaluable insight into retrospective 
diagnosis and the remedies for AR.  A total of 1,687 articles were identified with descriptions 
related to AR-like signs and symptoms. Both the PCA and HCA demonstrated a few herbs 
might share similar components which facilitated the efficacy of AR. Component 1 herbs were 
Xi Xin, Xin Yi, Bai Zhi, Bai Bu, Cang Er Zi, Chuan Xiong, Fang Feng, Huang Qi, Gua Di, Bo 
He and Bai Zhu (in descending order) with Component 2 influence in Chuan Xiong, Bai Xian 
Pi, Gua Di and Huang Qi (in descending order). The dendrogram also definitively cast Xi Xin 
as one of the outliers along with Xin Yi. While the clustering analysis demonstrates all the other 
herbs were able to provide the similar effects. Xi Xin was distinctive on its own. However, Xi 
Xin is famed for its dose-related adverse effects. Experimental results have demonstrated that 
AA-I in Xi Xin was within 3.1 mg to 26.6 mg, indicating negligible levels of toxicity. AA-I 
toxicity was concentrated, in the aerial parts rather than the roots, and in methanol extracts than 
water extracts. Water extraction which is synonymous to decoction preparation could further 
reduce the toxicity. Statistical significance indicated Xi Xin could possibly be able to provide 
more than just mere remedy of AR symptoms. Based on these results, this could be the platform 
for future studies to explore the compounds and the pharmacological targets, and dose-related 
safety of Xi Xin in order to ascertain its effects. A rationale based risk-benefit assessment on 
and regulated prescription of Xi Xin under scheduled drugs would be a better justification than 
the current blanket ban of this herb. 
 
It is undoubtable that evidence in both modern literature and classical texts suggest CHM could 
be a good form of remedy for the treatment of AR. In spite of the heterogeneity, varied 
experimental studies demonstrated the naturally occurring compounds have more to offer than 
just mere management of AR. 
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8.2. Overall completeness and applicability of evidence 
This rigorous SR is extensive and comprehensive in its search and meta-analyses. Searches 
included 17 English and three Chinese databases to identify all the up-to-date RCTs. Varied 
forms of Chinese herbs with oral and/or external administration for the treatment of patients 
with SAR and/or PAR of any age were also considered. Nearly 75% of the studies (47 out of 
62) did not categorise their participants into SAR or PAR and as a result, these studies were 
excluded from subgroup analysis according to the classification of AR. Except for seven studies 
did not provide age details of participants, more than 50% of the remaining RCTs mixed the 
children and adults as their subjects. This rendered subgroup analysis as per age group 
unfeasible. 
 
The CHMs that were popular in the RCTs differ from those of the classical texts. A comparison 
of the top ten herbs used for the management of AR in the SR and classical literature are 
summarised below (Table 24). It is noted that seven common herbs have been identified during 
the process of this project. They are: Huang Qi, Fang Feng, Xin Yi, Bai Zhi, Cang Er Zi, Gan 
Cao and Xi Xin.  
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Table 25. Comparisons of top ten herbs used for the management of AR in the SR and classical literature 
Rank Top ten herbs from SR Top ten herbs from classical literature 
1. Huang Qi (Astragali Radix) Xi Xin(Asari Radix et Rhizoma) 
2. Fang Feng (Saposhnikoviae Radix) Xin Yi (Magnoliae Flos) 
3. Xin Yi (Magnoliae Flos) 
Bai Zhi (Angelicae Dahuricae Radix) 
Bai Zhi (Angelicae Dahuricae Radix) 
4. Cang Er Zi (Xanthii Fructus) Bo He (Menthae Haplocalycis Herba) 
Gua Di (Pedicellus Trichosanthis) 
5. Gan Cao (Glycyrrhizae Radix et Rhizoma) Gan Cao (Glycyrrhizae Radix et Rhizoma) 
6. Xi Xin (Asari Radix et Rhizoma) Chuan Xiong (Ligustici Rhizoma) 
Fang Feng (Saposhnikoviae Radix) 
7. Dang Shen (Codonopsis Radix) Huang Qi (Astragali Radix) 
8. Wu Wei Zi (Schisandrae Chinensis Fructus) Cang Er Zi (Xanthi Fructus) 
Sheng Jiang (Zingiberis Rhizoma Recens) 
9. He Zi (Chebulae Fructus) Fu Zi (Aconiti Lateralis Radix Preparata) 
Tong Cao (Tetrapanacis Medulla) 
10. Chan Tui/yi (Cicadae Periostracum) Jie Geng (Platycodonis Radix) 
Ren Shen (Ginseng Radix) 
 
It is worth noting that the seven herbs used in the modern times were similar in ancient times 
by the CM physicians. In CM diagnostics, the combination of Huang Qi, Fang Feng, Xin Yi, 
Bai Zhi and Cang Er Zi is indicated to protect tonify Qi, dispel dampness, protect the Wei Qi 
and secure the exterior. Xi Xin warms the Lung and transforms phlegm. Gan Cao is commonly 
used to harmonise the formulation; but as a herb it can tonify the Spleen, reinforce Qi and stop 
cough. The substitution of Ren Shen in RCTs in the place of Dang Shen (as both herbs tonify 
Qi) is clear, as Ren Shen is extremely costly in current times. It could be seen from Table 24 
that CM physicians of the past prescribed warm herbs Sheng Jiang and Fu Zi to AR patients as 
cold predominates the CM pathogenesis of AR. Fu Zi is deemed in CM to possess excellent 
properties of warming the interior and expelling cold; however, this herb is banned in many 
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countries due to its toxicity. Gua Di, Tong Cao and Jie Geng can relieve nasal congestion. 
Current use of Wu Wei Zi and He Zi targets astringing where it is deemed these herbs constrain 
the Lung Qi and stop coughing. Chan Tui relieved wind-heat (a condition which wind-cold 
transformed into) and itchiness in AR. In contrast, Bo He was used to relieve wind-heat in 
ancient times. 
 
The data mining of the classical literature reflected Xi Xin as the top choice herb used by CM 
physicians in ancient times whereas Huang Qi has replaced Xi Xin in modern days. The use of 
Xi Xin in modern RCTs has relegated in part due to the strict regulatory restriction owing to 
the outcome of the scientific research of its toxic properties. In mainland China, the dosage is 
restricted within 1 to 3 g. This herb is currently scheduled in Australia and Europe. The popular 
use of Huang Qi could largely be attributed to its capabilities to tonify Qi, to rectify a major 
complaint of fatigue syndrome that often accompanies AR symptoms.  
 
The RCTs conducted in mainland China tended to focus on the effective rate to present CHM’s 
effects whilst the RCTs performed outside mainland China assessed CHM’s effects with 
different outcome measures (such as symptom score, quality of life and rescue medication 
score) by completing questionnaires. The effective rate is a composite outcome measure which 
has some limitations. For instance, the total effective rate was used to represent the global 
symptom improvement which makes changes of individual symptoms invisible and it is 
difficult to determine which component CHMs took effects on. Separate reporting of each 
individual symptom will make comparison of different studies feasible and further provide 
more detailed evidence to clinical practice. The use of the effective rate as an outcome 
assessment indicator may be due to lack of validated instrument for the measurement. 
Therefore, guidelines with appropriate outcome assessment tools need to be developed and 
promoted to facilitate clinical practice and research. 
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Due to the large variety of confounding variables, such as age (two to 82), sample size (20 to 
564), treatment period (from two weeks to three months), different formulations and low quality 
of evidence for the outcomes (more discussion in 8.3), no ideal standard treatment regime for 
AR management can be determined. 
 
8.3. Quality of evidence  
All the included studies are embedded with methodological limitations and the quality of 
evidence was consistently low across the board. 
 
Methodological issues are reflected by high or unclear risk of bias in selection (random 
sequence and/or allocation concealment), performance (except RCTs comparing CHM with 
placebo), detection, attrition and reporting across all the studies. It is noteworthy that the RCTs 
comparing CHM with placebo demonstrated relatively better quality. All these studies adopted 
double-blind design which led to low risk of performance bias. Three of them had low risk of 
selection bias for allocation concealment (Baba 1995; Hu 2002; Matkovic 2010). Particularly, 
the Baba 1995 study was a multi-centre (62 centres) and large scale (n = 220) RCT. However, 
the quality of trials comparing CHM with conventional therapies (drugs or immunotherapy), or 
CHM plus other therapy with same other therapy only, with or without co-interventions, was 
generally low or very low. 
 
Confounding variables in quality of reporting, participant attributes (i.e. age, gender, diagnosis, 
co-morbidity) and treatment protocol (i.e. co-intervention, formulation, treatment protocol) 
may contribute to the substantial clinical heterogeneity in this review. Clinical heterogeneity, 
also described as clinical diversity is mainly due to the variability in the participants, 
interventions and outcomes (Higgins & Green, 2011). Patient level data in the studies are sorely 
lacking in these RCTs. The Agency of Healthcare Research and Quality recommends analysis 
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of individual patient-level data in meta-analysis for better assessment of clinical heterogeneity 
(West et al., 2010). Despite the presence of statistical heterogeneity arising from clinical 
heterogeneity, CHMs for AR seem effective as an adjunct therapeutic option. It is transparent 
that based on the evidence of the SR, more rigorously designed RCTs are needed. 
 
8.4. Comparative scrutiny with other studies/reviews 
Insofar, only two reviews have been conducted in relations to CHM for the management of AR 
(Guo, Pittler, & Ernst, 2007; S. Wang, Tang, Qian, & Fan, 2012). Guo and his colleagues (2007) 
conducted a search on six English databases but did not affix a commencement date for the 
literature except for the end date (no date mentioned to Nov 2005) whilst Wang and her 
colleagues S. Wang et al. (2012) accessed three English databases (from 1999 to Jan 2011) and 
two Chinese databases (1999 to Feb 2011). The current review performed a more 
comprehensive literature search for 17 English databases and three Chinese databases (from 
respective inceptions to April 2016). The Guo 2007 review evaluated a spectrum of 
phytomedicinal herbs from traditional to Western herbs; RCTs included were placebo 
controlled or controlled against another active treatment. There was no information on the 
subgroup analysis conducted specifically for CHM. Wang and her colleagues (2012) narrowed 
the assessment of RCTs to comparison of CHM to placebo for PAR only. The extent of the 
scope of analysis has limited a spectrum of the AR conditions such as SAR. 
 
The Guo 2007 review included 16 double-blind RCTs, covering both Western and Chinese 
herbs. Three trials using Chinese herbs in Guo’s review were also included in the current review 
(Baba 1995; Hu 2002; Xue 2003a). The Guo’s review applied Jadad’s five-point scale to 
evaluate the methodological quality of includes studies and those three RCTs were given a 
score; four, five and five, respectively. The current review adopted the Cochrane Handbook’s 
instructions and assessed the risk of bias of each study. More than 90% of the studies consist of 
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unclear risk of bias in selection (allocation concealment) and performance as well as in 
categories of selection (random sequence generation), detection, attrition and reporting. Baba 
1995 had low risk of bias in selection (allocation concealment) and performance, and unclear 
risk of bias in selection (random sequence generation), detection, attrition and reporting. The 
Hu 2002 trial had low risk of bias in selection (both random sequence generation and allocation 
concealment), performance and detection, unclear risk of reporting bias and high risk of attrition 
bias. The Xue 2003a study had low risk of selection bias (random sequence generation) and 
performance bias, unclear risk of selection bias (allocation concealment), detection and 
reporting bias, and high risk of attrition bias.  
 
The Wang 2012 review also applied Jadad’s quality assessment for seven PAR trials in the 
meta-analysis. It reported a positive outcome for CHM in decreasing nasal symptom for all 
studies (Chui 2010; Hu 2002; Yang 2008; Yang 2010; Zhang 2004; Zhao 2009) when compared 
to placebo, except for Jung 2011 (Wang et al, 2012). It is important to note that four trials 
(Zhang 2004; Yang 2008; Yang 2010; Chui 2010) were not included studies in this current SR. 
Different selection criteria were the main reason for the exclusion of these trials. These trials 
did not qualify the criteria set out in this review. The inclusion of Zhang 2004 in Wang 2012 
review raised question about their selection criteria as the comparison in the study involved 
active intervention (CHM formula) in the treatment group versus (another CHM formula-Ping 
Wei San) in the control group. Similarly, in Chui 2009, the comparison was active intervention 
(CHM external) vs (CHM herbs – Di Huang and Dang Shen). Although the writers mentioned 
that in Chui 2010, the two herbs in the control group (Di Huang and Dang Shen) were of no 
specific value to treatment. Particularly, evidence in this project have indicated that Dang Shen 
was identified as one of the top ten herbs used in ancient times to manage AR-like signs and 
symptoms. Moreover, it is worth noting that all herbs possess bioactive value, least to say, Di 
Huang and Dang Shen. Unclear inclusion criteria could render an invalid and inaccurate 
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analysis. Further, the Wang 2012 SR was limited, as the focus was on PAR studies. SAR trials 
were not included in the review, which is an important spectrum of AR. The non-inclusion of 
SAR limits the scope of the meta-analyses within the entire review of CHM used for the 
management of AR. 
 
Similar to the previous reviews, this current SR also found some promising results of CHMs 
for treating AR. However, due to the high/unclear risks of bias and substantial heterogeneity 
across the included studies, large scale RCTs with rigorous design are required to confirm the 
findings.  
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Chapter 9  General conclusions 
 
This chapter provides an overview of main achievements, strengths and limitations for the entire 
project on CHM for the management of AR and its implications for clinical practice and future 
research. 
 
9.1. Main achievements 
This project investigated the clinical effects and safety of CHM for AR management by 
conducting three reviews on SR on modern clinical and experimental studies as well as classical 
literature. The SR is an all-encompassing in its review approach employing rigours in Cochrane 
reviews of interventions. All systematic evaluations in the different types of AR, types of 
interventions, different duration follow-ups and risks of bias of the 62 RCTs are covered in the 
criteria. This is also the only SR that covers the entire of the spectrum of AR modern literature 
search (up to April 2016). The findings of the SR have identified some positive results of CHM 
for AR management as well as methodological weaknesses in the included studies. 
 
The experimental studies reviewed all recently published in vivo and in vitro studies. The 
inclusion of WHO-selected medicinal herbs (only two of the herbs, Huang Qi and Xin Yi) 
provided a complete picture of the mechanisms of the five herbs identified from the SR. 
 
The exhaustive search on the ZHYD and ZGBCQS which covered 1,687 articles with 294 
articles yielded results of 163 herbs used for the management of AR in retrospective diagnoses. 
Analyses encompass not just mere frequency of citations but further analytics were undertaken 
to evaluate their potential for the management of AR. 
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9.2. Strengths and limitations 
9.2.1. Strengths of the study 
This project is a convergence of three reviews: a SR, a review of experimental studies and a 
review of the classical literature. The seamless progression of analyses of these three reviews 
provided a three-dimensional perspective, which no other projects have been undertaken. The 
SR provides a perspective on the outcomes of CHMs used in the RCTs and CHM’s effects and 
safety while the review of the classical texts casts an insight into the types of herbs and usage 
in the treatment of AR-like signs and symptoms by means of modern analytics. Last, a review 
of the experimental studies provides a pharmacological perspective onto their multiple 
efficacies aside from treatment of AR. Much research has been carried out to screen herbs for 
its chemical compounds however, not all the research fulfils the strict rigours of specimen 
protocol. This review sets out strict criteria in the paper selections adhering to scientific 
standards for evaluation. This approach is to ensure scientific rigours on the process of 
screening the herbs are accurate without issues of contaminants. 
 
9.2.2. Limitations of the study 
Attempts to avoid bias during the review process by the reviewers (JK and AY) were strictly 
respected. However, potential bias may still exist owing to limited access to the databases other 
than English and Chinese languages. One Japanese study was translated by a staffer (AT). 
Overall, literature was limited to English and Chinese language databases due to language 
barrier in this project. It is possible that researchers in other Asian countries (such as Korea and 
Japan) might have conducted a number of clinical studies in CM. In view of the lack of 
resources on the part of the reviewers, existing studies in AR may not be identified in this 
current review. 
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Many subgroup analyses have been carried out in terms of types of AR, types of comparisons, 
myriad drug interventions, different assessment points and use of syndrome differentiation. One 
glaring difficulty was to conduct a subgroup analysis according to age groups as majority of 
studies involved participants with mixed age ranging from two to 80 plus years without 
providing stratified data.  
 
The review for the experimental studies only evaluated the mechanisms of actions based on 
five top commonly used herbs for the treatment of AR from the RCTs. These five herbs are 
significant in the CHM for their effects and overall results unveil its versatility in targeting other 
system biology of diseases. Based on the results from the classical and modern literature, there 
are more herbs used in AR management, however, owing to the scope of this project, the review 
is confined to five herbs only.  
 
9.3. Implication for clinical practice  
Owing to the large variables, high heterogeneity and high/unclear risk of bias across the 62 
included studies in SR, it is impossible to develop a standard treatment protocol of CHM for 
AR management to assist clinical practice.  
  
The outcome of this project demonstrated CHMs, as an adjunct therapy could relieve AR signs 
and symptoms. CHMs oral and external when combined with WM oral and external were highly 
effective. However, there is no definitive conclusion to single out the most effective herb nor a 
standard formula, as varied herbal formulae administered in myriad forms were employed in 
the included RCTs. But results from herbs derived from the classical texts using analytics 
indicated Xi Xin could have the potential to offer relief for AR. Yupingfengsan (a wind-averting 
formula) was most commonly used in this review, with its three ingredients: Huang Qi 
(Astragali Radix), Fang Feng (Saposhnikoviae Radix) and Bai Zhu (Atractylodis 
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Macrocephalae Rhizoma). This herbal formula can be modified to fit the syndrome 
differentiation for the different types of AR in clinical practice. Practitioners need to be aware 
that AR’s diagnosis, definition and physiological construct differ vastly from that of the models 
in Western medicine. Slow onset and prolonged effects of the bioactivities of herbal medicine 
proven in the experimental studies should be taken into consideration in assessment of CHMs 
for AR. When using toxic herbs such as Cang Er Zi and Xi Xin by products, toxicities leading 
to renal failures and carcinomas are real and evidence based. Considerations for use of Xi Xin 
could be rescheduled by the policymakers in the wake of the evidence presented in this review. 
For practitioners, deliberate caution should be exercised when dispensing Cang Er Zi or 
formulating with Cang Er Zi. High dosage and prolonged use should be avoided. 
 
9.4. Implication for future research 
This SR had discovered many weaknesses of RCTs in relation to sequence allocation 
generation, allocation concealment, blinding process of participants, personnel and outcome 
assessors, completeness of the outcome data, possibility of selective outcome reporting and 
other sources of reporting bias in the process of conducting a RCT. It is endeavoured that future 
RCTs are strongly advised to address these weaknesses before launching a RCT. Design 
protocols are highly recommended for all AR RCTs to avoid discrepancies between the design 
and the conduct.  
 
The SR for AR also highlights one aspect of CM, which is the importance of syndrome 
differentiation for herbal formulation in RCTs. Syndrome differentiation is one of the key 
features in CM diagnosis and treatment. However, this has not been implemented in the design 
of RCTs. Although the subgroup analysis did not show distinctive difference in clinical effects 
when employing syndrome differentiation, this may be due to small number of included trials 
with syndrome differentiation as compared to those without it. Owing to the varied forms of 
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herbal administrations and the lack of syndrome differentiation, it is possible that the success 
of the treatment group is diminished. It is recommended that more trials with syndrome 
differentiation are required to render an accurate analysis of the effects of CHM. 
 
In addition, there are seven common CHMs identified in the reviews of the RCTs and classical 
literature for effective management of AR. It is endeavoured that further clinical studies could 
be carried out on the testing the mechanisms of other herbs listed in the top ten herbs derived 
from the data mining of the classical texts. This would provide more evidence on the effects 
and validate their use in drug development.  
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